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ABSTRACT
Inflammatory bowel diseases (IBD) include a range of pathologies, with ulcerative colitis
(UC) and Crohn’s disease (CD) representing the bulk of IBD cases. Both UC and CD are life-
long immune disorders which are the cause of significant morbidity with the incidences of
both diseases increasing globally. Chronic inflammation of the colon, such as that occurring
in ulcerative colitis or Crohn’s colitis is associated with an increased risk of colorectal
cancer. The mechanisms responsible for the transition from chronically inflamed tissue and
colorectal cancer remain largely unknown.
Defects in the formation of a colonic mucous lining impermeable to bacterial penetration
have been associated with inflammatory bowel diseases. Genetic ablation of the predominant
gel-forming mucin in the colon, mucin-2 (Muc2), produces a chronic colitis by permitting
contact between the host tissues and the micro-organisms resident within the colon. Animals
with defects in mucus synthesis also display an increased incidence of intestinal tumours,
the development of which may accelerated by the severity of the concomitant chronic
inflammation.
The present study therefore aimed to investigate the utility of using the Winnie mouse
to model the progression of chronic colitis to colonic cancer. Winnie carry a homozy-
gous missense mutation in Muc2, resulting in spontaneous colitis and ER stress due to
Muc2 misfolding. Since Winnie display features of UC, we intended to characterise the
molecular mechanisms mediating the transition from chronically inflamed mucosa to early
pre-cancerous lesions in these animals.
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Administration of the colonic irritant dextran sulphate sodium (DSS) in a regimen of three,
seven-day cycles in Winnie mice to simulate bouts of severe inflammation was trialled. The
distal colon of Winnie mice after completion of the DSS protocol revealed hyperplastic
mucosa with glandular morphological abnormalities resembling pre-cancerous change.
Architectural derangement consistent with high-grade dysplasia was present in 55% of
Winnie receiving DSS whereas these features were absent untreated Winnie or wild-type
mice (χ2 = 6.667, P ¡ 0.01). Penetration of crypts beyond the muscularis mucosae was
observed infrequently (27% of Winnie mice after DSS) but was absent in wild-type (WT)
animals irrespective of treatment. Although dysplasia-like changes were evident after the
completion of five DSS cycles, cessation of DSS administration allowed a return to a uniform
crypt morphology.
Three cycles of DSS increased expression of Ccl5, Trp53 by 10% and 28% (P <0.05) but
Cav1 decreased 44% in Winnie + DSS relative to WT + DSS. Expression of Myc was
unchanged in Winnie with or without DSS, but increased in WT following three cycles of
DSS. Changes in distribution of vimentin and N-cadherin were not observed in the colon of
Winnie suggesting that EMT was not involved in the manifestation of the observed pathology
in the Winnie colon.
Though the cancerous potential of the lesions observed in Winnie was unclear, the described
model may be useful in exploring the progression from chronic colitis to dysplasia. Persistent
alterations to Cav1 and p53 expression in particular, may be associated with an abnormal
regenerative response to pro-inflammatory stimuli in the colonic mucosa.
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CHAPTER 1
LITERATURE REVIEW
1.1 Epidemiology of UC, CD and IBD
Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative
colitis (UC), are a growing global health problem. Both diseases feature a chronic, relapsing
and remitting inflammation of the gastrointestinal tract which causes significant morbidity
for those affected. Since neither CD nor UC can be cured at present, life-long management
of the disease through pharmacological and dietary intervention is necessary to maintain
remission. Although a subset of patients experience the onset of IBD during childhood, the
peak age at which diagnosis of CD or UC typically occurs is during the late teen years to
early twenties. Presently, treatment for IBD involves inducing and maintaining a remission
of symptoms, therefore, patients with IBD must endure chronic, relapsing illness for the
remainder of their lives.
1.1.1 Incidence and prevalence
Incidence and prevalence of both CD and UC has historically been highest in the industri-
alised Western nations, particularly northern and central Europe, North America and the
United Kingdom [1, 2]. Canada for example has, for CD and UC, 20.2 and 19.2 per 100,000
incident cases respectively, and a prevalence of 319 and 248 per 100,000 for CD and UC.
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Geographical variation
A considerable degree of variation in both incidence and prevalence of CD and UC exists be-
tween populations, seemingly related to geographical region. Although previous researchers
have suggested a high–low gradient of IBD incidence and prevalence from the Northern
Hemisphere to the Southern Hemisphere, recent studies in Australia and New Zealand
provided evidence against this idea [3]. Incidences of IBD in both the Geelong region in
Australia (12.5 and 17.4 per 100,000/year, UC and CD respectively) and in Canterbury, New
Zealand (7.6 and 16.5 per 100,000/year, UC and CD respectively) [4, 5]. The incidence of
IBD in Australasia therefore closely resembles that of the Norther Hemisphere, but stands in
stark contrast to that of the remaining Asia-Pacific region. The incidence of IBD is generally
low in all Asian populations studied to date, though China displays considerable variation in
the estimated rates [6]. The Guangzhou region in China has an incidence of 1.09 and 2.05
per 100,000 for CD and UC respectively, whereas incident cases of IBD are relatively rare in
less urbanised areas. Incident rates of 1.25 and 1.30 for CD and UC respectively, have been
recorded in Hong Kong, suggesting that some variance may be explained by an association
between IBD and urbanisation [6]. Regions with low incidences of IBD also display a higher
incidence of UC cases than CD whereas the incidences of both diseases are presently close
to equal in Europe, North America and Australasia [1, 7]. In contrast, the ratio between CD
to UC incident cases in Hong Kong is close to parity, similar to high-incidence regions [6].
The few studies in Africa, and South America have also recorded low estimates of IBD
incidence rates [1, 2].
Temporal variation
Recent systematic review of population-based studies into the temporal trends in IBD
incidence and prevalence has revealed a global increase in the incidence of both CD and
UC [2]. While annual increases in incidence were observed in most studies (70% of UC and
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60% of CD), only 6% of UC and none of the CD studies reported a decrease in incidence.
Several populations with a historically low incidence of IBD have shown a trend toward an
increased incidence of IBD, particularly UC. Eastern Asia, particularly South Korea and
Japan have experienced increases in the rate of newly diagnosised cases of IBD in recent
decades [8–10]. Increased incidence of IBD in typically low-incidence regions appears to
favour UC more than CD. The ratio of CD to UC diagnoses in Asia is thought to be increasing
with time, a trend which may mirror the initial predominance in UC cases followed by an
increase in CD similar to the trend observed in Europe and North America [6, 11, 12].
In contrast, the last three decades have seen a possible stabilisation or slight decline in
annual incident cases of UC in regions of high-incidence such as Canada, Denmark and
the Netherlands [2]. While UC incidence has stabilised in high-incidence regions, incident
cases of CD has continued to increase to the point where the incidences of both diseases are
approaching parity. It might be assumed that the predominance of diagnosed UC cases in
Asia may also stabilise over time while CD cases increase [8].
1.1.2 Aetiological factors for UC, CD and IBD
Ethnicity
Studies in the United States have indicated differences in the susceptibility to IBD associated
with certain ethnic groups. While African-Americans display an equivalent rate of incidence
and prevalence to Americans of European heritage, peoples of Hispanic and Asian heritage
have comparatively lower rates of IBD [13]. Similar to the regions from which these
Hispanic and Asian populations originated from, UC was more prevalent than that of CD.
Immigrants from southern Asia living in the UK or North America have been the subject of
several studies. Indian immigrants in Leicestershire (78% of whom were first-generation)
displayed a higher incidence of UC during 1972–1989 [14]. A subsequent multi-centre
study in Leicestershire suggested an increase in the incidence of UC in both the indigenous
and migrant populations (7.0 and 17.2 per 100,000 respectively) [15]. Second-generation
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immigrants displayed comparable rates of disease, and with similar severity and extent
to that reported in the indigenous population. In contrast, first-generation immigrants in
Sweden were found to have a decreased risk of IBD relative to the Swedish population [16].
Immigrants from South Asia in Ontario, Canada, display a lower incidence of IBD than the
local Western European/North American population following migration to Canada [17].
The age at arrival appears to be important in determining the risk of developing IBD in
immigrants from low-incidence regions, with subsequent generations raised in Canada
displaying a similar incidence to the indigenous population. While it is clear that the
environment has considerable influence on susceptibility to IBD in early life, ethnicity
remains a likely modifier. For example, in immigrants in Sweden the risk of developing IBD
however was dependent on the origin of these immigrants, with second-generation migrants
from Iran and Iraq being particularly susceptible to UC and CD respectively [16].
Age
The majority of CD cases are diagnosed between the ages of 20–30 years [1]. In contrast,
UC is typically diagnosed later in life between the ages of 30–40 years, though it has been
suggested a second peak may exist between 60–70 years of age. Less frequent are the cases
of IBD arising prior to adolescence, often called paediatric IBD, which may account for
between 7% and 20% of total IBD cases. Generally, paediatric CD is more common than
paediatric cases of UC. Change in the incidence rates for paediatric IBD appear to reflect
the trend in incidence for IBD overall. Cases of paediatric CD in European populations have
been increasing in the last two to three decades whereas the incidence of paediatric UC has
remained unchanged or slightly decreased [18, 19].
Sex
Occurrence of CD has been reported as being slightly more frequent in females than in males
(10–30%) in populations with high incidences of CD [4, 20, 21]. However, the sex bias in
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CD has not been observed in areas of Europe and North America, where the ratio may be
equivalent [18, 22]. Occurrence of UC may be slightly more frequent in males [4, 20, 21].
1.1.3 Environmental factors
While genetic factors are likely to be involved in susceptibility to IBD, environmental factors
are doubtless a major driving force in the increasing IBD incidence. Two environmental risk
factors for IBD have consistently been identified in repeated aetiological studies: smoking
and appendectomy.
Smoking
Multiple studies have identified smoking as a behaviour associated with both CD and UC.
Meta-analysis of studies investigating a possible relationship between smoking and IBD has
confirmed the increased risk of CD (odds ratio = 1.76) and habitual cigarette smoking at
the time of diagnosis [23]. Former smokers may also be at a similarly increased risk of UC
relative to control populations. Conversely, active smoking at the time of diagnosis appeared
to be protective (odds ratio = 0.58) against UC. Interestingly, low incidences of IBD in Asia
and Africa co-incide with high smoking rates within the given regions, whereas regions in
which smoking rates are lower have high rates of IBD. The timing of exposure to smoking
is likely to be important to its effect on IBD, with the strongest association occurring in
adolescents [24]. Exposure to smoking in utero has also been associated the development of
CD later in life although this observation has not been reported by every study [25–27].
Appendectomy
A number of observational studies have associated appendectomy with protection from UC.
The course of disease for patients with UC appears to be modified significantly for those
who have undergone appendectomy prior to diagnosis. For example, a multi-centre study in
Japan observed a more limited anatomic extent and reduced relapsing disease in patients
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with UC and prior appendectomy [28]. Studies involving Australian UC patients have
associated appendectomy before diagnosis with lower rates of immunosuppressive therapy
or colectomy [29, 30]. However, several studies, including a systematic review, have failed
to observe the same associations between appendectomy and UC [31–33]. Recent study of
North American UC patients has suggested that appendectomy prior to diagnosis had no
significant effect on colectomy rates, whereas post-diagnosis appendectomy increased the
rate of colectomy [34]. While the subsequent meta-analysis supported the lack of protection
from colectomy attributable to appendectomy it appears likely that the onset of UC may be
delayed by prior appendectomy [29, 31, 34].
1.2 Pathological features of UC and CD
Patients with IBD typically display various non-specific symptoms associated with inflam-
mation or irritability of the bowel. Chronic diarrhoea is the symptom most often reported
among patients with IBD and is the prevailing symptom that prompts consultation with
a physician [35]. Eighty-five percent of patients with CD and 70% of patients with UC
experience an increase in the number of bowel movements. In patients with UC, constipation
associated with the acute phase of disease is also reported, albeit with considerably less
frequency than diarrhoea [36]. Colonic inflammation is the most likely cause of diarrhoea
in IBD, however, malabsorption of food and bile acids in the small intestine due to CD-
associated inflammation may also result in diarrhoea. Rectal bleeding and haematochaezia
are usually associated with distal colonic and rectal disease and hence are more common in
UC [37]. Increased urgency to defaecate and cramps occurring during defaecation (known as
tenesmus) are often associated with active inflammation of the anorectal region. Abdominal
pain is commonly reported by patients with either CD or UC and the location may vary
according to the extent of disease. Patients with UC often report lower left quadrant pain
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whereas the ileal inflammation that typically occurs in patients with CD may result in pain
and cramps in the right lower quadrant.
A number of local and extra-intestinal complicating diseases have been associated with IBD.
Fistulae and intestinal strictures are associated with sites of severe intestinal inflammation in
patients with IBD. Approximately 50%–60% of patients with IBD will develop at least one
extra-intestinal manifestation, such as arthritis, cutaneous lesions and primary sclerosing
cholangitis [35]. The large degree to which symptoms overlap between IBD and non-IBD
enteropathies, and the lack of biomarkers specific for either disease means that histological
examination is essential for diagnosis. Indeed, histological features are the basis for the
distinction between CD and UC.
1.2.1 Crohn’s disease
The majority of patients with CD experience episodic ”flare-ups” of acute disease followed
by periods of remission. Tissue damage caused by inflammation may take week to decades
to manifest. Damage to the intestine may be reversed by anti-inflammatory therapy, or
recovery may occur spontaneously.
Crohn’s disease may affect any region from the oral cavity to the anus. At diagnosis,
the proportion of patients with CD presenting with either ileal, colonic or ileocolonic
inflammation is approximately equal [38, 39]. One to four percent of patients with CD
display oesophageal, gastric or duodenal involvement [40]. Isolated perianal disease is also
observed in 2%–5% of patients newly diagnosed with CD. Chronic inflammation associated
with CD results in alterations to the intestine that are in most cases, histologically distinct
from UC. Neutrophilic accumulation and lymphoid aggregates in the intestinal mucosa are
present in the early stages of disease. In the ileum of patients with CD, areas of inflamed
mucosa are often interspersed with uninflamed regions. In the ileum, chronic inflammation
results in villous atrophy, reducing the absorptive function of the small bowel. Chronic
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inflammation also results in the progressive disruption of crypt structure. As the disease
progresses the characteristic transmural inflammation becomes evident. A defining feature
of CD with ileal involvement, is the formation of deep, fissuring ulcers penetrating into the
muscularis externa. A series of ulcers may also merge together to form lines that extend
longitudinally, eventually forming the cobblestone mucosa pattern associated with CD.
Variation in the anatomical location and disease activity of CD has made comparing clinical
studies somewhat difficult. To address some of these difficulties, the Vienna classification
of IBD clinical phenotypes was developed.
The Vienna classification identifies distinct clinical phenotypes of CD based on the age,
extent and severity of disease (Table 1.1). Following the initial diagnosis with CD, there
is little change in the involved regions of the gastro-intestinal tract within each patient.
However, follow-up examination after diagnosis revealed significant variation in CD disease
behaviour [41]. At diagnosis, approximately three quarters of patients studied presented with
non-stricturing, non-penetrating disease (B1). After diagnosis, the occurrence of patients
with B1-type disease declined, while a progressive increase in structuring and penetrating
disease was observed. Five years after diagnosis, half of patients with CD displayed a B1
phenotype whereas 21% presented with stricturing disease (B2) and 27% with penetrating
lesions (B3). After ten years the proportion of patients with stricturing and penetrating
disease increased to 32% and 37% respectively. The gradual change in disease behaviour
toward a penetrating/stricturing phenotype explains the prevalence of surgery among patients
with CD.
Strictures are more common in the small intestine than the colon and as such are a common
complication occurring in patients with CD [42]. Fistulae and perforations of the bowel
are also associated with CD. As the aforementioned complications are unaffected by anti-
inflammatory medication, surgical intervention is necessary. Surgical removal of segments
of the inflamed bowel is also indicated in patients with refractory CD. Approximately
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Table 1.1: The modified Vienna classification (Montreal) for Crohn’s disease
Age at diagnosis A1 <16 years of age
A2 between 17 years and 40 years
A3 >40 years
Location L1 ileal
L2 colonic
L3 ileocolonic
L4 isolated upper disease*
Behaviour B1 non-stricturing, non-penetrating
B2 stricturing
B3 penetrating
p peri-anal disease modifier†
* L4 is a modifier that can be added to L1–L3 when concomitant upper gastrointestinal
disease is present. † p is added to B1–B3 when concomitant peri-anal disease is present.
70%–80% of patients with CD will undergo intestinal resection at 20 years after diagnosis [1].
Furthermore, patients with stricturing disease are more likely to require recurrent surgeries
after the initial operation.
If inflammation is initially confined to the terminal ileum, symptoms of CD may not be
readily apparent. With increased spread of disease to distal sites in the intestine, or the
occurrence of systemic the symptoms of CD become evident [1]. Differentiation between
colonic CD and UC may be complicated by similar clinical features. Deep ulcerations,
strictures and fistulae are less common in the colon than in the ileum. As a result, some
patients with CD may be initially diagnosed with UC.
1.2. PATHOLOGICAL FEATURES OF UC AND CD 10
1.2.2 Ulcerative colitis
Chronic superficial inflammation limited to the colon and rectum is a key feature of UC.
Similarly to CD, the disease course of UC involves episodes of acute disease followed by
episodes of remission.
The anatomical extent of UC is far more limited than that of CD. Inflammation associated
with UC typically begins in the distal colon and/or rectum. While rectal involvement is not
always present in the paediatric subset of patients with UC, it is almost always present in
adult patients [43]. Over time inflammation spreads proximally from the initial site in the
colorectal region, potentially affecting the entire colon and caecum. It is estimated that 50%
of patients with UC will have developed pancolitis 20 years after diagnosis [1]. Although
inflammation of the terminal ileum is infrequent in patients with UC, pancolonic disease has
been associated with ”backwash” ileitis. Backwash ileitis in UC was initially believed to be
due to reflux of colonic contents through an inflamed and dysfunctional ileo-caecal valve.
However, the aetiology of ileitis in UC may be more complex than first thought. A study by
Haskell et al. suggested that colonic inflammation adjacent to the ileum although frequent,
was not necessary for ileitis [44].
Even extensive, pancolonic CD rarely affects the rectum, a site that is commonly inflamed
in patients with UC. Colonic inflammation associated with UC spreads proximally from the
distal colon forming a continuous lesion. Similarity exists between the histological features
of colonic CD and UC, especially in the early stages of disease. Chronic inflammation of the
colon results in accumulation of neutrophils in the mucosa and the formation of lymphoid
aggregates in the mucosa. Unlike CD, submucosal inflammation is minimal in UC and is
instead confined to the mucosa. Superficial ulceration of the mucosa is present and extends
proximally, and in a uniform fashion, along the colon as disease progresses. Crypt abscesses
are also frequent though fistulae are rarer than in CD. Perforation of the colon and resultant
haemorrhage is infrequent, affecting approximately 15% of patients with UC, but is seriously
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life-threatening. With the advent of immunosuppressive therapies and improved treatment
strategies, mortality of patients with UC is currently not significantly higher than the general
population.
1.2.3 Intestinal complications of UC
An array of intestinal complications have been associated with long-standing UC including
anaemia, fistulae, and more rarely, distension and perforation of the colon. Additionally,
the disease may be associated with colonic pseudopolypoid features. Pseudopolypoid
inflammatory polyps, are islands of non-ulcerated mucosa, submucosa, or muscularis,
surrounded by deep mucosal ulceration and are thus associated with active inflammation
[45]. The non-ulcerative mucosal projecting above the ulcerated bowel wall are typically
prominences of inflammatory leukocytic infiltrates and/or oedema, or alternatively may be
hamartomata. Unless the pseudopolypoid tissue contains glandular dysplasia, these lesions
are otherwise recognised as an insignificant risk of developing neoplasia.
Pseudopolyps may also serve as the basis for the infrequently observed post-inflammatory or
filiform polyp, usually within the distal colon and rectum. Filiform polyps are likely formed
during the regeneration of the ulcerated mucosa after the induction of remission in UC [46].
Despite its association with UC, filiform polyps have also been observed in association
with neuromuscular alterations indicative of hamartamatous change [47]. The non-ulcerated
epithelium may expand outwards from the under-surface of the pseudopolyp while the ulcer
is simultaneously regenerated from the base. In such cases a ”stalk” of submucosa supports
a genuine, thin, polypoid projection with complete mucosa extends into the lumen. Due
to their originating from normal regenerating mucosa, filiform polyps are also regarded
as having no risk of neoplasia, despite a lack of quantitative data regarding the incidence
of neoplastic transformation in these polyps [48]. Although these polyps may extend in a
branched fashion and even bridge the lumen, they are rarely the cause of clinically significant
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bowel obstruction [49, 50]. However, a small subset of patients may develop a ”giant” (> 15
mm) pseudopolyposis which have been in turn associated with intestinal intussusception.
Intestinal intussusception involves the ”telescopic” invagination of a segment of the intestine
into another intestinal segment. Intussusception most commonly involves the junctions of
the freely moving intestinal segments or those fixed retroperitoneally or adhesionally [51].
Intussusception may therefore be classified into entero-enteric, i.e. involving only the
small intestine; colo-colonic, confined to the large bowel; ileo-colonic, between ileum
and ascending colon; or ileo-caecal, between ileum and caecum only. Paediatric cases
account for the majority of cases of intussusception whereas adult cases account for only
5% of total cases [51]. In children, intussusception most often occurs idiopathically, with
no identifiable cause, or subsequent to viral or bacterial infection of the intestine [52] .
Conversely, aetiology of adult intussusception is identifiable in 90%–93% of cases [53–55].
Adult cases of intussusception are rare, however intussusception in adults with UC appear
to be rarer still. Few cases of intussusception in adults with UC have been described in the
literature, with one case of seemingly idiopathic colo-colonic intussusception, and another
associated with giant pseudopolyposis [56, 57]. Cases of intussusception are rare in patients
with CD and were associated with chronic haematoma, giant pseudopolyposis, fibroid
polyps, active inflammation and surgical resection [58–63]. A variety of intra-intestinal
abnormalities may therefore precede the occurrence of intussusception in adults with UC.
Though the exact mechanisms of intussusception aren’t well understood, a general patho-
genesis has been proposed. Lesions arising from the wall of the bowel may initiate the
intussusception by disrupting the normal peristaltic movement of local muscularis propria,
or perhaps through distortion of the adjacent fibrous and/or muscular tissue. The lesion
forms the leading point for the invagination or prolapse of the involved region of the bowel
wall into the intestinal lumen, which is progressively distended and forced aborally through
the propulsive motility of the surrounding musculature (Fig. 1.1A). The intussusception
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thus forms the characteristic ”telescope-like” structure within the adjacent bowel segment.
Constriction of the mesenteric blood vessels supplying the intussuscepted region of the bowel
produces an ischaemia and intraluminal bleeding (Fig. 1.1B). Without medical intervention,
adult intussusception is likely to progress, potentially resulting in strangulation, subsequent
necrosis of the intussusceptum and sepsis.
Figure 1.1: Mucosal prolapse and intussusception of the lower gastro-intestinal tract.
Intussusception describes the ”telescopic” invagination of the intestine within itself, fre-
quently involving the ileum of the small intestine. The invaginated ileum may advance
aborally into the caecum and proximal colon, the compressed tissues impeding the normal
transit of faecal matter. Mesenteric blood vessels supplying the intussuscepted tissue (intus-
susceptum) also become compressed by the surrounding intestine, obstructing venous return
via mesenteric veins. Obstructed blood flow results in an ischaemia of the intussusceptum
and engorged mesenteric blood vessels. Bleeding from the ischaemic intussceptum enters
the intestinal lumen producing bloody stools.
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Intussusception of the small intestine may be initiated by a range of lesions including
inflammatory lesions, non-neoplastic polypoid lesions, diverticula, adhesions and strictures.
Cancerous neoplasia, either primary or metastases, may serve as the lead-point for 18-
48% of cases of enteric intussusception. In contrast, in 43%–100% of cases of colonic
intussusception in adults, malignant neoplasia may be identified as a lead-point [51].
Rectal prolapse may be another complication associated with chronic ulcerative colitis [64].
Where most cases of rectal prolapse occur either in children or in the elderly, the incidence
of rectal prolapse in adolescents and adults may be increased by chronic colorectal disease.
Mucosal prolapse has been proposed as the likely cause of a set of similar disorders including
rectal prolapse, haemorrhoids, solitary rectal ulcer syndrome and colitis cystica profunda [65].
Though the rectum seems particularly susceptible mucosal prolapse, polypoid mucosal
prolapse has also been observed in the stomach and colon [66]. Mucosal prolapse may
present endoscopically as ulcerative, polypoid, or erythematous lesions The key histological
features of mucosal prolapse are a thickening and disruption of the muscularis mucosae.
Mucosal crypts are mildly distorted and hyperplastic, occasionally displaying a serrated
epithelium [67].
Whilst mechanistic evidence for is scant, it has been hypothesised that mucosal abnormality
induced by colonisation of the colorectum by bacteria or helminths triggers rectal prolapse.
Inflammatory responses to schistosomal infestation of the rectum are known to induce the
formation of a polypoid lesion (bilharzioma) within the rectal mucosa, which co-incide
with rectal prolapse [68]. Similarly infection with enterohepatic Helicobacter species in
susceptible laboratory mouse strains co-incides with a higher incidence of rectal prolapse.
Examination of murine rectal prolapse cases at Massachusetts Institute of Technology animal
facilities revealed that the majority (52%) of cases arose in mice with colitic disease or
known immunodeficiencies such as interleukin-10-deficient or recombination-activating
gene-1 (Rag1)-deficient strains [69]. That a variety of colorectal pathogens are associated
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with rectal prolapse would suggest that the inflammatory response to these pathogens is the
underlying aetiology of rectal prolapse.
Prolapsed rectum often displays a flaccid and fibrotic appearance upon examination, with
progressive degeneration of the pelvic and anorectal muscle and/or their innervating neurones
suggested as an underlying aetiological factor [70]. Neuromuscular remodelling induced by
chronic inflammation of the colon and rectum could explain the association of rectal prolapse
with infection through the progressive remodelling of connective tissue and local neurones.
Depletion of cholinergic motor neurones has been shown in prolapsed segments of rectum
from mice with chronic colitis, suggesting that chronic colitis results in a progressive loss of
rectal contractility [71]. However, it remains unclear whether a decline in neuromuscular
dysfunction in colitic animals precipitates rectal prolapse or whether it is produced by
additional stresses placed on the involved tissue following intussusception.
Notably a strain of lamellipodin-deficient mice displays a high incidence of rectal prolapse
in the absence of a florid inflammation [72]. Further investigation of the prolapsed rectum
revealed the existence of invasive adenocarcinoma within the involved tissue. The associa-
tion between rectal carcinoma and prolapse suggests that the cancer-induced alteration to
structure to the rectal wall may provide a lead point for intussusception of the rectal mucosa
(incomplete prolapse) and eventually a circumferential (complete) prolapse of the rectum.
Thus it would appear that the structural alterations to the mucosal and submucosal connective
tissues resulting from cancerous invasion render the affected rectal tissue liable to prolapse.
Most notable among these local complications is the association of UC with colorectal
cancer.
1.2.4 Epidemiology of colitis-associated neoplasia
Numerous studies have addressed the issue of increased risk of intestinal carcinogenesis in
patients with IBD. An association between an increased risk of developing CRC and colonic
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CD is well known [73]. Meta-analysis of reports of CRC incidence among patients with CD
has shown a 2.5–4.5-fold increase in risk relative to the general population [74]. Though
far rarer than CRC, small bowel cancer may be up to 33 times more likely in patients with
CD than in the general population. However, the majority of studies of CRC incidence
among patients with IBD have been focussed on UC. Discrepancy exists between the risk of
developing CRC in patients with UC between early and more recent studies. The degree of
CRC risk reported by studies utilising patients with UC from tertiary care centres [75] is
generally greater than that reported by population-based studies [76].
A population-based study of patients with IBD residing in Minnesota observed no difference
in the incidence of CRC relative to US population census data [42]. Diagnosis of UC-
associated CRC occurred at a relatively early age in the previous study, with a median age
at diagnosis of 51 years. Subsequent studies of a Danish cohort identified an earlier onset
of neoplasia in the chronically inflamed bowel of patients with UC relative to the non-IBD
population. The median age at which patients were diagnosed with CRC of 64 years in
patients with UC, compared to 71.6 years in non-IBD patients [76]. Recent population-based
analysis performed in Denmark by Jess et al. [77] has suggested an overall decline in the
risk of CRC development in patients with UC over a 30-year period. In contrast, Herrinton
et al. [75] had observed a stable incidence rate of CRC development in patients with IBD
over a 14.5-year time-frame. Differences in the trend of incidence rates may be partially
explained by stratification of age groups. Based on the Danish study, patients diagnosed with
UC between the ages of 0–39 years, are at greatly increased risk of developing CRC than
the general population [77]. In contrast, patients >39 years of age were at no greater risk of
developing CRC than non-IBD patients. Based on the associations already made between
severity and duration of UC, it seems likely that the greater extent of disease typically
exhibited by the paediatric UC subset at diagnosis and therefore longer duration of disease
would explain the disparity in CRC incidence between the age groups.
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Another explanation for discrepancies between the studies is due to changes in the manage-
ment of IBD during this time. The declining use of 5-aminosalicylic acid and sulfasalazine
coinciding with increased use of immunomodulators such as thiopurines (azathioprine,
6-mercaptopurine or methotrexate) and anti-tumour necrosis factor therapy (infliximab,
etanercept), has become increasingly prevalent [75, 78]. In the case of the Danish study,
endoscopic surveillance was minimal. Therefore improvements in chemopreventative ther-
apy for IBD are likely to be at least partly responsible for the diminished incidence of CRC
among patients with IBD. Cumulative incidence of CRC in patients with pan-colonic UC
was estimated to be 2% after 10 years of disease, 8.5% after 20 years, and 17.8% after 30
years [79]. A more recent study presented a lower estimate of cumulative CRC incidence
in pan-colonic UC; 2.5% after 20 years, 7.6% after 30 years and 10.8% after 40 years
disease duration [80]. When the incidence of dysplasia with CRC, the predicted rates were
closer to the estimates reported by Eaden et al. [79] 7.7% at 20 years and 15.8% at 30
years. Differences between studies may be explained by selection bias or differences in CRC
surveillance and treatments after diagnosis with IBD.
Sixteen studies examining ten year intervals of UC duration included in the meta-analysis
showed that 19% of patients developed CRC within the first ten years after diagnosis with
UC [79]. Similarly, twenty-one percent of patients with UC-associated CRC involved in a
retrospective analysis of Dutch hospital patients developed cancer in less than 8–15 years
of disease duration [81]. Using the same clinical database as Lutgens et al. but with a
larger patient cohort, Baars et al. observed CRC occurrence in 45% of patients less than ten
years after diagnosis with UC [82]. Unlike Lutgens et al. however, Baars et al. excluded
patients diagnosed simultaneously with CRC and IBD. Exclusion of patients presenting
with IBD and CRC concomitantly may be expected to underestimate the incidence of early
CRC, however the number of early CRC cases was higher in the latter study. The study by
Baars et al. described an association between age of diagnosis and the interval between
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CRC occurrence in patients with IBD. Patients diagnosed with UC at a later age were
expected to develop cancer within 5–10 years. Sporadic CRC incidence is low in patients
younger than 50 years old but increases sharply with age. The average age of diagnosis
amongst Australians is 69 years old which is close to the median age for diagnosis in
most industrialised countries [83, 84]. A similar relationship between incidence of colitis-
associated cancer (CACC) and age may reasonably be expected in 50–60 year old patients
with UC.
It is unlikely that the overall the risk of CRC occurrence in patients with IBD has been grossly
overstated. Eaden et al. estimated a cumulative incidence of 2% 10 years post-diagnosis
with IBD, a figure that has been confirmed by the results of studies published since [79].
An unanswered question in assessing the epidemiology of CACC involves the source of
discrepancies in the reported CRC incidence obtained from studies performed in recent years
between earlier studies. Whether the incidence of CRC in patients with UC has declined
due to evolving medical and surgical practices, or has been produced by differences in
study design and population may never be fully resolved. A largely unexplored aspect of
CRC associated with IBD is the mechanisms by which chronic inflammation contributes to
carcinogenesis in the colon.
1.3 Pathogenesis of UC
Understanding the origins of UC-associated neoplasia requires an understanding of the
pathogenetic basis for UC itself. The aetiology of UC is considered to lie in multiple host
and environmental factors. The culmination of these factors is suspected to produce an
exaggerated immune response to luminal bacteria, permitted perhaps by a defect in intestinal
barrier function.
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1.3.1 Genetic factors for susceptibility to UC
Genetic factors pre-disposing individuals to the development of UC have been the subject
of intense study in the last decade. Large genome-wide association studies have identified
several genetic loci associated with a modified risk of developing UC. Among the strongest
associations so far have been made between risk of UC and the genes encoding the human
major histocompatibility complex (MHC). Certain gene variants in the MHC-II complex
(human leukocyte antigen [HLA]) gene region have been associated with more extensive UC
and an increased risk of colectomy [85, 86]. Shared HLA variants between extensive UC
and primary sclerosing cholangitis (PSC) may also explain the shared associations between
these diseases [85, 87]. Since MHC-II is crucial for the presentation of antigenic peptides
by antigen-presenting cells, UC may arise as a result of inappropriate immune responses
arising from genetic abnormalities in immunoregulatory genes. Less frequent risk variants
for UC susceptibility can also be found in genes regulating mucosal inflammatory responses,
particularly those characterised by IL-17-expressing T-helper lymphocytes (TH17) such
as the interleukin-23 receptor (IL23R) and C-C motif-containing chemokine receptor-6
(CCR6) [88]. Additional UC-associated variants have also been identified in loci enconding
immunoregulatory interleukin-10 (IL10) and genes involved in the transduction of pro-
inflammatory cytokine signalling via the caspase-recruitment domain family member-9
CARD9 and Janus kinase-2 (JAK2), [88, 89].
Collectively these polymorphisms may represent a defect in pathogen recognition and
clearance and aberrant immune responses to the intestinal microbiota. Interactions between
defective immune responses and the microbes resident within the colon may thus be causative
factors in the pathogenesis of IBD.
1.3. PATHOGENESIS OF UC 20
1.3.2 Colonic mucus
While the innate and adaptive arms of the immune system are normally capable of preventing
and limiting infection, the overwhelming number of micro-organisms makes it highly
advantageous to separate them from the host tissues as much as possible. An impermeable
barrier would effectively segregate host tissue from microbes but would simultaneously
impair the primary absorptive function of the gastro-intestinal tract. Mucus, however,
presents a solution to this dilemma. In the colon, the secreted mucus forms two layers, an
adherent inner layer approximately 200 μm thick in humans and 50 μm thick in the mouse
and an easily removed outer layer [90]. The inner mucous layer is capable of excluding
objects down to 50 μm in size thus preventing bacteria contact with the colonic epithelium,
but still permitting the diffusion of water and small molecules. Clearly, the structure of the
intestinal mucous layers is crucial to the prevention of intestinal disease.
Colonic mucus differs in its composition from the mucus produced in other mucosal tissues
such as the lung, and even compared to other regions of the gastro-intestinal tract. The
essential components of mucus are the mucin family of proteins. Intestinal mucins in the
human are either secreted gel-forming mucins (MUC2, MUC5AC, MUC5B and MUC6) or
cell-surface mucins (MUC1, MUC3, MUC4, MUC12, MUC13 and MUC17) [91]. Secretion
of the Muc2 gel-forming mucin increases from the oral to the anal end, with mucin secretion
in the distal colon limited to Muc2 alone [92,93]. Human MUC2 encodes a 5,179 amino acid
protein synthesised in the endoplasmic reticulum (ER) of the intestinal goblet cell. It is in the
ER that MUC2 proteins dimerise via disulphide linkages of the CK domain of each MUC2
molecule [94]. Subsequent to dimerisation MUC2 is translocated to the Golgi apparatus
where the protein undergoes heavy glycosylation of intramolecular domains enriched in
proline, threonine and serine residues [95]. Further post-translational modification occurs
trans-Golgi, where MUC2 dimers form disulphide linkages between the N-terminal D3
domains to form a MUC2 trimer [96]. Interactions between the N-terminal D1-D2-D’D3
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domain-containing region of the MUC2 molecules to form hexagonal structures [97]. The
ordered packing of the complex MUC2 molecules into the secretory vesicle requires an
acidic environment (pH = 5) and abundant Ca2+. Release from the secretory vesicle would
therefore expose the folded MUC2 proteins to a neutral pH outside the cell and trigger
an unfolding of the MUC2 structure. Experimentally increasing the pH or the addition of
sodium bicarbonate has been demonstrated to dissolve the interactions between the MUC2
N-termini, permitting the unfolding of the MUC2 mucin into the extended net-like polymer
observed during release from secretory vesicles [97]. Modelling of MUC2 N-terminal
interactions has indicated the possibility that the MUC2 polymers may actually maintain
the stratified network structure even after release from the secretory vesicle [98]. Being the
primary secreted mucin in the distal colon, disruption of Muc2 function could be expected
to allow a persistent microbial colonisation of the colonic mucosa. Genetic ablation of
Muc2 in mice abolishes the stratified secreted mucous layer, resulting in a spontaneous,
chronic colitis [99]. Abrogation of genes regulating synthesis, secretion and folding of the
Muc2 mucin have also been demonstrated to permeabilise the inner mucous layer to the
luminal microbiota [100]. Segments of actively inflamed mucosa from patients with UC have
displayed a similar permeability to bacterial-sized material to that observed in genetically
modified animals which spontaneously develop chronic colitis [100]. Interestingly, while the
defect in the inner mucous layer was repaired when remission was achieved in patients with
UC, a minority of patients with UC in remission displayed a persistent permeabilisation of
the mucus barrier to bacterial-sized objects. Although it is unclear to what extent a primary
defect in the colonic mucous barrier contributes to the initiation of UC pathogenesis, animals
displaying defective mucin biosynthesis and secretion to produce chronic colitis remain an
appealing model of UC.
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1.3.3 Colonic microbiota
Interactions between the host immune system and the resident microbes within the intestine
are believed to represent a key aetiological factor in the pathogenesis of ulcerative colitis.
Variants of the genes encoding NOD2, ATG16L1 and MHC display strong associations with
susceptibility to IBD [88]. Since NOD2, ATG16L1 and MHC proteins are crucial in the
recognition and clearance of bacteria at mucosal surfaces, IBD-associated variants of these
genes would likely pre-dispose individuals to aberrant interactions between the host immune
system and the luminal microbiota [101]. Less clear is whether IBD-associated gene variants
result in an ’intolerance’ to non-pathogenic commensal microbes or whether IBD-associated
genes instead permit pathogenic expansion of specific subsets of microbial families.
Structural defects in the inner colonic mucous layer would allow greater numbers of bac-
teria not just to colonise the mucus but also the epithelial surface. Quantification of the
total bacterial burden associated with the colonic mucosa in patients with UC has revealed
abnormally high levels of bacteria [102]. That the burden of mucosa-associated bacteria in
patients with UC was similar between inflamed and non-inflamed colon suggested that the
observed bacterial expansion is unlikely to occur secondary to inflammation. An increased
bacterial burden associated with the mucosa raises the possibility of an opportunistic ex-
pansion of certain bacterial species. Profiling of the microbiota composition in IBD has
repeatedly identified reductions in the Firmicutes and Bacteroidetes phyla that predominate
in the non-IBD colon [103–105]. High proportions of Actinobacteria, particularly members
of Bacteroides and Prevotella genera, or Proteobacteria, particularly Enterobacteriaceae
members (Shigella spp. and Escherichia spp.) have been identified associated with UC
in disease-discordant twins [106]. In addition to adherent and invasive Escherichia coli
and Shigella spp., Fusobacterium varium was frequently identified in the or adjacent to
the colonic epithelium in patients with UC [107]. Alterations to the abundance of bacterial
species could be considered an expansion of bacterial species better adapted to the metabolic
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stresses imposed by ongoing inflammation in the colon. Mesalamine treatment, for example,
co-incides with a reduction in the abundance of Escherichia coli and Shigella spp. [103].
Thus, although colonisation of the defective mucus may precede chronic colitis in UC,
chronic inflammation seems to favour a microbiota favouring less diversity and a greater
abundance of pathogenic bacteria.
Expansion of potentially pathogenic bacteria associated with the colonic mucosa in patients
with UC could perhaps only occur at the expense of normal commensals. Reductions
in the abundance of members of the Firmicutes and Bacteroidetes in the normal human
colon are associated with active UC [103, 108]. Most notably, the Clostridales members
Faecalibacterium prausnitzii and Roseburia spp. are reduced in UC relative to healthy
patients [103, 109, 110]. While F. prausnitzii colonisation in the colon of patientws with
UC is reduced during active disease, the abundance of this bacterium may increase again
following the induction of remission [109]. Both F. prausnitzii and Roseburia spp. have been
identified as colonic commensals with anti-inflammatory properties in experimental colitis,
and may therefore protect against UC in uhumans [111, 112]. Part of the anti-inflammatory
effects of F. prausnitzii can be attributed to the production of short-chain fatty acids (SCFA),
particularly acetic, butyric and propionic acids. Production of SCFA may suppress the
production of pro-inflammatory cytokines through the inhibition of nuclear factor-κB (NF-
κB) and inducible nitric oxide synthase [113, 114]. Reduced faecal concentrations of acetate
and propionate have been associated with UC, and though butyrate concentrations may
be no different to the healthy colon, its metabolism by the colonic epithelium may be
impaired [110, 115]. In the absence of an abundant commensal population in UC, PRR
ligands such as lipopolysaccharide (LPS) from the bacteria colonising the colonic mucus
may thus provoke exaggerated inflammatory reactions. Congruent with the structural
abnormalities observed in the colonic mucous layer in patients with UC, an increased
abundance of mucolytic and sulphate-reducing bacteria including Ruminococcus gnavus,
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Ruminococcus torques and Desulfovibrio desulfuricans, Bacteroides fragilis and Bacteroides
vulgatus [116]. An increase in mucolytic bacteria may provide other commensals and
pathogenic bacteria with a source of nutrition. Clostridium difficile, Salmonella typhimurium
and Escherichia coli for example, are capable of utilising mucin metabolites produced by
mucolytic commensals. While a number of mucolytic bacteria increase in abundance in UC
the common mucolytic commensal Akkermansia muciniphila has been reportedly decreases
in UC [117]. Since A. muciniphila colonisation appears to be dependent on Muc2 either an
intrinsic defect in synthesis of colonic mucus, or an expansion of a combination of mucolytic
microbes may deprive A. muciniphila of suitable binding locations.
1.3.4 Aberrant immune responses in UC
Interaction between the luminal microbiota and the host immune system centres on the
colonic epithelium. The underlying colonic mucosa is home to a range of immune cells which
maintain an essential balance between pro-inflammatory responses to potential pathogens and
maintaining tolerance to beneficial commensals. The identification of the aforementioned
risk-variants such as IL23R and NOD2 associated with immune function suggest that the
recognition of, and responses to, microbial molecular patterns by the colonic epithelium and
the underlying mucosal immune cells may contribute to the chronic inflammation associated
with IBD. Concordant with the idea that microbial products trigger inflammation in IBD is
the observation massive infiltration of neutrophils, macrophages and CD4+ T-lymphocytes
to the inflamed colonic mucosa in UC. Lamina propria mononuclear cells isolated from
mucosal biopsies obtained from patients with UC and CD have shown increased reactivity to
commensal bacteria normally tolerated in the intestine [118, 119]. Furthermore, leukocytes
isolated from the inflamed mucosa of patients with CD have also been shown to produce
higher levels of interleukin-6 (IL-6), interleukin-12 (IL-12), IL-23 and tumour-necrosis
factor-α (TNF-α) in response to exposure to certain commensal bacterial species [120].
Hyper-reactivity of the innate immune system may favour the polarisation of T-lymphocytes
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toward pro-inflammatory phenotypes and suppress the development of immunomodulatory
regulatory T-lymphocytes, numbers of which are decreased in UC [121].
Consistent with the identification of the IL-23R as a risk factor associated with susceptibility
to UC and CD, neutralisation of IL-23 has proven to ameliorate chronic colitis in both UC
and mouse models of IBD [88, 122]. Since IL-23 is critical for the initiation, generation of
mucosal immune responses characterised by production of pro-inflammatory TH17 cytokines
such as interleukin-17A (IL-17A), it would follow that IL-17-type cytokines would be among
the key effectors of the tissue damage associated with chronic UC. Indeed, the mucosa of
patients with UC exhibits increased production of IL-17 family members with concomitant
expansion of IL-17A-producing CD4+ T-lymphocytes and APCs [123, 124]. The overall
effect of an IL-21/IL-23/IL-17-type inflammatory response would be expected to feature an
augmentation of neutrophil recruitment and elevated production of degradative proteinases
through production of granulocyte-colony stimulating factor (G-CSF) and IL-6.
IL-6 as an essential mediator that governs the early or acute phase of the immune response
against pathogenic insults, may be produced by a wide range of cell types, including intestinal
epithelial cells. The cytokine IL-6 is abundant in the colonic mucosa during the active phase
of IBD-associated inflammation and is itself capable of polarising immune responses toward
a TH17 profile via the [125].
Notably chronic production of IL-17 and the IL-17-promoting cytokines IL-21, IL-23, have
been shown to promote the growth of experimental colonic tumours in mice [126, 127].
Exactly how interleukin-17-type T-helper lymphocyte (TH17) promote tumourigenesis in
the colon is somewhat unclear. Several mediators of IL-17 responses, including IL-6,
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) have also been
implicated in colonic tumourigenesis [128–130]. Altogether, maintenance of the colonic
mucous barrier would seem to be essential for preventing chronic inflammation and by
extension, colonic cancer in the long-term.
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1.4 Initiation of carcinogenesis in the chronically inflamed
colon
Though connection between chronic inflammation and cancer is undisputed, the specific
mechanisms linking the ongoing immune-microbial interactions and oxidative stress to
the process of carcinogenesis is not yet fully understood. Carcinogenesis is a process
generally considered to require ’initiation’ through acquired or inherited genetic or epigenetic
alterations [131]. The alteration of genes during the initiation stage leads into the promotion
of tumourigenesis through the clonal expansion of the transformed cells by increased
proliferation and reduced cell death. The final stage of carcinogenesis is the progression
from a benign or precancerous lesion to invasive carcinoma. Progression is typified by an
increase in the size of the tumour, invasion into deeper tissue layers and metastasis to other
distant tissues.
Table 1.2: The Vienna classification for gastrointestinal epithelial neoplasia
Category 1 Negative for dysplasia/neoplasia
Category 2 Indefinite for dysplasia/neoplasia
Category 3 Non-invasive low-grade neoplasia (low-grade dysplasia/adenoma)
Category 4 Non-invasive high-grade neoplasia
4.1 High-grade dysplasia/adenoma
4.2 Non-invasive carcinoma (carcinoma in situ)
4.3 Suspicion of invasive carcinoma
Category 5 Invasive neoplasia
5.1 Intramucosal carcinoma
5.2 Submucosal carcinoma or beyond
The overwhelming majority (> 95%) of colonic neoplasia arises from transformed colonic
epithelial cells [132]. In the sequence proposed by Fearon and Vogelstein, colonic ade-
nocarcinoma arises from a benign, dysplastic precursor lesion (Fig. 1.2) [133]. Dysplasia
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is by nature a broad term as it includes a range of architectural and cytological changes
indicative of pre-cancerous change. The most commonly encountered dysplasia in the colon
is the polypoid epithelial outgrowth often referred to as an ’adenoma’ [132]. Dysplastic
lesions display increasing complex architectural abnormalities as the constituent cells ac-
quire additional oncogenic mutations. Grading the degree of architectural and cytological
change therefore reflects the risk of progression to malignancy [134]. While the progression
from non-dysplastic mucosa to dysplasia and onward to carcinoma, is preserved in UC, the
morphology of colitis-associated dysplasia is more varied. While 80% of dysplastic lesions
in patients with UC present as raised polypoid lesions, an additional 20% of display a ”flat”
non-polypoid morphology [135]. Raised, non-invasive polyps are readily detected during
standard endoscopy, and removed via endoscopic mucosal resection with minimal risk of
recurrence. Due to the lack of a raised lesion projecting into the lumen, flat dysplasia is
difficult to detect reliably in the inflamed colon without the use of chromoendoscopy [136].
Additionally, patients with IBD are also more likely to present with multifocal dysplasia, a
factor that when coupled with flat morphology suggests an exceptionally aggressive course
of disease [136]. Given the propensity of flat dysplasia for rapid progression to carcinoma, a
deeper understanding of the mechanisms that initiate or promote the early stages of colonic
carcinogenesis would be advantageous for future management of IBD.
1.4.1 Oxidative stress
Chronic inflammation is associated with the production of a large volume of harmful reactive
oxygen species (ROS) and reactive nitrogen species (RNS). Both of the terms ROS and
RNS encompass a range of free radicals and their intermediates. The ROS include the
radicals superoxide anion (O2
•-), hydroxyl (•OH), peroxyl (RO2
•) and alkoxyl (RO•) and
oxygen-derived intermediates singlet oxygen (O2), ozone (O3), hydrogen peroxide (H2O2)
and hypochlorous acid (HOCl) [138]. The RNS are predominantly derived nitric oxide (NO)
and its nitrosyl radical (•NO and ions — nitroxyl (NO-) and nitrosonium (NOS+). From
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Figure 1.2: Sequence of key genetic mutations in the pathogenesis of sporadic and
colitis-associated neoplasia. Sporadically occurring (top) and chronic colitis-associated
(bottom) pathways share a similar progression through dysplastic precursors (predominantly
adenoma in sporadic cases) to invasive carcinoma. Both pathways display differences in
the timing and frequency of the key oncogenic gene mutations. In the sporadic pathway
inactivating mutations in adenomatous polyposis coli (APC) alleles are associated with early
adenomatous dysplasia. Mutations in the Kirsten rat sarcoma viral oncogene (KRAS), are
associated with more intermediate stages of dysplasia, while deleted in colorectal carcinoma
(DCC) and homozygously deleted in pancreatic cancer, locus 4 (DPC4) are more freqent
in advanced adenoma. Transformation-related protein 53 (TP53, p53) mutations are also
associated with progression to carcinoma. In contrast, mutations in the transformation-
related protein 53 (TP53) frequent in the non-dysplastic, chronically inflamed epithelium
in UC. DCC/DPC4 mutations also occur earlier, associated with early stages of dysplasia,
whereas KRAS and APC mutations are rare comparative to the sporadic pathway and occur
in advanced dysplasia/carcinoma. Chromosomal instability and aneuploidy or microsatellite
instability (MSI) may occur at any time, potentially accelerating the acquisition of further
genetic mutation. Methylation of gene promoter regions have been observed in sporadic
dysplasia but are also active in the chronically inflamed colonic epithelium, suggesting that
these may initiate colitis-associated colorectal carcinogenesis. Adapted from Ullman and
Itzkowitz (2011) [137]
these nitrogen radicals intermediates including nitrite (NO2
-), peroxynitrite (OONO-) and
nitrogen oxides (•NO2, N2O3, N2O4) may be generated through interactions between NO
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and oxygen or its derivatives. Formation of ROS and RNS are primarily dependent on the
activity of reduced nicotinamide diphosphate (NADPH) oxidases (collectively called NOX
enzymes) and nitric oxide synthase (NOS) enzymes respectively. A number of NOX family
members have been identified in wide range of human tissues and cell types [138]. Most
widely distributed of the NOX family is NOX2, due to it being predominantly expressed
by phagocytes, regardless of tissue compartment. While most NOX enzymes are found
in phagocytes or neurones and endothelium, NOX1 is notable for its abundance in the
colonic epithelium [139, 140]. The NOS enzymes can be divided into four isoforms based
on their distribution — neuronal NOS (nNOS, NOS-1), iNOS (NOS-2), endothelial NOS
(eNOS, NOS-3) and mitochondrial NOS [141]. The nNOS and eNOS isoforms are thought
to be constitutively active and are restricted to certain cell types. Large increases in RNS
production must therefore arise due to increased activity of the inducible isoform iNOS,
which may be induced in most cell types provided with sufficient stimulus. While production
of ROS and RNS may provide important cues for diverse processes such as cell proliferation,
apoptosis and iron metabolism, these reactive species are crucial to inflammatory processes.
The ability to generate ROS and RNS is of considerable advantage to mucosal defence.
Animals deficient in either ROS or RNS are susceptible to Salmonella infection under
experimental conditions [142–144]. Inhibition of ROS/RNS production attenuates the
mucosal damage induced by chemical agents in animal models of chronic colitis, suggesting
that ROS/RNS generation is also crucial for perpetuating leukocyte recruitment and the
resultant inflammation [145, 146]. Therefore ROS and RNS may either directly or indirectly
limit the ability of bacterial pathogens to invade the intestinal mucosa. Both NADPH oxidase
and iNOS are expressed intracellularly by phagocytes, though neutrophils show higher
levels of ROS production than that observed in activated macrophages [141]. In contrast,
macrophages display greater production of RNS than neutrophils. Production of superoxide
and its derivatives from phagocytes may generally be elicited immediately the through
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assembly of existent NOX subunits to form an active enzyme complex [147]. In contrast,
RNS production via iNOS requires de novo synthesis of the enzyme. Increased transcription
of iNOS may be induced by common pro-inflammatory triggers including bacterial LPS,
interferon-γ (IFN-γ), TNF-α, interleukin-1β (IL-1β), presumably through the activation of
mitogen-activated protein kinase (MAPK), JAK-STAT-IRF and NF-κB pathways [148, 149].
Within phagocytes the generated NO·, superoxide and hydrogen peroxide may readily diffuse
through bacterial and fungal cell walls, where they inhibit normal microbial metabolism and
cellular replication by damaging essential proteins and DNA [150–152]. Generation of both
ROS and RNS by leukocytes and their release into the extracellular environment therefore
forms an inflammatory process important for limiting microbial invasion into host tissues.
Besides their direct antimicrobial effects of ROS and RNS, these reactive species may also
serve as key signalling events in the regulation of colonic mucosa. High levels of NOX1
expression in the colonic epithelium, particularly in the distal colon, co-incides with the high
bacterial load in the lumen and mucous layer. Naturally, epithelial NOX1 is not constitutively
active, and requires the ligation of PRRs like TLR5 to trigger its activation [153]. The
function of ROS produced by the colonic epithelium may fulfill a second line of defence
for microbes which manage to penetrate the inner colonic mucous layer. Production of
ROS by NOX1 and dual oxidase (Duox; another NOX family member) may serve as a
signal promoting the synthesis of serotonin from enterochromaffin cells thereby altering
intestinal secretion and motility, perhaps promoting bacterial clearance [154]. Additionally,
NOX/Duox-derived ROS in the colonic epithelium has been shown to precede activation of
the NLRP6 inflammasome and Muc2 exocytosis, thereby maintaining the thickness of the
mucous layer [155].
Conceivably, chronic exposure to microbial antigen could permit an accumulation of ROS
and RNS from both phagocytes and the colonic epithelium, perhaps contributing to the
pathogenesis of UC. Where ROS/RNS production overwhelms the ability of cells to limit
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their damaging effects, a scenario referred to as ”oxidative stress” arises [156]. Consistent
with chronic immune activation, the colonic mucosa of patients with active UC displays an
increased synthesis of iNOS, higher even than that detected in CD and concomitant increases
in peroxynitrite formation [157, 158]. Defective regulation of ROS or RNS may over time
result in the accumulation of excessive amounts of intracellular damage, perhaps permitting
genetic mutation and neoplastic transformation.
Given the broad range of metabolic processes that are disrupted by ROS/RNS produced
in chronic colitis, it may be unsurprising that these radicals have also been associated
with colitis-associated carcinogenesis. The inflammatory micro-environment features an
abundance of NO and ROS, facilitating the formation of NO-derived oxides, particularly
N2O3. Nitrogen oxides are capable of modifying a broad range of biological molecules.
Cysteine and haem are both subject to nitrosylation or nitrosation. The sulphur groups
common to cysteine and methionine are also vulnerable to oxidation. Both the peptidyl-ring
carbons in tyrosine and tryptophan, and the carbon of fatty acids are targets for nitration.
Nucleic acids may also be modified by oxidation or deamination by NO and intermediates
Hydroxyl and peroxynitrite radicals produced during inflammation attack deoxyguanosine
within both chromosomal and mitochondrial DNA, forming 8-hydroxyldeoxyguanine (8-
OHdG). Abnormal accumulation of nuclear 8-OHdG is detectable in the colonic epithelium
is detectable in the chronically inflamed colon of patients with UC [159]. Failure to remove
8-OHdG prior to synthesis of the complementary DNA strand, potentially results in guanine
(G) to thymine (T) G→T transversion mutations in the position of the modified base [160].
Superoxide and NO-derived N2O3 causes deamination of nucleotides to uracil, xanthine and
hypoxanthine [161, 162]. Peroxynitrite is also capable of introducing transversion mutations
in vitro through nitration of guanine [163]. Furthermore, peroxynitrite is also capable of
causing single-stranded DNA breakages [164]. Accumulation of ROS/RNS in the colonic
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mucosa during active UC could therefore be expected to introduce the aforementioned DNA
modifications, and eventually DNA mutation.
While DNA modifications induced by ROS/RNS may introduce mutations into the genome,
these may be repaired through DNA repair mechanisms. Base-excision repair is perhaps the
most important pathway for the repair of ROS/RNS-induced DNA damage [165]. Conceiv-
ably, inactivation of BER mechanisms would permit the accumulation of DNA mutation
due to ROS/RNS present in chronic inflammation. The first step of BER requires the
removal of inappropriate bases by lesion-specific DNA glycosylases [165]. The primary
DNA glycosylase involved in the excision of 8-OHdG bases is the MutY human homologue
(MutYH), mutations of which have been associated with inherited colon neoplasms [166].
Immunohistochemical analysis of MutYH and 8-OHdG in the colonic mucosa of patients
with UC has indicated levels of MutYH are reduced as oxidative DNA damage increases
during chronic inflammation [159]. The absence of MutYH mutations in the colonic mucosa
of patients studied by Gushima et al. suggested an alternate mechanism for the inactivation
of DNA repair. In addition to their effects on nucleic acids, ROS/RNS have a range of
deleterious effects on proteins. Peroxynitrites are capable of oxidising sulfhydryl and thiol
groups, inactivating catalytic domains of various enzymes. Importantly, ROS/RNS have been
demonstrated to inhibit the removal of oxidative DNA lesions by BER mechanisms. The
8-oxoguanine-excising DNA glycosylase OGG1 and the O6-methylguanine DNA methyl-
transferase which excises alkylated bases from chromosomal DNA, are both known to be
inhibited by NO-derived species [167,168]. Experimental evidence from genetic ablation
of the murine Ogg1 DNA glycosylase supports the notion of a prolonged colitis-induced
oxidative stress as an initiating factor in carcinogenesis. Long-term administration of a
colitogen in Ogg1-deficient mice produced colonic tumours in over half of the exposed
animals compared to 24% of wild-type animals [169].
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1.4.2 TP53 mutation
Transformation-related protein-53 (often simply referred to as p53), encoded by human TP53
and Trp53 in mice, is a central regulator of cellular metabolism and an important tumour
suppressor [170]. Loss of heterozygosity and p53-inactivating mutations are common in
cancers arising from a variety of tissues, indicating that repression of p53 confers some
survival advantage to the growth of neoplastic cells. Allelic deletion in the gene encoding
p53 has been reported in approximately 50-85% of colitis-associated neoplasia [171, 172].
Mutations in TP53 appear in the chronically inflamed mucosa of patients with UC preceding
the appearance of dysplasia [173]. UC-associated dysplasia and UC-associated carcinoma
displayed frequent mutations and loss of heterozygosity (76% and 83% respectively) [174].
Wild-type p53 may protect against DNA damage induced by ROS/RNS production by
repressing iNOS transcription, thus preventing the accumulation of oncogenic mutations
in the mucosa of patients with UC [175]. However, an over-abundance of the ROS/RNS
in colitis may over time, inactivate p53 through direct DNA damage in the TP53 locus. In
support of this hypothesis, certain TP53 mutations found in the colonic tumours in IBD
patients are infrequent in sporadic neoplasms. Notably, G→T tranversions similar to those
commonly induced by ROS have been reported in key tumour suppressor genes associated
with colonic carcinoma, including TP53 [173]. Higher frequencies of G→T and cytosine (C)
to adenine (A) C→A mutations in TP53 have also been observed in the inflamed UC mucosa
when compared to paired uninflamed mucosa or to uninflamed non-IBD mucosa [173].
Mutation of TP53 would therefore be expected to much more frequent in UC-associated
carcinoma than the rate of TP53 mutation in sporadic cancers. However, recent whole-
exome profiling suggests that the rates of TP53 mutation may be equivalent between the
two pathologies. Studying invasive carcinoma alone indicated that approximately 60% of
IBD-associated carcinoma possessed genetic mutation of the gene encoding p53, a rate
similar to that observed in sporadic CRC [176].
1.4. INITIATION OF CARCINOGENESIS 34
1.4.3 Chromosomal instability
Genomic instability is thought to be a process involved early in the progression from
chronic colitis to colonic neoplasia. Abnormally high rates of chromosomal mis-segregation
arising due to defective chromosomal alignment during mitosis, are commonly found in
tumour cells and may introduce point mutations such as nucleotide insertion, substitution
and deletion mutations [177]. Translocation, inversion and loss of chromosomal segments
may cause inactivation of tumour suppressor genes, permitting dysregulated cell growth.
Conversely, over-expression of genes favouring cell survival may occur due to amplifications
of chromosomal segments. Chromosomal alterations have been reported in the non-dysplastic
mucosa of 36% of colectomy specimens obtained from patients with UC [178]. Furthermore,
non-dysplastic tissue from two of the five patients displaying chromosomal instability and
43% of dysplastic tissue, also exhibited a loss of either the long arm of chromosome 18
(18q) or the entire chromosome 18. Loss of chromosome 18 or the 18q locus would abolish
transcription of the genes encoding DCC, SMAD2 and SMAD4 (DPC4), all of which
suppress tumour development [179]. Loss of chromosomal segments would therefore be
thought to result in a loss of heterozygosity in the 18q tumour suppressor genes. Despite the
reported frequency of abnormalities in this region, mutations in DCC and SMAD4 appear
to be relatively rare in early in IBD-associated tumourigenesis [180–182]. Chromosomal
instability may be a cause of DNA aneuploidy, i.e. an imbalance in chromosome number.
Aneuploidy is observed in 60–70% of sporadic CRC cells, with most aneuploidy involving
chromosomes 20q and 18q [183]. Cytometric assessment in UC-associated neoplasia
has associated frequent aneuploidy with dysplasia and carcinoma [184, 185] increases in
aneuploidy. DNA aneuploidy appears to be strongly associated with neoplasia, with little
aneuploidy detectable in non-dysplastic mucosa, but >80% of UC-associated dysplasia and
carcinomata also displayed aneuploidy [184]. Abnormal shortening of telomeres reportedly
co-incides with chromosomal instability and DNA aneuploidy in the colonic epithelium in
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patients with UC [186, 187]. Accelerated shortening of telomeres in UC may permit losses
of chromosomal segments and thus initiate neoplasia in long-standing chronic colitis [188].
However, chromosomal instability can only arise if DNA damage checkpoints or repair
mechanisms are inhibited. Excessively short telomeres will induce replicative senescence
through activation of wild-type p53 [189]. Mutation within TP53 however, may therefore
permit colonic epithelial cells in UC to proliferate despite excessive telomere shortening,
resulting the accumulation of chromosomal abnormalities and further genetic mutations,
thereby initiating neoplasia
1.4.4 Microsatellite instability
Microsatellite instability (MSI) describes small deletions or expansions of short (mononu-
cleotide to tetranucleotide) tandem repeats in the DNA. Microsatellites are prone to replica-
tion errors and have the potential to introduce frame-shift mutations if they are not repaired
prior to replication [190]. Repair of the incorrectly paired bases is performed primarily
by DNA mismatch repair (MMR) enzymes and thus high levels of MSI are considered
diagnostic of defective MMR mechanisms. Silencing of gene transcription or inactivating
mutations within the MMR genes MLH1 and MSH2 produce the high-level MSI (MSI-H)
phenotype associated with the hereditary non-polyposis CRC syndrome [191]. Neoplasms
arising in the distal colon of patients with UC seldom display high levels of MSI (MSI-H).
Analysis of MSI in colectomy specimens from 14 UC patients identified MSI-H dysplasia
and carcinoma from two patients [178]. A MSI-H phenotype has been reported at frequencies
between 0.7–17% in UC-associated neoplasia [192–195]. More recent analysis of MSI in the
laser-dissected colonic epithelium obtained from patients with UC revealed that the majority
of samples displayed low-level MSI (MSI-L) [196]. However, expression of MLH1, MSH2
and MSH6 was not impaired in the MSI-L colonic epithelium in the UC mucosa, suggesting
that if MMR activity is impaired, then this may occur through post-translational modification
of repair enzymes by ROS/RNS.
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1.4.5 Gene promoter methylation
In addition to genetic alterations described in this review, changes at the ”epigenetic” level
may also influence the transition from chronic colitis to neoplasia in IBD. Epigenetics,
here is used to refer to both inerited and non-inherited modifications to the DNA molecule
including DNA methylation, non-coding RNA and histone modification. Promoter regions
of many genes display enrichment of C-phosphodiester-G (CpG) DNA sequences. CpG
islands can be defined as 500–2000 bp long fragments of DNA within which CpG make up
more than 50% of the base pairings with an observed:expected CpG ratio of greater than
60% [191]. Methylation of the cytosine residues may therefore negatively affect the binding
of transcriptional enhancers and polymerases to suppress transcription of genes downstream
of the promoter region. Hypermethylation of tumour suppressor gene promoter regions
may therefore act as a substitute for genetic mutation in the same gene, thus promoting
carcinogenesis. Study of the rectal mucosa of patients with predominantly pan-colitic
UC has previously revealed a 10-fold higher amount of unmethylated CpGs than that
observed in the non-IBD rectal mucosa [197]. Although DNA hypomethylation increased
as inflammation increased in severity, the amount of hypomethylation remained almost
8-fold higher in inactive disease relative to non-IBD controls. Global hypomethylation is
similarly reported in sporadic CRC suggesting that this feature may may be involved in the
progression of colitis to neoplasia [198]. Cytosine methylation is maintained by the DNA
cytosine-5-methyltransferase-1 (DNMT1), whose expression positively correlates with the
progression to dysplasia and carcinoma in UC [199,200]. Despite an reduction in methylation
overall, hypermethylation of specific promoter regions may predispose individuals with
long-standing UC to colonic cancer. A positive relationship between p16 and p14 promoter
hypermethylation and the progression of UC-associated neoplasia [201, 202]. Additionally,
the promoter of the gene encoding E-cadherin (CDH1) displayed methylation in 93%
of dysplasia specimens obtained from long-standing UC as opposed to just 6% of non-
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dysplastic mucosa and 0% of non-IBD controls [203]. Comparison of promoter methylation
between UC-associated neoplasia and sporadic cancers has indicated lower methylation of
the O6-methylguanine-DNA-methyltransferase (MGMT), MLH1, both CDKN2A p16 and
p14, oestrogen receptor-α and SFRP1 promoters in UC-associated carcinoma relative to
sporadic CRC [204, 205]. UC-associated neoplasms seem unlikely to possess the ’CpG
island-methylator phenotype’ characterised by frequent methylation of MMR genes such as
MLH1 and the tumour suppressor CDKN2A [206]. DNA methylation in UC is therefore a
potential mechanism by which neoplasia is initiated and/or promoted in the absence of key
oncogenic genetic mutations.
1.4.6 Wnt signalling pathway
The structure of the colonic crypt is organised such that the rates of cell division and cell
death are tightly regulated. Proliferation of colonic epithelial cells is determined by a
number of signalling pathways involving interactions with the surrounding epithelium and
basement membrane. The Wingless/int-1 (Wnt) pathway is a critical signalling pathway that
directs proliferation and differentiation of the colonic crypt cells within the crypt structure.
Since dysplasia are identifiable due to their abnormal crypt morphology, where perhaps
an uncontrolled proliferation produces outgrowth of the crypt structure, subversion of the
Wnt pathway may precede carcinoma. The adenomatous polyposis coli gene (APC) earns
its name from the familial adenomatous polyposis disorder (FAP) a disorder in which
patients inherit a germ-line APC inactivation mutation, and as a result, are predisposed to
the development of large numbers of benign colonic adenomata. Although the majority
of dysplastic lesions arising from the un-inflamed colon display APC mutations, colitis-
associated dysplasia and even the resultant carcinomata display comparatively fewer APC
mutations [207]. The relatively high frequency of APC mutation in sporadic dysplasia
may be explained by the essential negative regulation on cell-cell contact-dependent cell
proliferation that APC provides. The cell-surface protein E-cadherin is an essential mediator
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of epithelial cell polarity and proliferation [208]. Homotypic interactions between E-cadherin
molecules on adjacent epithelial cells determine the activity of several proteins associated
with the cytoplasmic terminal of E-cadherin. One such protein is β-catenin, which in the
absence of E-cadherin binding the E-cadherin of neighbouring cells, is released into the
cytoplasm and relocates to the cell nucleus, where it acts as a transcription factor. The
APC gene product, together with axin and GSK-3β, forms a protein complex capable
of phosphorylating the N-terminal serine/threonine residues of β-catenin [209]. Rapid
phosphorylation, ubiquitinylation and subsequent proteasomal degradation limits the amount
of active β-catenin that may be transported to the nucleus. Nuclear β-catenin activates
TCF/LEF transcription factors and enhanced transcription of cyclin-D1 (CCND1) and
myelocytomatosis oncogene c-Myc (MYC) which in turn increases cellular proliferation
[210, 211]. Mutation of APC would thus assist in the acquisition of the ability for epithelial
cells to proliferate irrespective to adjacent cell contact, and could conceivably account for the
exophytic pattern of growth in sporadic colonic dysplasia. Alteration to the Wnt-β-catenin
pathway is thought to occur early in adenoma formation and is thus believed to be an
important initiating step in colonic carcinogenesis, allowing accelerated accumulation of
further mutations. Despite the lack of APC mutations in IBD-associated neoplasia, mutations
elsewhere in the Wnt pathway are not absent entirely. Indeed, mutations in genes elsewhere
in the Wnt/β-catenin signalling pathway such as SOX9, FZD8, AXIN1 and TCF7L2, may
account for the lack of APC mutations IBD-associated cancers [176]. Alternatively, transient
cytokine signalling via (NF-κB or STAT3) may increase β-catenin may instead circumvent
the need for APC or Wnt/β-catenin mutations [212, 213].
Similarly to sporadic CRC, IBD-associated colorectal cancers are mostly adenocarcinomata
[132]. Mucinous carcinomas compose a large proportion of the carcinoma phenotypes
arising from IBD, up to 50% estimated by some studies. Signet-ring cell carcinomas are
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more numerous, perhaps ten-fold more common in patients with IBD compared to the
general population.
1.4.7 SMAD4
Mutation or deletion of SMAD4 (DPC4) has been associated with sporadic colorectal
carcinoma [214] The role of the SMAD4 mutation in the progression of sporadic colorectal
carcinoma appears to be significant in advanced neoplasms. Immunohistochemical analysis
of SMAD4 expression indicated that decreased or complete loss of SMAD4 expression
was frequent in sporadic CRC but rare in normal mucosa [215]. Stratification of colorectal
neoplasms into adenoma and invasive carcinoma (stage I-IV) has revealed the timing of
SMAD4 loss of heterozygosity or deletion in the sporadic carcinogenesis. Analysis of 115
sporadic colorectal neoplasms indicated that SMAD4 mutation was absent in sporadically-
occurring colorectal adenomata and early stage invasive carcinoma [216, 217]. SMAD4
mutations became more common as cancer progressed to metastasis, with 31% of tumours
with distant metastases exhibiting SMAD4 mutations [216]. These findings suggest that loss
of SMAD4 expression may promote metastasis in colorectal adenocarcinomata. SMAD4
is a transcription factor involved in the transduction of TGF-β signalling via the TGF-β
receptor. Loss of SMAD4 expression in colorectal neoplasms has been correlated with a loss
of E-cadherin expression, potentially facilitating detachment from neighbouring epithelial
cells and metastasis to other sites [218, 219]. Of particular interest is the occurrence of
SMAD4 mutations in colorectal neoplasms exhibiting MSI. Primary colorectal carcinomas
and CRC cell lines displaying MSI rarely show evidence of abnormal SMAD4 expression
[215, 220]. Lei et al. did not observe SMAD4 mutation in a series of ten colitis-associated
carcinomas [181]. Similarly Hoque et al. did not observe SMAD4 mutation in a series of
five carcinomas resected from patients with UC- or CD-associated carcinomas [221]. In
contrast to the results from carcinomas one specimen of HGD was also analysed which was
positive for SMAD4 mutation. Hoque et al. included neoplasms from various locations
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in the colon and rectum. Therefore SMAD4 mutations are unlikely to active in the early
tumourigenesis in the IBD-associated neoplasia.
1.5 Animal models of UC
Replication of carcinogenesis in patients with UC would ideally involve the spontaneous
onset of a relapsing and remitting chronic colitis and an increased rate of colonic neoplasia.
Chemicals such as dextran sodium sulphate (DSS), and the hapten, 2,4,6-trinitrobenzene
sulphonic acid (TNBS), are commonly used to induce acute and chronic colitis. Colitis
induced by either DSS or TNBS differs in their induced immunopathology and histopathol-
ogy. DSS is considered to produce an inflammation more reminiscent of human UC, where
tissue damage is mostly restricted to the colonic mucosa, whereas TNBS will often induce
transmural damage.
1.5.1 Dextran sulphate sodium
Colitis induced by dextran sodium sulphate (DSS) is perhaps, at present, the most widely
used experimental model of chemically-induced colitis. Similar to heparin, DSS is composed
of heavily sulphated polysaccharide polymers of varying lengths, and may be separated into
high and low molecular weight fractions. Analysis of the colitogenic properties of three
different molecular weights of DSS; 5 kDa, 40 kDa and 500 kDa showed that the resultant
inflammation differed according to their weights [222]. Polymers were of 40 kDa mass
produced the more severe inflammation of the distal colon while distal colonic inflammation
was mild or absent in the other fractions studied. DSS is conveniently administered through
the drinking water, typical for a period of 5–7 days to simulate acute inflammation, or
administered in a cyclic fashion to instead simulate chronic colitis [223]. Chronic colitis
is typically induced through administration of a cyclic regimen of 5–7 days oral DSS
challenge, followed by a longer 5–14 day recovery period. Similar to UC, DSS-induced
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colitis is most severe in the distal colon, which displays extensive crypt and epithelial cell
damage accompanied by infiltration of numerous neutrophils among other leukocytes into
the intestinal mucosa, tissue oedema and severe ulceration [224]. Concordant with DSS-
induced injury in the colon mice undergoing prolonged DSS challenge will exhibit weight
loss, loose stools and diarrhoea, and rectal bleeding. Cessation of DSS administration will
however, permit a gradual repair of mucosal damage and result in a remission of symptoms.
Whether complete recovery from repeated bouts of DSS-induced colitis is achieved in every
case is questionable. Since duration and severity of chronic colitis in human patients with
UC is associated with an increased risk of colonic neoplasia, it would stand to reason that
mouse models of colitis would be similarly predisposed. Epithelial dysplasia in the inflamed
colon of mice exposed to repeated bouts of DSS administration over an extended period
induce [225, 226].
It has been suggested that DSS has a direct cytotoxic effect on intestinal epithelial cells,
effectively abrogating intestinal barrier function and thereby facilitating exposure to com-
mensal microbes [227, 228]. Although some evidence for a direct toxic effect exists [229],
DSS-induced inflammation is likely initiated by penetration of the normally sterile colonic
inner mucous layer in mice has been demonstrated to precede colonic inflammation [100].
Through as yet unknown mechanisms, DSS is capable of rapidly altering the structure of
the inner colonic mucous layer, thereby allowing the passage of beads of 0.5 μm and 2
μm in diameter through the inner mucous layer and into intimate contact with the colonic
epithelium [230]. That DSS-induced inflammation is concentrated in the distal colon where
the dependence on Muc2 for formation of the colonic mucus is highest would suggest that
DSS may interact directly with Muc2. Luminal commensals and pathogenic bacteria resident
in the outer colonic mucus thus come into contact with the colonic epithelium and mucosal
immune cells thereby stimulating pro-inflammatory immune responses. The ability for DSS
to permeabilise the inner colonic mucous layer to the luminal microflora would explain the
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lack of a requirement for the adaptive immune involvement in DSS-induced colitis. While
T-lymphocytes are deemed critical to the colonic pathology in IBD, injury induced by DSS
has been shown to occur independent of functional T and B lymphocytes [231, 232]. Since
deficiency in either B-lymphocytes or T-lymphocytes still permits the induction of colitis by
DSS, it seems likely that DSS-induced injury is primarily derived from the mucosal innate
immune system in response to increased bacterial products within the mucosa [233].
Dependence on the non-specific luminal microflora is perhaps the accounts for the the
necessity to optimise the concentration of DSS administered different mouse strains. For
example C57BL/6 mice are more susceptible to chronic inflammation induced after 3–5
cycles of DSS recovery as opposed to BALB/c mice [234]. As a result variable concentrations
of DSS are reported in the literature, as are the length and number of DSS cycles employed.
Table 1.3: Colitis-associated neoplasia in DSS-induced murine models
Strain Mutation Treatment Duration References
SWR WT 5% 7 days of DSS, 14 days recovery,
variable timepoints
[225]
C57BL/6J WT 4% 4 cycles of 4 days DSS, 12 days
recovery
[235]
CBA/J WT 3% 9 cycles of 7 days DSS followed by
14 days recovery
[226]
C57BL/6J WT 2.5% 12 cycles of 7 days DSS followed
by 10 days recovery
[236]
C57BL/6J WT 0.7% 15 cycles of 7 days DSS followed
by 10 days recovery
[237]
C57BL/6J WT 0.1%-0.4% 60 days [238]
1.5.2 Interleukin-10
IL-10 is a key cytokine that is responsible for immune tolerance in the intestinal mucosa.
IL-10 is produced by T-lymphocytes, macrophages, some B-lymphocytes, dendritic cells and
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thymocytes. IL-10 is a cytokine that regulates both innate and adaptive immune functions
by inhibiting macrophage function and also inhibiting TH1 responses. IL-10-deficient mice
spontaneously develop an inflammation involving both the colon and small intestine by
the age of two months [239]. Histological features of the Il10-/--associated colitis included
epithelial hyperplasia with crypt abcesses accompanied by leukocytic infiltrates in the
mucosa and submucosa [239]. Notably, inflammation in Il10-/- mice occurred despite being
maintained in specific pathogen-free conditions. Although avoidance of specific pathogens
was unsuccessful in preventing intestinal inflammation associated in Il10-/- animals, the
ability of antibiotics to ameliorate the disease suggested that inflammation was likely
triggered by an abnormal reaction to commensal microbes [240]. The notion that an
Il10-deficiency triggers a non-specific immune response against the resident microbiota
is supported by the permeability of the colonic mucus to bacteria-sized material in Il10-/-
mice [100]. Though IL-10 is an immunoregulatory cytokine, recent evidence suggests that
it has an essential function in mucus production and secretion directly through IL-10R1
expression by colonic goblet cells [241]. Therefore, the Il10-/- mouse likely represents a
model of IBD where a defect in mucus biosynthesis precipitates a chronic immune response
directed against luminal commensals. Considering that Il10-/- produces extensive colitis, it
may be expected that these mice are susceptible to colonic cancer. Twenty-five percent of
Il10-/- mice from a C57BL6 ×129OLa background developed adenocarcinoma after three
months of age [239]. The incidence of adenocarcinoma in Il10-/- animals increased with age,
with 60% of animals presenting with adenocarcinoma after six months.
1.5.3 Mdr1a
The multi-drug resistance protein gene Mdr1a (ABCB1 in the human, the murine ortho-
logues being Abcb1a and Abcb1b) encodes an ATP-binding efflux transporter protein with a
possible role in the regulation of luminal bacteria in IBD. Mdr1a expression in the murine
intestine is limited primarily to the apical surfaces of differentiated intestinal epithelial
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cells, and a population of mucosal leukocytes [242]. Pharmacological inhibition of Mdr1a
function has been shown to permit emhanced bacterial attachments to the apical surface of
immortalised colonic epithelial cell monolayers in vitro [243]. When housed in specific
pathogen-free conditions, mice with homozygous Mdr1a ablation spontaneously developed
a severe pan-colonic inflammation by the average age of 20 weeks [242]. The colitis in-
duced by Mdr1a deficiency resembled the histopathology of UC, featuring enlarged crypts,
leukocytic infiltration, crypt abscesses and ulceration. Consistent with the function of Mdr1a
in inhibiting bacterial colonisation of the colonic epithelium, colitis induced by Mdr1a
deficiency is ameliorated by antibiotic therapy [242]. Providing still further evidence for
increased exposure to commensal bacteria, cells isolated from colonic lymphoid tissue
of the Mdr1a-deficient animals displayed a heightened proliferative response to bacterial
antigens. Supporting a possible role for Mdr1a dysfunction in human IBD, the abundance
of human Mdr1a transporter has been shown to decrease as disease severity increases in
UC [244]. Despite the correlation between Mdr1a expression and active inflammation in
UC, it remains unclear whether down-regulation occurs primary to colitis or whether is
Mdr1a down-regulated by the inflammation. Of particular relevance is the observation
that Mdr1a deficiency in the ApcMin/+ mouse has been shown to reduce the formation of
intestinal polyps [245]. Homozygous Abcb1 gene deletion reduced tumour multiplicity by
up to 50% in the small intestine and colon of ApcMin/+ mice. This result runs counter to the
reasoning that chronic inflammation predisposes the inflamed tissue to neoplasia. Given the
broad range of substrates which utilise the Mdr1a efflux transporter, further exploration of
these substrates may explain the apparent paradox in the induction of colitis and subsequent
neoplasia.
1.5.4 Gαi2
The α subunit of the inhibitory GTP-binding protein Gi2 (Gαi2) protein is expressed in many
cell types including intestinal epithelial cells and intestinal lymphocytes. Deficiency of Gαi2
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in 129SvEv genetic background mice produces a progressive chronic inflammation in the
intestine by the age of 8–12 weeks [246]. The disease associated with Gαi2-deficiency is
characterised by mucosal ulceration, crypt abscesses and mucin depletion, with the most
severe symptoms in the distal colon. Interestingly, Gαi2-deficiency exhibit an abnormal
adaptive immune response to the luminal microbiota and a greater resistance to suppression
by regulatory T-lymphocytes [247, 248]. Consistent with the chronic, progressive colitis,
approximately 30% of Gαi2-deficient mice develop non-polypoid, colonic adenocarcinoma
by the age of twelve weeks, with colonic dysplasia visible in 50% of mice as early nine
weeks [246, 248].
1.5.5 Muc2
Velcich et al.. described a truncating mutation in Muc2 (C57BL6/J ×129SvOla background)
that produced a total abrogation in Muc2 synthesis [99]. Associated with the abolition of
Muc2 was the disappearance of the characteristic acidic polysaccharide-containing granules
that identify the goblet cell. While heterozygous Muc2 mutants (Muc2-/-) displayed normal
weight gain, but displayed occult bleeding indicative of erosive intestinal disease. Homozy-
gous gene deletion of the gene encoding mucin-2 Muc2 produces a spontaneously occurring
phenotype characterised by weight loss, diarrhoea, intestinal bleeding [249]. Histological
examination of Muc2-/- reveals immune cell infiltration, loss of goblet cells, crypt elongation
and superficial ulceration of the mucosa [249]. Ectopic expression of the Muc6 gastric
mucin was reported in the colon of mice with homozygous Muc2-/-.
Unlike wild-type mice, Muc2-/- mice displayed a crypt hyperplasia and infrequent exophytic
epithelial tumours, some invasive, throughout the small and large intestine. Notably, tumours
arising in the colon in Muc2-/- mice were infrequent relative to those of the small intestine.
Of the 21% of Muc2 mutants that had developed colonic tumours by the age of 12 months,
only one mouse was reported to have multiple colonic tumours.
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1.5.6 Winnie
Of particular interest for the study of UC is Winnie strain of mice which harbour a single-
nucleotide, missense mutation in the Muc2 gene that encodes a full-length protein. Missense
mutation in the Muc2 D3 domain of Muc2 inhibits oligomerisation of Muc2 and would
therefore reduce the effectiveness of the secreted colonic mucus in excluding the luminal
microbiota from the colonic epithelium [250]. Misfolded Muc2 also accumulates within
the secretory goblet cells of the colonic epithelium and subsequently leads to activation of
the unfolded protein response (UPR) and endoplasmic reticulum (ER) stress [250]. The
combination of ER stress and a defective secreted mucus in Winnie is associated with a colitis
affecting the middle and distal colon, producing diarrhoea. The colitis in Winnie mice shares
some of the same histological features of UC with mucin depletion, crypt branching and
elongation and focal neutrophilic crypt inflammation and the formation of crypt abscesses
[250]. Likewise, the immunopathology in the Winnie colon is characterised by expansion of
CD11c+ APCs and activated DCs (CD11c+ MHC-IIhi) with TH17 polarisation of mucosal
immune responses [251]. Mucosal barrier dysfunction in the Winnie mouse results in a
complex colitis involving both an innate immune element and a TH17-mediated adaptive
immune response similar to the cytokine profile observed in patients with IBD [123]. While
Muc2-deficient animals are prone to intestinal neoplasia, the susceptibility of Winnie mice
to colonic neoplasia remains unclear.
1.6 Aims and hypothesis
Evidence for the tumour-promoting effects of various pro-inflammatory mediators is con-
stantly accumulating. Less is known about the transition from a normal mucosa to the early
pre-cancerous mucosa. It is advantageous therefore to replicate such a transition in vivo
in order to better characterise molecular events and trial interventions in colitis-associated
colonic tumourigenesis.
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Therefore the aim of this project was to investigate the potential for colonic carcinogenesis
in an experimental model of chronic spontaneous colitis initiated by a goblet cell defect:
i) Examine the effect of repeated bouts of severe colitis on pro-cancerous change in a
model of a colitis initiated by defective Muc2 synthesis.
ii) To identify potential mechanisms by which colitis initiates pro-cancerous changes in
the colonic epithelium.
CHAPTER 2
MATERIALS AND METHODS
2.1 Prepared solutions
Phosphate-buffered saline (PBS) (1×, pH 7.3)
Compound Quantity Manufacturer
Phosphate-buffered saline (20×) 50mL Amresco, Solon, OH, USA
Distilled water 950mL
Diluted pre-prepared stock solution of PBS (20×) in distilled water. Stored at RT.
10% Neutral buffered formalin (NBF)
Compound Quantity Manufacturer
Formalin (37%) 50mL VWR International, Brisbane, Australia
PBS (1×, pH 7.3) 450mL
Formalin solution diluted in PBS, mixed and stored at room temperature.
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Sodium citrate buffer (10mM, 0.05% Tween-20, pH 6.0)
Compound Quantity Manufacturer
Trisodium citrate, dihydrate 2.94g Amresco, Solon, OH, USA
Tween-20 0.5mL Amresco, Solon, OH, USA
Distilled water up to 1L
Prepared as a 1× solution, pH adjusted to 6.0 and stored at 4°C.
Sodium acetate solution (0.1M)
Compound Quantity Manufacturer
Sodium acetate 8.2g Amresco, Solon OH, USA
Distilled water up to 1L
Sodium acetate added to distilled water and mechanically agitated to ensure complete
dissolution. Stored at room temperature.
Acetic acid solution (0.1M)
Compound Quantity Manufacturer
Glacial acetic acid (99.7%) 5.74mL VWR International, Brisbane, Australia
Distilled water up to 1L
Glacial acetic acid diluted in distilled water and mixed. Stored at room temperature.
Acetate buffer (pH 5.5)
Compound Quantity Manufacturer
Sodium acetate (0.1M) 180mL
Acetic acid (0.1M) 20mL
Combined acetic acid and sodium acetate solutions. Adjust pH to 5.5 if necessary. Stored at
room temperature.
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Aqueous glycerol solution (1%)
Compound Quantity Manufacturer
Glycerol 10mL Amresco, Solon, OH, USA
Distilled water up to 1L
Glycerol added to distilled water and agitated to dissolve.
Sodium periodate solution (1mM)
Compound Quantity Manufacturer
Sodium metaperiodate 2.0g Sigma-Aldrich, Sydney, Australia
Acetate buffer (0.1M, pH 5.5) 200mL
Periodate dissolved in acetate buffer (pH 5.5) with mechanical agitation. Kept at room
temperature.
Potassium metabisulphite solution (0.5%)
Compound Quantity Manufacturer
Potassium metabisulphite 1g Ajax, Melbourne, Australia
Hydrochloric acid (0.15M) 100mL
Distilled water 100mL
Hydrochloric acid diluted in distilled water. Metabisulphite dissolved in the hydrochloric
solution.
Alcian Blue solution, pH 1.0
Compound Quantity Manufacturer
Alcian blue 8GX 1% Gurr Scientific, Oxford, UK
Hydrochloric acid (0.1M) 100mL
Mixed mechanically for 1 hour. Stored at room temperature and filtered through Whatman
paper immediately prior to use.
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Schiff’s reagent (Mowry’s variant)
Compound Quantity Manufacturer
Pararosaniline 0.5g Gurr Scientific, Oxford, UK
Sodium metabisulphite 5g Ajax, Melbourne, Australia
Hydrochloric acid (37%) 3mL VWR International, Brisbane, Australia
Distilled water up to 200 mL
Mixed mechanically for 2 hours, filtered through Whatman paper and volume adjusted to
200mL with distilled water. Stored at 4°C before use.
Antibody diluent (2% Bovine serum albumin (BSA), 0.05% Tween-20)
Compound Quantity Manufacturer
BSA (2%) 10g Bovogen Biologicals, Melbourne, Australia
Tween-20 0.25mL Amresco, Solon, OH, USA
Thiomersal 0.25mL BDH, Poole, UK
PBS (1×, pH 7.3) up to 500mL
BSA dissolved in PBS, added thiomersal and mixed mechanically until completely
dissolved. Adjusted pH to 7.2–7.4 with hydrochloric acid. Volume of Tween-20 added and
resulting solution stored at 4°C.
3,3’-diaminobenzidine (DAB) solution
Compound Quantity Manufacturer
DAB solution 0.16mL Biocare Medical, Concord, CA, USA
DAB buffer 3.2mL Biocare Medical, Concord, CA, USA
Volume of the pre-prepared DAB reagent is mixed into the chromagen substrate buffer
solution. Filtered immediately prior to use.
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Haematoxylin (Carrazzi)
Compound Quantity Manufacturer
Haematoxylin 2g Gurr Scientific, Oxford, UK
Glycerol 200mL Amresco, Solon, OH, USA
Potassium metaperiodate 0.2g Ajax, Melbourne, Australia
Aluminium potassium sulphate 50g Ajax, Melbourne, Australia
Haematoxylin dissolved in glycerol, potassium periodate is dissolved in 300mL of the
distilled water with agitation overnight. Diluted periodate is added to the haematoxylin
solution, mixing well after every addition. Potassium metaperiodate dissolved in remaining
distilled water with warming. Potassium periodate is added to the haematoxylin-alum
sulphate-glycerol mixture. The final mixture is shaken well and is ready for use
immediately.
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2.2 Animal Procedures
2.2.1 Ethics statement
All animal procedures were performed in accordance with the Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes of the National Health and Med-
ical Research Council. The study was approved by the Animal Ethics Committee of the
University of Tasmania (protocol #13329).
2.2.2 Animal care and housing
Winnie mice (homozygous Muc2 mutant; C57BL6/J background) were re-derived from stock
maintained by the Monash Animal Services (Monash University, Melbourne, Australia)
into the specific pathogen-free Cambridge Farm Facility (University of Tasmania Animal
Services, Tasmania, Australia) for breeding purposes. Eleven to twelve week-old inbred
Winnie and C57BL6/J mice of both sexes were sourced from the University of Tasmania
Animal Services and transferred to the laboratory at the University of Tasmania School of
Health Sciences. After transferral to individual cages animals were acclimatised to their
holding environment for at least seven days before commencing experiments.
Animals were held in a room at the University of Tasmania School of Health Sciences. where
temperature was maintained at 21°C± 4°C, with unregulated humidity and artificially lit
for 12 hours each day. Presence of specific pathogens within animals was not monitored,
however animals were housed within a individually ventilated Maxi-Miser caging unit
(Thoren Caging Systems Inc., Hazleton, PA, USA). Although caging provided animals
with high-efficiency particulate-absorbing (HEPA) filtered air (HEPA), the room in which
animals were housed was supplied by unfiltered air. Mice would therefore be exposed to a
non-sterile environment when animals were weighed, food and water changed. Protocols
to limit microbiological contamination were therefore used in housing and monitoring
mice. Every week mice were transferred to a clean cage containing autoclave-sterilised
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corncob bedding (Andersons, Maumee, OH, USA) and were permitted ad libitum access
to γ-irradiated and autoclaved rodent feed (Barastoc Rat & Mouse, Ridley AgProducts,
Australia) and autoclave-sterilised, tap-water. All surfaces and equipment used to handle
mice were disinfected prior to coming into contact with animals to limit exposure to any
additional microbes and pathogens.
Based on a small number of available mice, dysplasia-like mucosal lesions were observed in
2/3 Winnie mice and submucosal crypt extension in 1/3 Winnie mice following three cycles
of 1% DSS. In contrast none of the untreated Winnie mice displayed histological features
indicative of anything more than mild inflammation. Based on crude proportions, as few as
4 Winnie mice per treatment group may be used to identify a difference in dysplasia Sample
sizes sufficient to identify a large effect size, assuming a power of 0.8 and a significance
level of 0.05, could be achieved with as few as 7 animals per group if a factorial analysis of
variance (ANOVA) was used.
2.2.3 Exacerbation of colitis with dextran sulphate sodium
In order to exacerbate colitis in Winnie, a solution of DSS was administered in a cyclic
regimen. Each cycle of the experimental DSS regimen consisted of the administration of
DSS for seven days before substitution of 1% DSS for water for an additional seven days.
Winnie and C57BL6/J littermates were randomly allocated to one of two groups. A group of
twelve Winnie and six C57BL6/J mice received a 1% w/v DSS (40,000–50,000 Da; USB,
Affymetrix Inc., Cleveland, OH, USA) diluted in the sterile tap water. Alternatively a DSS
’vehicle’ control group of six Winnie and four C57BL6/J animals, were administered sterile
drinking water only. Mice in the experimental group received DSS in a total of three cycles
over 42 days, with a single Winnie mouse euthanased prior to the conclusion of the DSS
regimen. Mouse body weight and disease symptoms (e.g. diarrhoea, rectal bleeding) were
monitored daily during the experiment. Euthanasia, defined as humane killing to relieve
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pain and distress as per the Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes, was necessary in a single case of excessive morbidity and weight loss
following the first DSS cycle. In the case of both euthanasia and experimental termination
(day 42), mice were humanely killed via CO2 asphyxiation and cervical dislocation, in
accordance with the Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes, before the abdomen was dissected and colon removed.
2.3 Histopathology
2.3.1 Tissue processing
The length of the colon from ileo-caecal junction to the rectum was recorded. The colon was
subsequently opened along its longitudinal axis and the luminal contents were removed prior
to weighing the organ. The colon was bisected longitudinally and one half was prepared
using the Swiss roll technique [252]. The remaining colonic tissue was dissected and snap-
frozen for molecular analyses. Swiss rolls underwent 24-hour fixation in 10% (v/v) NBF at
room temperature before being transferred to 70% ethanol. Intestinal rolls were processed
by first dehydrating tissue through progressively increasing concentrations of ethanol (2×
changes of 95% ethanol, followed by 4× 100% ethanol), then cleared of alcohol through 2×
changes of xylene and finally infiltration with 2× changes of molten Histo-Prep paraffin
wax (Fisher Scientific, Philadelphia, PA, USA) at 60°C. All processing steps were automated
using a Citadel 1000 tissue processor (Shandon Scientific, Runcorn, UK). Swiss rolls were
immediately transferred to an embedding station (HistoCentre 2; Shandon Scientifcc) and
embedded in Histo-Prep paraffin wax. Sections were cut at 5µm with at least three levels
50 µm apart obtained using a rotary microtome (Leica 1512). Sections were stained with
Gill’s haematoxylin and eosin Y (H&E; HD Scientific, Sydney, Australia). Slides stained
with H&E were evaluated for inflammatory features and neoplasia.
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2.3.2 Histpathological evaluation
Histological inflammation was graded in a blinded fashion by a single observer based on
previously used criteria (refer to Fig. A2) [251]. Briefly, crypt architectural distortion was
graded 0-5, frequency of crypt abscesses graded 0-3, crypt hyperplasia graded 0–4, extent of
mucosal damage graded 0–4, goblet cell depletion graded 0–4, extent of inflammatory infil-
tration graded 0–4 and frequency of lamina propria polymorphonuclear (PMN) leukocytes
graded 0–3. The inflammation score for each individual region (distal, middle and proxi-
mal colon) was derived from the sum of the score for each of the aforementioned criteria.
Assessment of dysplasia was performed independently by two pathologists (RF and TB)
blinded to experimental groupings. Crypts involved in glandular profunda were classified
as non-dysplastic lesions. Dysplastic change and submucosal invasion were graded as no
change (0), low-grade dysplasia (1), high-grade dysplasia (2) and invasive carcinoma (3).
Overall inter-observer agreement on the classification of dysplastic change was estimated
to be moderate (κ = 0.41, P = 0.005). In cases of disagreement, the highest grade of either
observer was adopted.
2.3.3 Mucin histochemistry
Paraffin-embedded tissue sections (3 μm thickness) were de-waxed and washed in 0.1 M
sodium acetate buffer (pH 5.5) at 2°C for 5 min. Sections were then oxidised using 1 mM
sodium periodate diluted in 0.1M acetate buffer (pH 5.5) for 10 min. Periodate solution was
rinsed off with 1% aqueous glycerol followed by distilled water each for 5 min. Sections were
subsequently treated with Schiff’s reagent (prepared the previous week) at room temperature
for 15 min. Sections were rinsed in three changes of 0.5% potassium metabisulphite in 0.05
M hydrochloric acid for 5 min. Sections were thoroughly rinsed with running water for
5 min, rinsed in distilled water then stained with acidic Alcian blue (pH 1.0) for 15 min.
Sections were rinsed, stained with Gill’s haematoxylin, dehydrated and mounted using DPX.
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2.4 Immunohistochemistry
Slides were dewaxed and exposed to heat-induced epitope retrieval (4 min at 121°C) in a
sodium citrate buffer (pH 6.0) in a decloaking chamber (Biocare Medical, Concord, CA,
USA). Slides were cooled to room temperature in running tap water and washed in 1×
Tris-buffered saline (TBS) 2 min/wash. Endogenous peroxidase activity was blocked by
incubating slides in 3% H2O2 in methanol for 20 min, followed by 3 × 2 min washes
(twice with distilled water, followed by one wash with 1× TBS). To reduce signal from
endogenous IgG Background Sniper (Biocare Medical) was applied to the slides for 20
min and washed off with 3 × 2 min washes with TBS. Rabbit anti-human beta-catenin
(clone E247; Abcam, Cambridge, UK), applied at a 1:500 dilution or rabbit anti-human
Ki67 (clone SP6; Abcam), applied at a dilution of 1:100 was incubated with the slides for
1 h. Anti-vimentin (Cell Signalling Technology, Danvers, MA, USA) and anti-N-cadherin
(Cell Signalling Technology) were used at 1:250 and 1:400 dilutions respectively. Excess
primary antibody was removed with 3 × 2 min washes with TBS prior to application of
HRP-conjugated anti-rabbit secondary polymerised antibody (Biocare Medical) for 30 min.
Slides were thoroughly rinsed with 1× TBS for 3×2 min washes before the addition of
a proprietary 3,3’-diaminobenzidine (DAB) chromagen solution (Biocare Medical) for 4
min. Tissue was subsequently counterstained with Corrazzi’s haematoxylin, dehydrated and
mounted with dibutyl pthalate in xylene (DPX; Sigma-Aldrich, Sydney, Australia).
2.4.1 Assessment of epithelial cell proliferation
In order to evaluate cellular proliferation within the colonic crypts, nuclei labelled by anti-
Ki67 within the crypt epithelium were quantified. From each animal, multiple fields of
view were evaluated with at least 15 well-oriented crypts assessed by dividing them along
their longitudinal axis, approximately into thirds: apical (top), middle and base. Both
Ki67-expressing cells and unlabelled epithelial cells within each of the assessed crypts were
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Table 2.1: List of antibodies
Antigen Clone Reactivity Origin Product No. Supplier
β-catenin Monoclonal
(E247)
Mouse Rabbit 32572 Abcam
Cxcl5 Polyclonal Mouse Rabbit 2549R Bioss
Ki67 Monoclonal
(SP5)
Mouse Rabbit 16667 Abcam
N-cadherin Monoclonal
(D4R1H)
Human,
Mouse
Rabbit 13116 Cell Signalling
Technology
Vimentin Monoclonal
(D21H3)
Human,
Mouse
Rabbit 5741 Cell Signalling
Technology
counted and were expressed as a percentage of Ki67-positive cells of the total number of
cells within the epithelium. The proportion of Ki67-expressing cells was also expressed
relative to the total cell count for the either the top, middle and basal crypt regions.
2.4.2 Assessment of β-catenin
Images of the colonic mucosa were collected using the 40× objective on a IX71 microscope
(Olympus, Tokyo, Japan) and the attached DP21 microscope camera (Olympus, Tokyo,
Japan). Ten random fields were selected for the segment of colon and the image was de-
convoluted using ImageJ v1.60 [253] and the colour de-convolution extension based on
the algorithm designed by Ruifrok and Johnston to separate [254]. The colour channel
containing DAB staining was used to determine the percentage of the area of the visual
stained using the primary antibody.
2.5 RNA purification
Whole-thickness colonic tissue was homogenised using rotor-stator generator probes (Omni
International, Marietta, GA, USA) and RNA extracted using the RNeasy Mini spin column
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kit (Qiagen, Melbourne, Australia) according to the manufacturer’s instructions. To minimise
genomic DNA contamination DNAse I (Qiagen) digestion was performed ”on-column” dur-
ing the RNA extraction protocol. Integrity and concentration of extracted RNA was assessed
using the Experion Eukaryotic Total RNA electrophoretic system (Bio-Rad Laboratories).
Samples with an RNA integrity number (RIN) > 7 were deemed suitable for RT-qPCR.
Complementary DNA (cDNA) was synthesised from RNA samples using the iScript Reverse
Transcription enzyme and reagents (Bio-Rad) using reaction conditions suggested by the
manufacturer.
2.6 Real-time quantitative polymerase chain reaction
Screening for potential markers of colonic carcinogenesis was performed using pre-designed
96-well Tier I RT-qPCR array plates containing lyophilised primers for 91 genes, refer to
Table A.1. Fifty picograms of cDNA was added to each well of a 96-well plate and mixed
with a SYBR Green master mix (Bio-Rad) prior to thermal cycling using a StepOnePlus
RT-qPCR system (Applied Biosystems, Foster City, California, USA). Gene expression
was quantified using the comparative ΔΔCT method [255] where the threshold cycle (CT)
for each gene was normalised to the average of three reference genes (Actb, Gapdh, Hprt).
Relative gene expression in the DSS-treated animals was compared to control animals and
presented as 2-ΔΔCT . To confirm the results from the intial RT-qPCR array, differentially
expressed genes were amplified using TaqMan probe/primer sets. Two-hundred nanograms
of cDNA from each sample was added to a a PCR reaction including the Taq polymerase
enzyme mix supplied within the TaqMan Fast Master Mix (Applied Biosystems, Foster City,
CA) and a single TaqMan probe/primer mix. Identities of the primers used are listed in
Table A.2. Relative gene expression was quantified using Gapdh as a reference gene.
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2.7 DNA purification and bisulphite conversion
Segments of distal colon were minced prior to lysis with proteinase K using the DNA Tissue
lysis kit (Kurabo Bio-Medical, Osaka, Japan). DNA lysates were purified using the colum-
based QuickGene 810 system (Kurabo) and eluted in nuclease-free water. Extracted DNA
was quantified using the Qubit 3.0 fluorometric system (Qiagen). Unmethylated cytosines
in genomic DNA were converted to thymine using the bisulphite treatment supplied with
the EpiTect Bisulfite conversion kit (Qiagen) according to the manufacturer’s instructions.
Three microlitres of bisulphite-converted DNA was used as the template for a 20 μL PCR
amplification containing a mixture of MyTaq high-sensitivity DNA polymerase (0.5 U;
Bioline Australia Pty, Sydney, Australia), forward and reverse primers (0.2 μM) and 1 mM
dNTPs, 3 mM MgCl2. Forward and reverse primers designed to amplify bisulphite-converted
DNA were predicted using the PyroMark Assay Design software v2.0 (Qiagen), refer to
Table A.3 for sequences). Reverse primers with 5’-biotinylation were synthesised and
subsequently purified through HPLC to remove free biotin (Geneworks, Adelaide, Australia).
Thermal cycling was performed using a C-1000 thermal cycler (Bio-Rad) with a single
polymerase activation at 95°Cfor 60 sec, followed by a sequence of DNA denaturation at
95°C for 15 sec, annealing at 55°Cfor 15 sec and extension at 72°C for 10 sec, for a total of
40 cycles.
2.8 CpG methylation sequencing
Added PCR-amplified DNA (10 μL) to each pyrosequencing reaction with sequencing
primer at 2 μM concentration. Pyrosequencing was performed using the PyroMark Gold
(Qiagen) nucleotides, enzymes and substrate, with sequencing performed using the QSeq
pyrosequencing system (Bio Molecular Systems, Coomera, Australia).
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2.9 Statistical analysis
Change in body weight over time was compared using repeated-measures analysis of variance
(ANOVA). Incidences of graded histological lesions were compared between treatment
groups stratified within genotype using the Mantel-Haenszel χ2 statistic. Comparisons
between means of each unique combination of genotype and treatment were performed
using a two-way ANOVA model. Differences in histological scores between anatomical
regions were tested post-ANOVA using Tukey’s multiple pairwise comparisons test. To
determine differences in the calculated survival curves for time to rectal prolapse between
DSS and untreated Winnie mice, a Mantel-Cox analysis was performed using GraphPad
Prism v5.03 (GraphPad Software, San Diego, CA, USA). Non-parametric Spearman’s
rank correlation was used to test for monotonic relationships between relative transcript
abundance and dysplasia scores (non-dysplastic = 1, low-grade = 2, high-grade = 3, dysplasia
with submucosal component = 4). In all cases, a P-value less than 0.05 was deemed to be
statistically significant.
CHAPTER 3
HISTOPATHOLOGICAL
CHARACTERISATION OF
DSS-INDUCED INJURY IN THE
WINNIE COLON
3.1 Introduction
The association of genes involved in the maintenance of mucosal integrity with susceptibility
of UC and the development of a spontaneous chronic colitis in mice with defects in mucin
synthesis have implicated these defects in the causation of UC. Key to our understanding
of UC pathogenesis was the generation of the Muc2-/- mouse. Genetic abrogation of
murine Muc2 abolishes the sterile, inner colonic mucous layer, rendering Muc2-deficient
animals susceptible to colitis caused by colonisation of the colonic mucosa by the luminal
microbiota [90, 249]. Muc2-/- mice develop a chronic colitis characterised by a mucosal
neutrophilic infiltrate, crypt damage, reparative hyperplasia and depletion of goblet cell
mucin [99, 249]. While the Muc2-/- mouse model has proven to be useful for understanding
the pathogenesis of UC, Muc2 expression, although decreased, is not totally absent from
the colonic epithelium [256, 257]. Furthermore, compensatory increases in the synthesis of
the secreted mucin-6 (Muc6) are also observed in Muc2-/- mice, but not seen in UC [249].
Extrapolation from models of a primary mucous defect where Muc2 is somewhat intact, may
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therefore be more reliable when applied to human UC. The differences between UC and
Muc2-/- mice may stem from a primary defect in the secretory goblet cells. However, the
pathology produced by total Muc2 abrogation displays several discrepancies when compared
to human UC.
Similarly to aforementioned Muc2-/- mouse strain, the Winnie strain of mice develop a
spontaneous colitis due to homozygous missense point mutations in Muc2. The Winnie
Muc2 mutation results in a single amino acid substitution in the N-terminal D3 domain in
the Muc2 protein, which adversely affects the oligomerisation of Muc2 [250]. Theoretically,
prevention of Muc2 oligomerisation could prevent the formation of the mesh-like Muc2
polymers which form the basic structure of the inner mucous layer essential for the size-
dependent exclusion of the luminal microbes [90,98]. The misfolding of Muc2 interferes with
its secretion from the ER and Golgi of the colonic goblet cells, triggering the unfolded protein
response in the colonic goblet cells of Winnie mice [250]. Increased ER stress corresponds to
an increased epithelial apoptosis similar to that in patients with UC, supporting the concept
of a primary secretory cell defect as an aetiologic factor in UC.
A significant gap in our understanding of the disease process in UC is how the theoretical
secretory defect contributes to neoplastic transformation of the colonic epithelium. The
highly organised structure formed by polymerisation secreted Muc2 mucin is essential to
preventing contact between the luminal microbiota and the host immune response thereby
preventing chronic colitis in animal models. Maintenance of the colonic mucus is therefore
essential for both the prevention of colitis and appears to be protective against colonic
tumourigenesis. Concordant with the persistent exposure to the luminal bacteria and chronic
inflammation, Muc2-/- display an increased incidence of colonic neoplasia. Homozygous
Muc2 deletion in mice of C57BL6/J × 129SvOla background was associated with increased
incidence of tumours in the small intestine, colon and rectum relative to animals with wild-
type Muc2 [99]. Whereas colonic adenocarcinomata have been reported in the Muc2-/- and
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Il10-/- models, no incident of colonic neoplasia has yet been reported in Winnie mice, even
at twelve months of age [99, 239, 250]. Induction of a secretory cell ER-stress response and
a defective Muc2-dependent mucous layer therefore makes the Winnie mouse an potential
model for the pathogenesis of UC-associated neoplasia.
3.2 Aims/Hypothesis
Since total abrogation of colonic Muc2 produces adenocarcinoma of the colon within 12
months, it was hypothesised that Winnie mice would display an increased incidence of
adenocarcinoma compared to mice with wild-type Muc2. The length of time needed to
observe pre-cancerous changes in the colon of Muc2-/- animals limits the usefulness of this
model for studying neoplasia resulting from an impaired mucous barrier. Since Winnie mice
display a subtotal depletion of the colonic mucus we anticipated that colonic neoplasia would
require at least 6–12 months to develop, we intended to exacerbate the existing chronic
colitis to accelerate tumourigenesis.
3.3 Results
3.3.1 Clinical observations following three cycles of DSS
Twelve week-old mice of both C57BL/6J (Muc2 wild-type) and Winnie (Muc2 mutant) were
monitored throughout the experiment for the clinical symptoms indicative of disease severity.
Wild-type mice (n = 4) displayed no clinical signs of disease and gained weight normally
when they received drinking water only for 42 days (Fig. 3.1A). While extended exposure to
1% DSS produced a mild diarrhoea in C57BL/6J mice with wild-type Muc2 (n = 6), 1% DSS
did not appear to exert an appreciable effect on the trend toward a increased body weight
over the course of the experiment. Individual Winnie mice were clinically asymptomatic
apart from recurrent episodes of a mild, non-watery diarrhoea. Bouts of diarrhoea were
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typically accompanied by slight but reversible losses in body weights of individual Winnie
mice (Fig. 3.1B).
A
B
Figure 3.1: Daily change in body weight of mice during the three cycle DSS regimen.
Twelve week-old Winnie mice (Muc2 mutant) and age-matched C57BL/6J mice (wild-
type Muc2) receiving drinking water only, or three cycles of 1% DSS. Body weight was
recorded each day and recorded as percentage change from the starting body weight prior to
commencement of the experiment (day 0). A. Comparison of average body weight change
between untreated C57BL/6J mice, which received drinking water only for 42 days, and
C57BL6/J mice exposed to three cycles of 1% DSS. B. Average body weight change between
untreated Winnie mice, which received drinking water only for 42 days, and Winnie mice
exposed to three cycles of 1% DSS. Each point represents the mean percentage change in
body weight relative to the initial body weight. Error bars depict standard deviation (SD)
from the mean. Grey bars represent days during which mice were administered DSS.
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However, the average body weight of control Winnie mice (n = 6) during the experiment
remained relatively stable over the 42 days of the experiment. Compared to the wild-type
C57BL6/J, Winnie mice displayed a higher sensitivity to the administration of DSS in
the drinking water (n = 11). Oral administration of DSS at 1% w/v for 7 days induced a
bloody, watery diarrhoea co-inciding acute with weight loss which continued 1-2 days after
cessation of DSS administration. The only mortality during the experiment occurred when
one Winnie mouse receiving the first DSS cycle developed disease and excessive weight loss
necessitating euthanasia. The overall trend in body weight change in Winnie was attenuated
by three cycles of 1% DSS administration.
Upon termination of the experiment, when mice had reached an age of approximately 18
weeks, mice were killed and the colon dissected for further examination. Colon length
measured from the caecum to the rectum, and the wet colon weight were measured as gross
indicators of disease severity. The absolute length of the colon in Winnie mice exposed to
the DSS regimen was decreased by an average of 24% compared to Winnie mice receiving
drinking water alone (Fig. 3.2A). In contrast, the weight of the whole colon from Winnie
mice administered DSS was, when standardised to body weight, no heavier than Winnies
receiving only drinking water (Fig. 3.2B). Colons of Winnie mice administered 1% DSS,
despite being the same weight on average as untreated Winnie, displayed visible features
indicative of chronic inflammation. The colon from Winnie following three cycles of 1%
DSS was noticeably whitened in colour with apparent thickening of the colonic wall relative
to untreated animals, and displayed enlargement of mesenteric lymph nodes compared to
control Winnie mice (Fig. 3.2C).
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Figure 3.2: Clinical features of DSS-induced colitis in Winnie. A. Mean colon length
at termination. B. Mean colon weight relative to body weight at termination. C. Gross
appearance of the Winnie colon at termination. Representative images of Winnie colon after
receiving three cycles of water only (top) and the colon of Winnie receiving three cycles
of DSS (bottom). Error bars depict SD from the mean. *, mean significantly different (P
<0.05) in Winnie + H2O compared to all other groups.
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3.3.2 Histopathology
Histological examination of the colon was undertaken to characterise the pathology induced
by three cycles of 1% DSS in the Winnie colon. Compared to the wild-type C57BL6
(Fig. 3.3A) and wild-type exposed to three DSS cycles (Fig. 3.3B), diffuse leukocytic
infiltration into the mucosa, and to a lesser extent the submucosa, was common in the distal
and mid-colon of Winnie mice (Fig. 3.3C & 3.3D). In these mice, crypt architecture in
the distal colon was occasionally irregular and frequently elongated, with infrequent crypt
abscesses observed in both the mid-colon and distal colon.
At the time of termination (day 42), severe damage to the distal and mid-colon of Winnie
mice exposed to DSS remained evident (Fig. 3.3D). DSS administration in Winnie resulted in
an increased influx of leukocytes into the mucosa and submucosa. Large mucosal aggregates
of mononuclear leukocytes were frequent, and often extended into the expanded submucosal
compartment. Glandular profunda was identified in the distal colon involving the larger
lymphoid aggregates, which expanded beyond the muscularis mucosae. Areas of superficial
mucosal erosion and crypt loss were observed, frequently with foci of crypt fission adjacent
the erosion (Fig. 3.3D). Generally, the mucosa of the Winnie distal colon was extensively
thickened and contained hyperplastic crypts following repeated DSS exposure. In addition
to the typical inflammatory effects observed in Winnie, we assessed the colon for early
neoplastic changes. Crypt hyperplasia within the distal and mid-colon of Winnie mice
exposed to DSS was often accompanied by foci of abnormal crypt architecture resembling
dysplasia.
Forty-five percent of Winnie mice displayed crypt abnormalities consistent with a low-
grade dysplasia after administration of DSS (Table 3.8), whereas aberrant crypts were
only observed in one untreated Winnie. Low-grade lesions displayed marked architectural
distortion, with subtle cytological features such as crowding of epithelial nuclei and increased
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ratio of nucleus-to-cytoplasm (Fig 3D). Low-grade lesions were absent from all wild-type
animals except for one of six C57BL6/J mice exposed to DSS (Table 1).
Changes to crypt architecture, frequency of crypt abscesses, crypt hyperplasia, the extent
of mucosal damage, mucin depletion, extent of inflammatory infiltration and frequency of
lamina propria neutrophils were graded in a blinded fashion. Examination of the colon was
divided into three segments: proximal colon (PC) , mid-colon (MC) and distal colon (DC).
Crypt abscesses were defined as crypts containing an intra-luminal accumulation of cellular
debris and neutrophils. The number of crypt abscesses observed in each segment of colon
was counted for each level of section. Crypt abscesses were not observed in the untreated
wild-type C57BL6 or those administered 1% DSS, in any of the three intestinal segments
(PC, MC and DC) (Fig. 3.4). Winnie mice however, displayed a median crypt abscess score
of 1.5 and 1 for the mid-colon and distal colon respectively, while the proximal colon was
unaffected. Exposure to three cycles of 1% DSS seemingly increased the frequency of crypt
abscesses in the distal colon but not the proximal and mid-colon.
Loss of normal crypt architecture was graded for each intestinal segment for each of the
genotypes and treatment groups. Normal crypt architecture was found throughout the entire
colon of untreated C57BL6 mice (median of 0). Median scores for all intestinal segments
in C57BL6 mice following exposure to 1% DSS were also at baseline, though 1/6 mice
displayed a mild glandular irregularity (grade 1) in the distal colon. For crypt length a
median score of 1 (150–199 μm) was recorded for crypt length in the proximal colon of
untreated C57BL6 mice, but a median of 0 for all other segments (<250 μm and <200 μm
for middle colon and distal colon respectively).
While crypt length was within the baseline range following 1% DSS in C57BL6 mice for
proximal colon and distal colon, the median score for the distal colon was 0.5 suggesting a
heterogeneous increase in crypt length. Crypt length was markedly increased in DSS-treated
and untreated Winnie mice (median scores were >2) throughout the colon. Crypt elongation
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in Winnie was most pronounced in the distal colon segment, with 50% of animals displaying
crypts longer than 350 μm in both untreated and DSS groups.
Depletion of goblet cell morphology was completely absent in both untreated and DSS-
treated C57BL6 mice. Winnie on the other hand displayed a reduction (median scores ≥
1) in identifiable goblet cells primarily in the mid-colon and distal colon in both untreated
and DSS-treated animals. Goblet cell numbers appeared largely unaffected by the Winnie
mutation or 1% DSS with median scores of 0.5 and 0 respectively.
Untreated C57BL6 mice displayed a diffuse non-neutrophilic leukocytic infiltrate, with
occasional small follicles, consistently throughout the colonic mucosa regardless of segment
(median score = 0). The median score for inflammatory infiltrate remained low even after
the administration of 1% DSS although a increased scores were more likely in the distal
colon (median score of 0.5) of mice following 1% DSS administration. One of these animals
in particular, displayed a marked leukocytic infiltration in both the submucosa and mucosa
of both mid-colon and distal colon. Neutrophils in the mucosa of the colon were infrequent
in the colon of C57BL6 mice, with or without exposure to three cycles of 1%DSS, with
an average of <5 PMN cells per high-power field (40× objective). Although average
numbers of PMN cells per field were similar to C57BL6 mice in untreated and DSS-treated
Winnie mice, Winnie exhibited foci of neutrophilic crypt abscesses and mucosal leukocytic
aggregates containing relatively high numbers of neutrophils.
Neutrophilic infiltrates were prominent in mucosal aggregates in mucosa where crypts were
attenuated or absent. Tissue damage was generally absent in untreated and DSS-treated
C57BL6 mice, however the three-cycle DSS regimen induced infrequent, focal attenuation
of the surface epithelium in the distal colon in 2/6 mice and the mid-colon in 1/6 mice.
Tissue damage was more frequent in the mid-colon and distal colon of Winnie compared to
C57Bl6 mice. Five of the six untreated Winnie mice displayed at least focal attenuation of
the surface epithelium, and dilation of the colonic crypts in the distal colon, with a median
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score of 1. Following three cycles of 1% DSS the median score was 2, with 8/11 (72%)
of mice displaying extensive attenuation of the surface epithelium and glandular dilation.
Three of the eleven mice also displayed prominent mucosal erosion due to necrosis of the
glandular epithelium in the distal colon. Proximal colonic mucosal damage was in contrast,
low, with median scores of 0 for both Winnie and DSS-treated Winnie mice.
Overall, the histopathological changes observed in Winnie differed significantly from that
observed in the C57BL6 genotype control groups when the histopathological parameter
scores were summed (Fig. 3.5). Cyclic DSS exacerbated the severity of inflammation in
both middle and distal segments of Winnie mice relative to untreated Winnie mice, while
DSS had only a minor influence on inflammation in the proximal colon (Fig. 3.5).
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Figure 3.3: Distal colonic mucosal alterations induced by three cycles of dextran sul-
phate sodium. A. Representative image of the distal colon obtained from one of four
untreated C57BL6 mouse. B. C57BL6 distal colon exposed to dextran sulphate sodium
(DSS). Image representative of six eighteen week-old C57BL6 mice exposed to three cycles
of 1% DSS. C. Distal colon of Winnie mouse without exposure to DSS. Crypts are hyper-
plastic and the mucosa displays an active mucosal inflammation, indicated by the presence
of neutrophils among an influx of other leukocytes. D. Distal colon representative of Winnie
mouse without exposure to DSS. Crypts are hyperplastic and mucosa displays a marked in-
filtration of leukocytes, including neutrophils. Image representative of six untreated Winnie
mice examined. E. Distal colon of Winnie mouse displaying colonic hyperplasia and mild
focal dysplasia following three cycles of 1% DSS. Mucosa displays features of an active
chronic inflammation, with prominent submucosal leukocytic infiltrate. Extensive crypt
hyperplasia is visible with a focus of atypical glandular architecture (asterisk). Note the loss
of surface epithelium. Numerous mitotic figures are evident. Image representative of the
hyperplasia and dysplastic foci total of eleven Winnie mice exposed to three cycles of 1%
DSS. All sections stained with H&E, scale bar is equivalent to 100 μm in A and B and 50
μm in C–E.
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Figure 3.4: Characteristics of histological inflammation in Winnie following three cy-
cles of 1% DSS Microscopic changes in the mucosae of both WT and Winnie mice (aged
18 weeks) either untreated, or exposed to three cycles of 1% DSS, were examined.. The
number of crypt abscesses, severity of crypt distortion, degree of crypt elongation, extent of
goblet cell loss, severity of inflammatory infiltration, numbers of lamina propria (LP) PMN
cells and severity of mucosal tissue damage were graded in at least three levels from each
animal. Horizontal bars represent median score for each of the groups analysed: untreated
C57BL6 (n = 4), C57BL/6 + DSS (n = 6), Winnie (n = 6), Winnie + DSS (n = 11) Boxes
represent upper (75th) and lower (25th) percentiles of the data. Whiskers represent (1.58 ×
interquartile range).
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Figure 3.5: Severity of inflammatory damage in the colon following three cycles of 1%
DSS in Winnie. Histological sections obtained from eighteen week-old mice were scored
for inflammatory features in a blinded fashion at three levels at least 50 μm apart for colonic
segments (proximal, middle and distal colon). Scores for individual mice at each level were
were summed for both control Winnie mice (n = 6) and Winnie mice receiving DSS (n
= 11) for each anatomical division of proximal (PC), middle (MC) and distal (DC) colon.
Horizontal line indicates median. Summary of summed histological scores presented in
Fig. 3.4. Bars represent mean score for each grouping in the experiment. Error bars represent
standard deviation (SD). *, P <0.05, **, P <0.01, ***, P <0.001.
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Figure 3.7: High-grade dysplasia and submucosal penetration in Winnie. A. Distal
colon of Winnie following three cycles of 1% DSS. Mucosa ulceration persists with the
mucosa featuring a prominent leukocytic infiltrate with focal extension into the submucosa.
Crypts frequently displayed branching, dilation and distortion from the normal straight
tubular structure. Instances of distorted glands interconnected the base are visible above
crypts misplaced within the submucosa separated by an intact muscularis mucosae.
B. Distal colon displaying branching crypts within inflamed mucosa. A neutrophilic in-
filtrate is prominent in the mucosal erosion to the left of the regenerating crypts. Mildly
distorted, laterally branching gland was visible penetrating a seemingly deformed muscularis
mucosae, entering the submucosa. C. Winnie distal colonic mucosa after DSS exposure.
Distorted and atypical hyperplastic glands (asterisk), with focal infiltration into underly-
ing submucosa through an otherwise intact muscularis mucosae (arrowhead). D. Higher
magnification of A. Atypical mucosal and submucosal glands display relatively bland cy-
tology; nuclear polarity mostly intact, though nucleus:cytoplasm ratio is increased. Mitotic
figures are common beyond the crypt base. Region of crypt epithelium displaying loss of
nuclear polarity (arrowheads). Note the stroma associated with submucosal glands. E. Low
magnification image of the mid–distal colon of Winnie with severe mucosal hypertrophy
following three cycles of 1% DSS. F. Higher magnification of E distal colonic mucosa
featuring abnormal hyperplastic crypts. Multiple large mucus-containing cysts have formed
(M), apparently formed by confluent dilated crypts lined with hyperplastic goblet cells. G.
Higher magnification of E. Crypts displayed back-to-back arrangement associated with
high-grade dysplasia. Multi-focal penetration of the muscularis mucosae by the overlying
abnormal crypts (arrowheads). H. Instance of submucosal crypt penetration in greater detail.
Focal penetration of the submucosa by atypical mucosal crypt. Stained with H&E, scale bar
represents 100 μm in B and C, 50 μm in G & H, 20 μm in D. Images obtained from 4/11
Winnie mice exposed to three cycles of 1% DSS.
High-grade lesions were observed in the distal half of the colon in 55% of Winnie mice
exposed to DSS but were absent from the colon of untreated Winnie and all wild-type mice
(Table 3.8). High-grade crypt lesions displayed the severe architectural distortions such as
cribriform (Fig. 3.7A–C) or back-to-back (Fig. 3.7E–H) glandular arrangements associated
with colonic dysplasia. In 27% of Winnie mice exposed to DSS, crypt epithelium could
be observed within the submucosa underlying apparently dysplastic lesions separated by
an intact muscularis mucosae (Table 3.8). Submucosal glands were lined with columnar or
flattened cuboidal enterocytes but displayed minimal nuclear atypia (Fig. 3.7). Serial sections
demonstrated continuity between abnormal mucosal glands and those in the submucosa. No
obvious stromal reaction was associated with the submucosal glands. Notably, submucosal
3.3. RESULTS 77
Figure 3.8: Incidence and severity of dysplasia-like atypia. The colon of Winnie mice
exposed to three cycles of 1% DSS (n = 11) and untreated Winnie (n = 6) was examined
for dysplastic change. Untreated C57BL6 mice (n = 4) C57BL6 exposed to three cycles
of 1% DSS (n = 6) were included as genotype controls. Lesions were graded as either
non-dysplastic, low-grade or high-grade dysplasia and dysplasia with submucosal extension.
The maximum grade of lesions observed was recorded for each mouse and the percentage
of mice for each combination of treatment and genotype displayed animals The incidence
of dysplasia-like lesions in Winnie mice was markedly increased by administration of DSS
(Mantel-Haenszel χ2 = 6.667, P < 0.01).
3.3. RESULTS 78
glands were usually observed in close proximity to the submucosal vasculature and mirrored
the laterally spreading growth pattern seen in the mucosa.
3.3.3 Mucus staining in the Winnie colon
Alcian blue staining was present in the crypt epithelium of Winnie mice in a vesicular form or
external to the cell adjacent to the apical surface of the epithelium, indicating the presence of
sulphomucins. Staining with Alcian blue was frequently observed in the absence of staining
with the Schiff’s-positive material in the epithelial cells of the Winnie distal colon (Fig. 3.9A).
Increased co-mingling of sulphomucin and sialic acid/neutral hexose staining occurred in
cells appeared to co-incide with a position in the crypt epithelium closer to the surface
epithelium. In the inflamed mucosa of the Winnie distal colon however, vesicular staining
of the epithelium was markedly reduced (Fig. 3.9B). No obvious shift in the pattern of
mucus O-acetylation was observed in Winnie mice regardless of DSS treatment. Following
repeated DSS-induced injury, the inflamed mucosa also showed a general depletion of
mucosubstances from within the epithelium and the cell surface (Fig. 3.9A).
Crypts penetrating the muscularis mucosae also displayed a visible absence of vesicular
staining in the epithelium (Fig. 3.9C-D). In a single case, an abundance of secretory cells,
containing mostly vesicles of mixed staining, was apparent within hyperplastic colonic
crypts (Fig. 3.9D.
3.3. RESULTS 79
A B
C D
E
Figure 3.9: Pattern of mucus in the distal colon of Winnie mice following exposure to
three cycles of DSS. Winnie mice were allowed access to water only or exposed to three
cycles of DSS. Sections of colon were stained with Alcian blue and Schiff’s reagent following
oxidation with periodic acid. A. Distal colon of Winnie having received only water for six
weeks. B. Distal colon of Winnie having received water only. Crypt abcesses are visible.
Note the mucus depletion in the involved crypts. C. High-grade lesion in distal colon of
Winnie having received three cycles of DSS. Note the mucin depletion in the distorted crypts,
including those penetrating into the submucosa. While cellular debris can be observed in
the crypt lumen, little secreted mucosubstance is visible. D. High-grade lesion arising in
the distal colon of Winnie exposed to three cycles of DSS. Note the hyperplastic goblet
cells containing an increased proportion of sialylated mucin. E. Percent of mucosal area
(high-power field from 40× objective) occupied by stained sulphomucins in the distal colon
of Winnie. Images obtained from n = 3 for untreated and treated Winnie respectively. Plotted
bars represent mean, error bars represent 1 SD from the mean. Scale bar represents a distance
of 50 μm.
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3.4 Discussion
Due to the absence of colonic tumours reported in Winnie mice of up to 12 months of
age, and the relatively low incidence of colonic neoplasia in a similar time-frame, even
in the more permissive mixed 129Sv background, we anticipated the need to accelerate
carcinogenesis. Further insult to the colon was therefore provided to exacerbate the pre-
existing inflammation in the Winnie colon. The distal colon of Winnie mice proved sensitive
to exacerbation with a relatively mild insult of 1% DSS and resulted in the loss of only a
single animal.
Histological examination of the colon of Winnie mice following repeated exposure of 1%
DSS revealed florid reparative lesions with features resembling colonic dysplasia. Consistent
with the ability of DSS to permeabilise the inner colonic mucous layer, the distal colon
in Winnie mice displayed more severe tissue damage after three cycles of 1% DSS than
the same concentration Muc2 wild-type C57BL6/J mice. Acute administration of 1% DSS
produced a colitis characterised by superficial erosion and prominent mucosal inflammatory
infiltrates, accompanied by neutrophils, all indicative of an active mucosal inflammation.
Much of the DSS-induced tissue damage in Winnie mice remained at the end of the three
DSS cycles with areas of mucosal erosion interspersed between regions of hypertrophic
mucosa in the distal half of the colon. Therefore 1% DSS was suitable for the induction of
extensive distal colonic mucosal damage and repair with only a single mortality. Similar to
Muc2-/- mice, crypt hyperplasia was frequent in the distal colon of Winnie following three
cycles of 1% DSS. The distal colon of Winnie mice that received DSS also displayed foci of
abnormal crypt architecture resembling the dysplasia reported after repeated administration
of DSS [225, 226]. While DSS appeared to rapidly produce foci of non-polypoid dysplasia
in the distal colon of 100% Winnie mice under our experimental conditions, the neoplastic
potential of these lesions remains uncertain. The time-frame used in the present study was
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considerably shorter than the 120+ days used by Cooper et al. and any incident dysplasia in
Winnie might therefore be expected to be comparatively less advanced [225].
Penetration of crypt epithelium into the submucosa was observed in 27% of Winnie mice
exposed to DSS as opposed to 17% and 0% in the control Winnie group and both C57BL/6
groups respectively. Minimal fibrosis was observed surrounding the laterally spreading
submucosal glands and were frequently associated with small breaches of the muscularis
mucosae. The close proximity of glands entering the submucosa to blood and lymphatic
vessels perhaps suggests that crypts may infiltrate the submucosa through weak points in
the muscularis mucosae through which these vessels pass. The penetration of apparently
dysplastic crypts into the submucosa raises the possibility of an early invasive carcinoma.
A fraction of the abnormal crypts, including those penetrating the submucosa, displayed a
lateral branching of the epithelium at the crypt base, extending parallel to the muscularis
mucosae. Horizontal growth resulting in ”L” or ”inverted T” shaped crypts, accompanied
by bland cytologic morphology, are histological features frequently associated with the
pre-cancerous sessile serrated adenomata [258]. Dysregulated epithelial cell growth may
contribute to the abnormal crypt architecture associated with the serrated adenomatous
lesions. Simultaneously increased proliferation and inhibition of apoptosis has been offered
as a mechanism underlying the abnormal crypt morphology within serrated adenomatous
lesions [259]. Chronic inflammation of the colon may also promote a comparable dys-
regulation of epithelial homeostasis in UC [260]. Elongated laterally growing crypts may
therefore arise in response to colitis, their branching perhaps permitting the re-population
of the glandular mucosa after crypt loss. If however, oncogenic mutations such as those
in Trp53 exist within the regenerative epithelium this lateral spread may permit the rapid
expansion of dysplastic or cancerous cells, an effect termed ”field cancerisation” [261].
Identification of early invasive carcinoma in the context of a chronic colitis is complicated
by the co-existence of similar morphological characteristics in non-neoplastic epithelium.
Repeated insult using DSS produced the florid inflammatory hyperplasia, some of which
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displayed dysplasia and infiltration into the submucosa. Diverticular penetration of colonic
crypts, such as that occurring in colitis cystica profunda, although uncommon, is observed
at a higher frequency in patients with UC. Allen et al. reported that in patients with IBD
who exhibited no evidence of dysplasia, the misplaced colonic crypts were composed of
non-dysplastic epithelium [262]. Conversely, misplaced epithelium was dysplastic in 82%
of patients with neoplasia arising from UC. Thus, penetration of crypts into the submucosa
even when dysplastic crypts are involved, may occur independent of any neoplastic pro-
cess. Mechanisms explaining the occurrence of the glandular profunda in colitis are not
well-understood. It is possible that during tissue repair following acute inflammation, the
regenerative epithelium either expands into an ulcerated submucosa, or is forced through
the muscularis at points where lymphatics or by infolding of a hyperplastic polyp. Deep
ulceration and abscesses may also permit access of dysplastic glandular epithelium into the
submucosa which may persist while the dysplastic mucosa above regresses. Occasionally
herniation of colonic crypts into submucosal lymphoid tissue was observed in animals
exposed to DSS, which we labelled glandular profunda. Glandular profunda, despite their
dysplastic appearance and the discontinuity of the overlying muscularis mucosae, have
no recognised neoplastic potential and are thus discounted from any diagnosis of invasive
carcinoma [263].
Several characteristics of invasive carcinoma have been identified that distinguish carcinomas
from glandular profunda/diverticula/herniation [263]. To classify a suspect lesion in animal
models of intestinal cancer as carcinoma, the presence of several histological features should
be examined. The first is a higher grade of nuclear atypia than the overlying mucosa, i.e.
an invasive gland with high-grade dysplasia beneath a low-grade dysplastic mucosa [263].
Mucosal herniation is not typically associated with a desmoplastic reaction, especially
one without a prominent inflammatory cell infiltrate [263]. Non-neoplastic epithelium
penetrating into lymphoid tissue also displays a dysplastic morphology, and therefore it is
easier to distinguish herniation from invasion in the absence of prominent inflammatory cell
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infiltration. In keeping with their dysplastic phenotype, invasive glands are more likely to
be of a sharp angular or irregular shape. Significant cell loss and the presence of cellular
debris exudate in the crypt lumen may also suggest the presence of carcinoma. In the case of
mucosal herniation the gland is displaced into the submucosa along with the lining basement
membrane whereas invasive glands do not. While the abnormal glands in Winnie following
three cycles of DSS display dysplasia-like architecture, occasionally luminal debris, the
nature of the surrounding connective tissue was not easily discerned.
Mucus production in the colonic epithelium is altered in both inflammation and in colonic
tumours. Colonic goblet cells in Winnie mice displayed focal reduction in intracellular
mucins stained by either Alcian blue or PAS. Severe mucin depletion was observed more
frequently in the distal colon Winnie mice following three cycles of 1% DSS in crypts
displaying a dysplastic morphology. Mucin-depleted crypt foci have been offered as a very
early precursor to colonic adenocarcinoma initiated by azoxymethane [264]. While mucin
depletion may be indicative of a neoplastic transformation in the azoxymethane model
where the colon is uninflamed and mutations in β-catenin are frequent, the significance of
mucin depletion in the abnormal crypts in the chronically inflamed Winnie colon is less
certain. Besides mucin depletion, mucin production in the neoplastic colonic epithelium
appears to shift from the secretion of heavily O-acetylated mucus to non-O-acetylated
mucus [265]. Changes in O-acetylated sialomucins may be detected using the mPAS method,
which in Winnie labelled crypt foci where non-O-acetylated sialomucins were increased
while sulphomucins decreased. While the mucosa in most Winnie mice displayed a general
reduction in mucus-containing cells, goblet cell hyperplasia was observed in a single animal.
In addition to the aforementioned mucus alterations in Winnie, goblet cell hyperplasia
was also on display in the colon of a single animal after exposure to three cycles of DSS.
Observation of a goblet cell hyperplasia is in agreement with the resistance of the colonic
goblet cells to apoptosis in the Winnie colon [250]. Goblet cell hyperplasia has similarly
been reported in patients with UC and CD, and also adjacent to neoplasia in patients with
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either UC or CD [266, 267]. Due to the unusual morphology of goblet cell hyperplasia, their
potential as neoplastic precursors has been investigated. Total colectomy specimens studied
by Lee et al. identified goblet cell hyperplasia adjacent to the colonic adenocarcinoma
in 80% of cases [268]. Goblet cell hyperplasia in CD were frequently shown to display
p53 over-expression when adjacent to carcinoma [267]. Since excessive p53 protein is
associated with dysplasia and carcinoma, it is plausible that goblet cell hyperplasia may
precede dysplasia and carcinoma in the chronically inflamed colon.
3.5 Conclusion
Exacerbation of colitis over three cycles of 1% DSS in Winnie mice with impaired colonic
mucin secretion produced extensive mucosal hypertrophy in response to inflammation.
Abnormal, dysplasia-like crypt foci were present within the hyperplastic mucosa and in
several instances penetrated into the submucosa. Study of later time-points post-DSS
administration would provide evidence as to whether laterally spreading crypts infiltrating
the submucosa underlie the rapid progression of colitis-associated neoplasms. Additionally,
markers of abnormal cellular proliferation or apoptosis may be useful in determining the
neoplastic potential of these lesions.
CHAPTER 4
EFFECT OF EXTENDED DSS ON
THE INDUCTION OF COLONIC
NEOPLASIA IN WINNIE
4.1 Introduction
At present the most reliable model for simulating neoplasia arising from the chronically
inflamed colon involves the administration of azoxymethane (AOM) and subsequent dextran
sulphate sodium (DSS) [269]. While the AOM-DSS protocol provides a model for studying
colonic neoplasia driven by colonic inflammation, it relies upon the induction of carcinogen-
esis primarily through specific mutations in the β-catenin and Kras pathways [270, 271]. In
contrast, the Winnie mutation provides a potentially unique starting point for the initiation
of neoplasia. How the presence of ongoing goblet cell ER-stress in addition to the primary
defect in the colonic mucous barrier influences carcinogenesis in the large intestine is a
question that is largely unexplored.
Carcinogenesis is a time-dependent process and is thus sporadically occurring carcinoma
is most typically observed in elderly animals. Inflammation appears to accelerate carcino-
genesis associated with mutations acquired subsequent to exposure to potent genotoxic
carcinogen such as AOM [272, 273]. A single injection of AOM (10mg/kg) followed by oral
administration of 2% DSS for seven days has been shown to be sufficient to produce colonic,
adenomatous neoplasia in 100% of animals (outbred, male ICR mice), within 20 weeks [272].
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While such a protocol induced a rapid onset of colonic neoplasia with high incidence in ICR
mice, C57BL6/N mice proved less susceptible to colonic neoplasia, correlating with their
increased resistance to DSS-induced colitis [273]. The comparative resistance of C57BL6
to colonic neoplasia may be overcome by simply increasing the number of DSS cycles
thereby increasing the incidence of neoplasia to 100% [269]. Similarly, when using DSS
alone, incidence and time until onset of neoplasia will likely be dependent on the duration
of colitis, i.e. the number of DSS cycles, and the interval between DSS administration and
examination.
Administration of DSS alone appears to be capable of inducing colonic dysplasia, producing
a varied morphology reminiscent of the colitis-associated dysplasia observed in patients with
UC [225]. Duration of colitic disease would thus be expected to increase the incidence of
neoplasia in Winnie. However, the incidence and time required for any colonic neoplasia
in Winnie is unknown. The incidence of dysplasia or neoplasia naturally within the colon
of Winnie mice has yet to be reported in mice up to one year-old [250]. While three cycles
of 1% DSS appeared to induce epithelial dysplasia in the distal colon of all Winnie mice,
submucosal crypts were uncommon and if genuinely invasive, in the early stages of growth.
Definitive invasive carcinoma however, was not observed and thus additional cycles of 1%
DSS may allow for further neoplastic progression in the colon. In addition to the number
of DSS cycles, the time allowed until the colon is examined is another factor which will
determine incidence and severity of any detected neoplasms. For example the incidence
of cancer in outbred Swiss-Webster following four cycles DSS was increased by 15% if
post-mortem examination was delayed by 120 days [225].
Under our conditions, three cycles of DSS were tolerated by Winnie mice with minimal
mortality. It was assumed that additional cycles (seven days DSS, plus 7 days H2O) may be
similarly tolerated without significant mortality. Extending the duration of both the severe
DSS-induced insult, and allowing a longer period of time following DSS administration
should therefore allow colonic dysplasia in Winnie to progress to a more advanced stage.
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The decision was made to increase the DSS regimen from Chapter 3 by another two DSS
cycles (seven days of 1% DSS, seven days of drinking water), an additional month of DSS
administration to exacerbate the damage to the colonic epithelium.
4.1.1 Hypothesis
We hypothesised that five cycles of 1% DSS administration would increase the incidence of
carcinoma in the distal colon of Winnie mice, relative to three cycles of DSS.
4.2 Results
4.2.1 Clinical observations
To test the ability of DSS to induce neoplasia in the colon of Winnie mice, a group of twelve
week-old Winnie mice were exposed to a cyclic 1% (w/v) DSS regimen of five cycles length
(n = 8), whereas a control group of mice (n = 7) received only autoclaved tap water (Fig. 4.1).
Figure 4.1: Protocol for exacerbation of colitis using dextran sulphate sodium. All mice
were approximately twelve weeks of age at the beginning of the experimental procedure. A
solution of 1% (w/v) DSS dissolved in autoclaved tap water was administered through the
drinking water for a period of seven days. A period of seven days of DSS administration
followed by seven days recovery period where mice received drinking water only, was
considered to constitute a single cycle. Five cycle DSS regimen where Winnie mice (n = 8)
were exposed to a DSS regimen of three cycles length, while a control group of mice (n = 7)
received only autoclaved tap water. Mice were killed at various time-points during and up
until 190 days had passed since the beginning of the first DSS cycle.
Mice were monitored throughout the experimental protocol for the external manifestations
of colitis and general morbidity. Individual Winnie mice displayed recurrent episodes of a
mild, non-watery diarrhoea consistent with a mild colitis. Winnie mice displayed the more
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severe symptoms of rectal bleeding, weight loss and diarrhoea after the commencement
of each DSS cycle, persisting until DSS administration ceased. Individual Winnie mice
from both the control group and DSS-treatment group developed visible rectal prolapse
throughout the course of the experiment, necessitating their euthanasia. Four of seven
(57%) Winnie mice from the control group were euthanased within 56 days after the
commencement of DSS administration. Two of three cage-mates allocated to the control
group were euthanased due to excessive weight loss within 24 hours. Necropsy of these two
animals revealed intussusception involving the terminal ileum, proximal colon and part of
the caecum (Fig. 4.2A). The intussusception in both cases resulted in total occlusion of the
colon and was associated with an expansion in the size of the caecum (Fig. 4.2B).
Since such a large number of intussusception/prolapse cases occurred in the control group,
we conducted a Mantel-Cox analysis to determine if DSS was associated with protection from
intestinal intussusception or rectal prolapse. When cases of euthanasia due to intussusception
and prolapse in Winnie mice were considered together, survival analysis indicated that there
was no difference in survival between treatment groups (χ2 = 3.30, P = 0.069; Fig. 4.3).
The unexpected mortality in the control group made comparisons between untreated Winnie
mice with Winnie mice receiving the five cycles of 1% DSS. Only Winnie mice receiving
drinking water displayed a trend toward increased weight gain with age (Fig. 4.4). Co-
inciding with symptoms of severe colitis, e.g. rectal bleeding, Winnie mice receiving five
cycles of DSS displayed a similar pattern of weight loss recorded in mice receiving three
cycles of DSS. Weight loss occurred approximately 1–2 days after commencement of DSS
administration and persisted for several days afterward before weight gain was observed
again.
4.2.2 Histopathology
To determine the extent of histomorphological changes in the colon of Winnie mice follow-
ing repeated DSS-induced inflammation, sections of H&E-stained colon were examined
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Figure 4.2: Intussusception of the caecum, small intestine and colon in Winnie. A.
Gross morphology of the undissected colon from a euthanased Winnie mouse. Note the
”ballooning” of the oral end of the colon and the discolouration of the caecum and anal end
of the enlarged proximal section. B. Partially dissected colon from A. demonstrating the
total obstruction of the colon caused by telescoping of the proximal colon and ileum within
the distal colon.
microscopically. Histological analysis of the two cases of intestinal intussusception revealed
an ischaemic inflammation was present in the mucosa and submucosa consistent with the
restricted blood flow to the in-folded intestine (Fig. 4.5A-B).
Histological analysis of the colon immediately after repeated administration of 1% DSS
for a total of four cycles revealed an abnormal regenerative crypt morphology in the single
animal examined. Consistent with an ongoing active inflammation, neutrophilic infiltration
was visible and often accompanied by crypt branching, distortion and hyperplasia in the
distal and middle colonic segments (Fig. 4.6A). Dysplasia-like lesions in the distal half of
the colon were not detected. The single animal killed 14 days after the end of the fifth DSS
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Figure 4.3: Survival of Winnie mice from intussusception/prolapse of the colorectum.
Survival analysis of euthanasia due to rectal prolapse or colonic intussusception in Winnie
mice. Winnie mice from the control group (H2O; n = 7) were compared to Winnie mice
receiving cyclic administration of 1% DSS (n = 8). Vertical bars represent censored events
(deaths due to other causes).
cycle still displayed the characteristic crypt hyperplasia in the background of a prominent
mucosal leukocytic infiltrate (Fig. 4.6B). Mild crypt distortion was evident along with crypt
fission in the inflamed distal and middle colonic mucosa. Analysis of a single animal after
the five cycles of 1% DSS displayed only mild distortions of the glandular architecture and a
modest crypt hyperplasia in the distal colon indicative of a return to the mild colitic Winnie
phenotype (Fig. 4.6C). By the age of 38 weeks (120 days since cessation of the fifth DSS
cycle), mice displayed the histological features of a mild colitis similar to that observed in
Winnie without repeated exposure to 1% DSS (Fig. 4.6D). The mucosa displayed a moderate
level of leukocytic infiltration into the mucosa of the distal and middle colonic regions. Crypt
architecture appeared mostly normal, with only occasional distortion and mild elongations.
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Figure 4.4: Body weight change in DSS-induced colitis Winnie mouse. Daily change
in body weight of Winnie mice during the five cycle DSS regimen. Body weight was
recorded each day and recorded as percentage change from the starting body weight prior
to commencement of the experiment (day 0). Each point represents the mean percentage
change in body weight relative to the initial body weight. Error bars depict standard deviation
(SD) from the mean. Grey vertical bars identify the seven day period during which DSS
solution was administered.
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Figure 4.5: Representative histopathology of intestinal intussusception in untreated
Winnie mice. A. Low-magnification field showing invagination of the villous ileum (top
of the image) within the colon (bottom of the image). Ischaemia is present in both small
and large intestine, but most prominent in the compressed segment of the intusscepted
ileum. B. Higher magnification of A showing detail of the in-folded small intestine/caecum.
Lymphocytic aggregates and neutrophils have accumulated in the mucosa and crypts show
a mild structural distortion. Submucosa is expansive with high volume of bleeding visible.
Stained with H&E. Scale bar represents 100 μm in A and 50 μm in B.
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Figure 4.6: Histological changes in the colon of Winnie after extended cycles of DSS.
A. Histology of the Winnie colon aged 20 weeks, immediately after the end of the fourth
DSS cycle. Note the hypertrophic mucosa containing distorted crypts. B. Distal colon from
Winnie at the age of 24 weeks, 14 days after cessation of the five-cycle DSS regimen. Crypt
epithelium displays marked distortion of the normal glandular architecture, reduced mucin
production and displays elongated basal nuclei with frequent mitotic figures. C. Histology
representative of the distal colon from Winnie mouse aged approximately 24 weeks, 86
days after cessation of the five-cycle DSS regimen. Marked inflammatory infiltrate present
with crypt distortion and elongation. Dysplastic-like lesions were absent from the colonic
mucosa. D. Distal colon from Winnie mouse aged approximately 38 weeks, 120 days after
cessation of five-cycle DSS regimen. Colonic mucosa approaching normal crypt length and
architecture with only a mild inflammatory infiltrate in the mucosa and submucosa. Stained
with H&E. Scale bars represent a distance of 50 μm.
4.3 Discussion
Since we observed an increased incidence of dysplasia-like crypt foci in the Winnie distal
colon following three cycles of 1% DSS, we planned on a five cycle-long DSS regimen
with the aim of producing more advanced dysplasia. Here we describe the histopathological
effects observed in the colon of Winnie twelve week-old Winnie mice over the course of
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190 days. Histologically, the pathology induced in the distal colon by five cycles of 1% DSS
was not remarkably different from that induced by three cycles of 1% DSS.
Occurrence of rectal prolapse is a relatively uncommon complication arising in mice due
to inflammation of the colorectum, such as in enterohepatic Helicobacter or Campylobac-
ter infection [69, 274]. Increased incidence of rectal prolapse is observed in Il10-/- and
lamellipodin-deficient mice, suggesting that rectal prolapse occurs secondary to an immune
defect permitting bacterial colonisation [69]. Subsequently, lamellipodin-deficient mice
have been shown to be prone to carcinoma of the rectum and the affected segment appears
vulnerable to prolapse [72]. Adenocarcinoma of the distal colon induced by AOM and DSS
similarly increased the incidence of prolapse in outbred ICR mice [272]. Similar to Il10-/-,
Winnie mice are prone to the development of rectal prolapse, with up to 25% of animals
developing rectal prolapse after reaching 12 months of age [250]. Similar initiating factors to
those involved in intestinal intussusception have been suggested to precipitate rectal prolapse.
Intestinal intussusception of the human adult intestine is a rare event when compared to
the number of juvenile cases [51]. While the majority of paediatric intussusception cases
are considered idiopathic, though some cases may be induced by rotaviral or bacterial
infection [52], adult intestinal intussusception typically occurs secondary to pre-existing
pathology [51]. Benign and malignant polyps, carcinomata, strictures and diverticula, may
all serve as lead points for invagination of a proximal segment of the bowel into the lumen
of the distal bowel [51]. Through the induction of inflammation through the intraperitoneal
injection of bacterial LPS, Nissan et al. were able to induce intussusception involving
either small or large intestines in 26% of adult BALB/c mice [275]. Supporting the theory
that inflammation precipitates intussusception in the adult intestine, blocking the effects
of TNF-α or NO reduced the incidence of intussusception, while increasing available NO
precursors increased the incidence of intussusception. Notably, strain effects modify the
incidence of intussusception induced by LPS in mice. The C57BL/6 strain demonstrate
considerably higher resistance to LPS-induced intussusception than the BALB/c strain and
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the outbred ICR strain [276]. Both BALB/c and C57BL/6 mice were shown to produce
similar levels of pro-inflammatory TNF-α, IL-6 and NO in response to LPS suggesting that
the basis of susceptibility to intussusception may not be due to differences in immunological
responses to LPS [276]. Given that inflammatory, and a variety of other non-neoplastic and
neoplastic lesions increase the incidence of intestinal intussusception, it might be expected
that exacerbation of chronic inflammation in Winnie using DSS would promote intussus-
ception. Unexpectedly, all cases of intussusception in Winnie mice occurred in co-housed
litter-mates which were assigned to the control group and thus never received DSS at all.
While an inflammation of the distal colon would still have been present in untreated Winnie,
no obvious lesions that could be considered to act as a lead-point for the intussusception
could be identified histologically.
The occurrence of complicating intestinal intussusception in Winnie, involving either ileum-
proximal colon or prolapse of the rectum, may arise as a consequence of neuromuscular
perturbation. A hypothesised neuromuscular defect preceding the occurrence of intestinal
intussusception is supported by animal models [275]. Inhibition of smooth muscle contrac-
tion by MnCl2 co-incided with an increased incidence of intussusception regardless of the
employed mouse strain [276]. The relative resistance of C57BL/6 mice to LPS-induced
intussusception may therefore be explained by the co-inciding hyper-contractile response
when compared to BALB/c mice. The occurrence of intestinal intussusception and prolapse
in Winnie could also be attributed to defects in the intestinal motility of these animals. Study
of the colonic innervation in the chronically inflamed Winnie colon has identified reduc-
tions in cholinergic, noradrenergic and sensory neuronal nerve fibres relative to wild-type
C57BL/6 [277]. The prolapsed rectal mucosa in Winnie displays further reduction still
in smooth muscle innervation. Decreases in inhibitory motor neurones and cholinergic
nerve fibres in particular were associated with rectal prolapse [71]. Investigation into the
contractile activity of the distal colon in Winnie has explained some of the functional effects
of the neurological damage previously reported in Winnie. Decline in the density of intact
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colonic cholinergic nerve fibres corresponds with a decreased amplitude of colonic excita-
tory junction potential and reduced smooth muscle contraction in response to cholinergic
stimulation [278]. Simultaneously, inhibitory neurotransmission into the smooth muscle of
the distal colon in Winnie was diminished. Purinergic neurotransmission was decreased,
particularly the fast component of the inhibitory junction potential in the smooth muscle
of the Winnie distal colon relative to C57BL/6 [278]. Additionally, distal colonic smooth
muscle in Winnie mice was resistant to NO-induced relaxation relative to C57BL/6 mice,
despite equivalent numbers of nNOS-expressing inhibitory motor neurones present in both
Winnie and the wild-type [277, 278]. Some of these changes in neurotransmission within the
distal colon can be explained the presence of a local inflammation. For example, purinergic
transmission is impaired in the colon of mice following administration of DSS, likely due
to an inflammation-induced inhibition of purine synthesis and transport [279]. Similarly,
the distal colonic smooth muscle in Il10-/- mice displayed an absence of a relaxation in
response to nitrergic signalling [280]. The source of the defect in nitrergic neurotransmission
in Winnie however requires further investigation. Though they were not analysed in the
present study, changes to the musculature of the distal colon and rectum have also been
observed in Winnie. Hyperplastic thickening of the muscularis externa in the distal colon of
12–16 week-old Winnie is likely consistent with the ongoing inflammation [278]. Further
thickening of the rectal muscularis externa by approximately four-fold has been observed in
Winnie with rectal prolapse relative to Winnie without prolapse [71]. However, the presence
of exacerbated histological damage associated with the prolapse makes it uncertain as to
whether the thickening occurs as a result of inflammation secondary to the prolapsed tissue.
Generation of ROS/RNS may produce dysfunction in DNA repair enzymes, and induce
genetic mutation in the DNA of epithelial cells may explain the relationship between
duration and severity of colitis. Studies utilising cyclic administration of DSS in mice
have demonstrated that the incidence of dysplasia and cancer is related to the severity of
inflammation. Cooper et al. reported an association between dysplasia and carcinoma and
4.3. DISCUSSION 96
high grades of histologic inflammation [225]. If animals were killed immediately after the
end of the four cycles of 5% DSS the incidence was approximately double that observed if
mice were examined 120 days after the four DSS cycles (204 days in total). Winnie mice
exposed to five cycles of 1% DSS displayed the dysplasia-like phenomenon in the distal
colon similar to that observed after three cycles. However, the histological examination of
Winnie mice killed at time-points up until 120 days after the end of the five-cycle experiment,
revealed a regression in the complexity of the abnormal crypts. At 120 days after the end of
the five-cycle experiment, when mice were approximately 39 weeks-old the incidence of
dysplasia-like lesions was low. Considering that the morphology of dysplasia-like lesions
appeared to be less severe in animals which had experienced the longest period of recovery
post-DSS, it is possible that these lesions are of non-neoplastic origin. It should be noted
however, that colonic tumours initiated by DSS alone occur at a low frequency. Although
an tumour incidence of 37.5% was reported in outbred Swiss-Webster mice 120 days after
four cycles of DSS, a similar DSS regimen produced an incidence of 12.5% C57BL/6
mice [225, 235]. While DSS alone, or the resulting colitis, has been shown to initiate
neoplasia in the absence of tumourigenic genetic mutations, long-term exposure is required
and the incidence of neoplasia is relatively low.
The addition of AOM to the DSS-induced colitis provides a reproducible model of colitis-
driven colonic neoplasia with a short duration from administration to tumour onset. One
advantage to using the AOM-DSS model is that the progressive, pre-neoplastic change in
the histology of the colonic mucosa has been studied in detail.
In a time-course study of AOM-DSS in ICR mice, adenomatous tumours could be identified
in 40% of mice as early as the third week after AOM administration [273]. Tumour
incidence increased rapidly, increasing to 100% of mice by the sixth week from AOM
administration. Adenocarcinoma was identifiable early, detectable within the colons of 40%
of animals. Similar incidences of neoplasia are also observed in BALB/c mice, though the
incidence of neoplasia in C57BL/6 mice is considerably decreased despite using the same
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protocol [273]. Considering that the C57BL/6 strain are among the mouse strains known
to display resistance to colonic carcinogenesis, use of AOM-DSS or even AOM alone, in
Winnie would be informative [263].
The earliest observed lesion preceding AOM-induced adenomatous tumours is the ”aberrant
crypt focus” (ACF). Expansion of the ACF is thought to occur through crypt fission, by
which clusters of abnormal crypts are formed. Expansion of ACF via the process of crypt
fission is likely to be facilitated by the mucosal ulceration induced by DSS. Regenerating
mucosa adjacent to ACF may allow abnormal crypts to rapidly spread laterally through the
mucosa. Identification of ACF may be performed by examination following staining with
methylene blue, however this was not performed.
Under the assumption that the Muc2 mutation in Winnie had no effect on colonic tumourigen-
esis, and given the small number of mice which survived to 38 weeks, it might be reasonable
to see few Winnie animals displaying neoplasia. While the C57BL/6 strain is relatively
resistant to the induction of colonic inflammation and neoplasia by DSS, defective Muc2
secretion was expected to render Winnie mice susceptible to colonic neoplasia similar to total
Muc2 abrogation [99]. Since an increased number of DSS cycles has been shown repeatedly
to accelerate the onset of neoplasia, we assumed that the duration required to observe the
incidences of neoplasia (68% by twelve months) reported by Velcich et al. was due to
the low-level of inflammation present in Muc2-/- animals [99]. While further experiments
utilising larger cohorts of mice are necessary to obtain more accurate evidence for the rate
of neoplastic progression in the severely inflamed Winnie colon, this experiment raises the
possibility that the Winnie Muc2 mutation suppresses tumourigenesis.
4.4 Conclusions
While prolapse of the rectum is a known complication of the Winnie mutation, intestinal
intussusception has to our knowledge, not previously been reported in Winnie. Despite
the association between rectal prolapse and the Winnie phenotype, more severe colitis
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induced by repeated DSS administration did not appear to influence the rate of prolapse and
intussusception. Foci of abnormal crypts were observed within the distal half of the colon in
Winnie after repeated administration of 1% DSS but were absent from control Winnie mice.
Crypt derangement however, may be a transient phenomenon, with mice displaying little
evidence of dysplasia-like crypts 120 days post-cessation of the cyclic DSS protocol.
CHAPTER 5
INVESTIGATION OF MOLECULAR
PATHWAYS REGULATING
TRANSITION FROM COLITIS TO
DYSPLASIA
5.1 Introduction
Detection of early dysplasia within the chronically inflamed colon, is difficult due to the
morphological similarities between dysplastic and regenerative epithelium. Since certain
molecular changes in neoplastic precursor cells are likely to precede the manifestation of
obvious morphological abnormalities, detection of these changes may aid in the identification
of early dysplasia in IBD.
The most obvious feature common to both regenerative and dysplastic epithelium is that
of abnormal proliferation of the crypt epithelium. Several investigators have assessed the
validity of discrimination between regenerative changes and genuinely neoplastic transfor-
mations using the pattern of cellular proliferation in the colonic epithelium. Two markers of
cell proliferation in particular have been studied in colorectal neoplasia, the nuclear proteins
Ki67 and proliferating cell nuclear antigen (PCNA). The monoclonal anti-human Ki67
antibody (clone MIB-1) used extensively in a diagnostic setting to visualise cell proliferation
in humans has limited reactivity to the homologous mouse Ki67 (Mki67). Monoclonal
anti-mouse Mki67 (TEC-3 clone) antibodies however, have been reported to replicate the
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effectiveness of the anti-human Ki-67 antibodies in detecting cellular proliferation in FFPE
murine intestinal specimens [281]. The form of Ki67 detected by the MIB-1 antibody is ob-
served in cycling cells, present in G1, S, G2 and M phases, but is absent in the G0 phase [282].
Immunoreactivity with anti-Ki67 antibodies therefore corresponds to proliferative status of
the labelled cell. In the normal human colonic mucosa the strongest labelling with Ki67 is for
the most part, confined to the basal third of the crypt epithelium, the so-called proliferative
zone. Under active inflammation and regeneration the crypt epithelium exhibits an apparent
expansion of the Ki67+ proliferative zone toward the luminal surface [283].
Invasiveness and metastasis of epithelial cancers has been associated with a phenotypic
conversion from a differentiated epithelial cell to a motile cell type resembling mesenchymal
cells during embryogenesis [284]. The so-called epithelial-mesenchymal transition (EMT)
could conceivably permit a transformed cell to detach from the surrounding tissue and mi-
grate into separate tissue compartments thus facilitating invasion and metastasis of tumours.
Attachment of epithelial cells to the neighbouring epithelial cells is mediated by several fam-
ilies of cell-surface proteins which form the adherens junctions. A key membrane-spanning
protein critical for the maintenance of epithelial integrity and polarity in the colon is the
epithelial cadherin (E-cadherin) through its signalling via β-catenin [208]. Absence of ho-
motypic interaction between E-cadherin on adjacent epithelial cells results in the activation
of the associated β-catenin, which then shuttles to the nucleus to form a transcriptional
regulation complex with lymphoid enhancer-binding factor (LEF). Excessive levels of active
β-catenin, due to genetic mutations in APC or the gene encoding β-catenin (CTNNB1) are
thought to promote neoplasia through their contribution to the up-regulation of genes encod-
ing Myc and cyclin-D1. While oncogenic β-catenin signalling appears to correspond to the
altered proliferation and differentiation of epithelial dysplasia, it may also be involved in
the EMT. be less useful for the escape from the adjacent stroma seen in advanced neoplasia.
Loss of E-cadherin may also amplify the effect of oncogenic β-catenin on transformation
of the colonic epithelium [285]. Silencing of E-cadherin (Cdh2) transcription by promoter
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methylation has also been suggested as a possible risk factor for neoplasia in patients with
UC [202]. Changes in adhesion molecules such as E-cadherin is associated with a transition
to a mesenchyme-like phenotype in epithelial cells [286]. Cadherin switching, such as a
reduction of functional E-cadherin co-inciding with an increased cell-surface expression
of the neuronal cadherin (N-cadherin) has been proposed as a marker of EMT, and is one
characteristic observed in cancers [287]. Ectopic expression of the vimentin intermediate
filament in epithelial cells also corresponds with increased potential for invasiveness and
metastasis in colonic adenocarcinoma cells [288]. Detection of these features in the colonic
epithelium in the colonic epithelium of Winnie may thus indicate the transition to a neoplastic
phenotype.
5.2 Aims/Hypothesis
Since a number of molecular pathways have been identified that may predispose the chron-
ically inflamed colonic epithelium to neoplasia, we intended to first analyse the gene
expression within the distal colon of DSS-treated and untreated Winnie and wild-type mice.
Increased cellular proliferation and nuclear localisation of β-catenin in the distal colonic
epithelium of abnormal crypts in Winnie after three cycles of inflammation were expected.
Since E-cadherin is frequently lost in IBD-associated neoplasia it would be expected that the
abnormal distal colon in Winnie would display a molecular signature indicative of EMT.
5.3 Results
5.3.1 Epithelial cell proliferation in the Winnie colon
Aberrant patterns of crypt epithelial cell proliferation have been identified in precursors to
colonic neoplasia. Immunoreactivity for Ki67 protein was therefore employed as a means to
identify proliferative cells within the colonic epithelium. Normal Ki67 labelling in untreated
C57BL6 mice extended uniformly for approximately a third of the crypt’s total length
(Fig. 5.1A). Examination of the intracryptal distribution of Ki67-expressing epithelial cells
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revealed < 20% of the total cells were labelled by the anti-Ki67 antibody in the apical
portion of the crypts in the distal colon C57BL6 mice (Fig. 5.1A). Higher proportions of
labelled cells were visible within the middle and basal regions of crypts in the C57BL6 distal
colon, approximately 52% and 68% respectively (Fig. 5.1B & C). Three cycles of 1% DSS
in C57BL6 mice produced an apparent expansion of the proliferative zone in the crypts of
the distal colon (Fig. 5.1B). While the proportion of Ki67-positive cells in the top (Fig. 5.1A)
and middle (Fig. 5.1B) crypt divisions was similar to untreated C57BL6 mice, the DSS-
treated animals displayed an increased proportion of Ki67-positive cells in the crypt base
(90%). In Winnie the proliferative zone of the colonic crypt appeared to frequently extend
to approximately half to two-thirds of the total crypt length in the distal colon (Fig. 5.1C).
Despite an apparent shift in the distribution of Ki67-expressing epithelial cells, the proportion
of labelled cells was not markedly different in the top ( 25%), middle (60%) and basal (67%)
crypt divisions when compared to both untreated and treated C57BL6 (Fig 5.1A–C). Most
cells within the crypt base in Winnie expressed Ki67 (Fig. 5.1C) and like in C57BL6 mice,
the proportion of Ki67-positive cells decreased progressively from the middle (Fig. 5.1B) and
upper (Fig. 5.1C) portions of the crypt. Chronic exacerbation of colitis in Winnie using three
cycles of DSS extended the Ki67-reactive proliferative zone toward the surface epithelium
further than that typically seen in Winnie (Fig. 5.1D). Crypts with dysplasia-like architectural
distortion in Winnie displayed more diffuse Ki67 labelling throughout the crypt length. The
diffuse labelling was also retained as a feature of glands penetrating into the submucosa.
Despite the diffuse pattern of Ki67 expression, the proportion of Ki67-expressing cells in the
top and middle crypt divisions were not markedly different from the distal colon of untreated
Winnie or either untreated or treated C57BL6 mice (Fig. 5.1A–5.1C). When the whole crypt
length was considered, the proportion of Ki67-expressing cells was overall not markedly
different between any of the combinations of genotype and treatment (Fig. 5.1D). Thus,
potential alterations to proliferative cell localisation are likely to co-incide with an increase
in the total cell number within the crypt.
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5.3.2 β-catenin localisation in the Winnie colon
To assess whether oncogenic perturbations in epithelial Wnt/β-catenin signalling were present
in the chronically inflamed mucosa, we analysed the intracellular distribution of β-catenin
immunohistochemically. Localisation of β-catenin in the colonic mucosa of untreated Winnie
mice was restricted to the cell membrane of polarised cell types, specifically the colonic
epithelial cells, endothelial cells and the glial cells of the myenteric plexus (Fig. 5.2A).
Expression of β-catenin in the colonic epithelium was strongest at the lateral membranes
between adjacent epithelial cells. Distribution of β-catenin in the colonic epithelium of
Winnie mice remained largely unchanged after three cycles of DSS (Fig. 5.2B & 5.2C).
Weaker cytoplasmic labelling may also be observed in the apical epithelium and epithelial
cells of the crypt base in both untreated and DSS-treated Winnie mice. However, no nuclear
translocation of β-catenin was evident in normal or any of the dysplasia-like lesions in
Winnie mice after three cycles of DSS administration.
5.3.3 Gene expression analysis
To identify potential molecular pathways resulting in an abnormal epithelial regenerative or
dysplastic response, we employed an pre-designed, commercially available qPCR array of
targets associated with gastro-intestinal neoplasms (identity of genes covered are listed in
Table A.1. Gene expression was compared between the distal colon of an untreated Winnie
animal and a Winnie animal with severe distal colonic disease (shown in Fig. 3.7E-H) after
three cycles of DSS. Transcript amplified by 13 primer sets displayed greater than a two-fold
difference between untreated and DSS-treated animals (Fig. 5.3).
Differences in genes thought to influence neoplastic processes in the distal colon were
subsequently assessed in Winnie following three cycles of DSS (primer information listed
in Table A.2). Three cycles of 1% DSS increased expression of caveolin-1 (Cav1 in the
wild-type colon (Fig. 5.4). In the Winnie colon however Cav1 expression was no different
between untreated and DSS treatment. Three cycles of DSS induced an increase in C-C-
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Figure 5.1: Immunohistochemical detection of Ki67 in Winnie distal colonic mucosa A.
Immunostaining of Ki67 in the distal colon of untreated C57BL6 mice. Image representative
of Ki67 localisation in the distal colon of the four C57BL6 mice examined. B. Distal
colonic Ki67 localisation representative of six C57BL6 mice exposed to three cycles of
1% dextran sulphate sodium (DSS). C. Distal colon of Winnie mouse without exposure
to three cycles of DSS. Ki67-labelling in the epithelium is visible apically approximately
half the crypt length. D. Ki67 immunolabelling of the Winnie distal colon exposed to three
cycles of DSS. Crypt base proliferative zone extends approximately two-thirds of the crypt
length. Submucosal gland (arrowhead) displays few positive nuclei. E-G. Proportion of
cells labelled by anti-Ki67 antibodies of the total cells in the apical (E), middle (F) and
basal (G) region of crypts in the distal colon. H. Proportion of Ki67-expressing cells of the
total number of cells within the full crypt length. All images were drawn from untreated
wild-type (n=3), wild-type + DSS (n=4), untreated Winnie (n=3) and Winnie + DSS (n=4).
Differences between means for which P <0.05 was deemed significant. Bars represent mean
of the proportion of Ki67-expressing cells of the total crypt epithelial cell nuclei counted.
Error bars represent one standard deviation from the mean. Differences between means were
considered significant if the P <0.05. Scale bars represent a length of 50 μm.
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Figure 5.2: Absence of β-catenin nuclear translocation in Winnie mucosa A. Distal
colon representative of the six untreated Winnie mice studied. Staining specific to β-catenin
is localised to the cell membrane of the colonic epithelium and to the plasma membrane
of endothelial and glial cells. B. Representative image of the distal colon Winnie mice
subjected to three cycles of 1% DSS (n = 11). Expression of β-catenin was predominantly
limited to the cell membrane to the cell membrane of epithelial cells without any nuclear
accumulation. Scale bars represent 50 μm. C. Relative area area of tissue stained using
anti-β-catenin antibody obtained from 10 random fields at 400× magnification. All images
were drawn from untreated Winnie (n=5) and Winnie + DSS (n=7). Plotted bars represent
mean of the relative area, errorbars equal to 1 SD of the mean. Differences between means
for which P <0.05 was deemed significant. Scale bar represents 50 μm.
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Figure 5.3: Screening for potential markers of neoplastic transition in the Winnie colon.
Relative mRNA transcript abundance for 88 target genes on a commercially available PCR
array (refer to Table A.1 for gene) between a single Winnie mouse exposed to three cycles
of 1% DSS and a single age-matched Winnie mouse that had received only water. A. Genes
for which relative abundance of mRNA transcript was increased in Winnie following three
cycles of 1% DSS relative to untreated Winnie. B. Genes for which mRNA transcript is
decreased in Winnie following three cycles of 1% DSS compared to untreated Winnie.
Bars represent fold change in relative transcript abundance (2-ΔΔCT) relative to an average
of three reference genes; beta actin, (Actb), glyceraldehyde-3-phosphate dehydrogenase
(Gapdh), hypoxanthine guanine phosphoribosyl transferase (Hprt) with all changes relative
to expression in the untreated Winnie distal colon.
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motif-containing chemokine ligand-5 (Ccl5) mRNA transcript in the Winnie distal colon
relative to wild-type mice treated with DSS. Expression of Myc was approximately two-fold
higher in the distal colon of wild-type mice after DSS compared to untreated wild-type
mice. In contrast three cycles of DSS produced no detectable effect on Myc expression in
the Winnie distal colon. Expression of murine transformation-related protein p53 (Trp53) in
the distal colon of Winnie mice was not appreciably altered from baseline following three
cycles of DSS. Treatment with DSS however induced a higher level of Trp53 transcription
in Winnie than in WT mice. None of the remaining genes displayed a detectable difference
between genotype or treatment groups.
Figure 5.4: Relative transcript abundance of genes regulating inflammation and cell
proliferation. Transcript abundance measured from 25 ng of template based on the linearised
2-ΔCT method, where each gene of interest was normalised to the relative abundance of a
reference gene (Gapdh). Box plot depicts interquartile range (IQR) either side of the median
for untreated C57BL/6J mice (n = 3), C57BL/6J mice exposed to three cycles of 1% DSS (n
= 6), untreated Winnie mice (n = 6) and Winnie mice exposed to three cycles of 1% DSS (n =
11). Whiskers represent 1.5 IQR approximately equivalent to 5%-95% confidence intervals.
*, P < 0.05; **, P < 0.01.
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The existence of a potential relationship between the relative abundance of the measured
mRNA transcript in the distal colon of pooled Winnie and C57BL6 mice and the grade of
dysplasia was tested using Spearman’s rank correlation (Table 5.5). We observed monotonic
increases in the gene expression of Ccl5 (ρ = 0.46) and Spp1 (ρ = 0.40) correlated with
increasing severity of dysplasia. All of the other genes analysed displayed no discernible
statistical association between gene expression and histological severity.
5.3.4 Immunohistochemical detection of Cxcl5
Although Cxcl5 levels in the colon may reflect progression of colonic neoplasia, no difference
in the expression of this chemokine in the colon at the gene level was observed. Since
Cxcl5 relative abundance was variable within the distal colon of Winnie mice we sought to
investigate the source and distribution of the Cxcl5 protein within colonic tissue. Wild-type
mice displayed a diffuse cytoplasmic staining in the colonic crypt epithelium only, with
strongest staining intensity typically in the surface epithelium (Fig. 5.6A).
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Figure 5.5: Spearman’s correlation between mRNA transcript abundance and dyspla-
sia severity. Relationship between relative mRNA abundance (ΔΔCT) and severity of
dysplasia in the distal colon was tested using Spearman’s rank correlation. Estimate of
Spearman’s co-efficient of correlation (R) and corresponding P-value for each gene are
given.
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Exposure of the distal colon of wild-type mice to three cycles of 1% DSS did not produce
considerable increases in the intensity of the surface epithelium in the distal colon (Fig. 5.6B).
Stronger staining intensity corresponding to Cxcl5 protein became more frequent in the top
third of the colonic crypt in Winnie compared to the wild-type animals studied. Similarly,
colitis induced by the Muc2 mutation in Winnie mice was associated with an increase in
Cxcl5 protein levels within the intestinal epithelium (Fig. 5.6C). An additional insult of 1%
DSS in Winnie mice appeared to increase the vesicular pattern of Cxcl5 staining in the distal
colonic epithelium, and most notably, increased the abundance of mucosal and submucosal
leukocytes (Fig. 5.6D-5.6E). Abnormal crypts induced by three cycles of DSS in Winnie
often displayed a marked, focal reduction in cytoplasmic Cxcl5 staining (Fig 5.6F). One
animal presenting with a lesion of extensive high-grade dysplasia displayed an abnormally
low level of cytoplasmic Cxcl5 expression in the colonic epithelium whereas lamina propria
leukocytes displayed intense cytoplasmic staining (Fig. 5.6F). Overall however, the relative
distribution of Cxcl5 was not markedly different between any of the combinations of
genotype and DSS treatment.
5.3.5 Epithelial-to-mesenchymal transition
To assess the possibility of EMT occurring in the chronically inflamed colon of Winnie mice,
we analysed the immunohistochemical localisation of two mesenchymal markers, vimentin
and N-cadherin. N-cadherin in the colon of six 18–20 week-old Winnie mice was observed
predominantly between inner and outer coats of the tunica muscularis corresponding to
location of the myenteric plexus, although an infrequent staining of an elongated cell type
was also observed in the mucosal stroma (Fig. 5.7A). No discernible changes in the pattern
of N-cadherin-specific staining were observed in the colon of the Winnie mice following
three cycles of DSS administration (n = 11) compared to age-matched mice which never
received DSS (Fig. 5.7B). No epithelial localisation was observed in Winnie mice even in
crypts penetrating into the submucosa. Increased N-cadherin immunostaining was observed
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Figure 5.6: Immunohistochemical detection of Cxcl5 in Winnie distal colonic mucosa
The distribution of Cxcl5 was assessed in the mucosa of both wild-type and Winnie mice,
with or without prior exposure to three cycles of 1% DSS. A. Distal colon representative
of four 18-20 week-old wild-type C57BL6 mouse without DSS exposure. B. Distal colon
representative of six analysed wild-type C57BL6 mouse exposed to three cycles of 1%
DSS. C. Distal colon from 18-20 week-old Winnie without DSS exposure. Cxcl5 labelling
displayed a diffuse cytoplasmic pattern within the colonic epithelium. D. Exposure to DSS
increased the intensity of epithelial staining in the hyperplastic mucosa, particularly in the top
half of the crypt. Note the vesicular intracytoplasmic staining within epithelial cells. Intense
cytoplasmic staining was also observed in mucosal leukocytes. E. Distal mucosa of Winnie
exposed to DSS. Dysplastic glands displaying focal reduction in epithelial Cxcl5. Note that
laterally spreading epithelium penetrating the muscularis mucosae retains Cxcl5 expression.
F. Mucosa of distal colon in Winnie post-DSS exposure. Weak Cxcl5 immunolabelling is
present within the cytoplasm of the epithelial cells lining dysplastic glands. Counterstained
with haematoxylin. G. Average area stained by the anti-Cxcl5 antibody relative to total area
obtained from 10 random fields at 400× magnification. Plotted bars represent mean of the
relative area, errorbars equal to 1 SD of the mean. All images were drawn from untreated
wild-type (n=2), wild-type + DSS (n=4), untreated Winnie (n=3) and Winnie + DSS (n=7).
Differences between means for which P <0.05 was deemed significant. Scale bar represents
50 μm.
in the submucosal stroma associated with a sporadic colonic adenoma (Fig. 5.7C). However,
no epithelial staining was observed. Epithelial expression of N-cadherin was similarly absent
in invasive carcinoma of the colon in both of the two patients with IBD analysed (Fig. 5.7D).
Vimentin was frequently observed in the mucosa, submucosa and smooth muscle tunic of
the Winnie colon, apparently localised to the cell membrane and cytoplasm of an elongated
cell population (Fig. 5.8A). Occasional rounded cells displaying cytoplasmic vimentin were
observed in the lamina propria and epithelial compartments, though epithelial cells were
negative for vimentin. Notably smooth muscle cells did not appear to display vimentin
expression, with staining in the muscularis tunica localising to myenteric neuronal/glial
cells.
Exposure to three cycles of DSS in the Winnie distal colon resulted in an increase in the
intensity and density of vimentin staining within the mucosal lamina propria and within the
connective tissue of the submucosa (Fig. 5.8B). Again, epithelial expression was absent from
the colonic epithelium. Vimentin in the two patients with IBD generally remained associated
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Figure 5.7: Immunohistochemical detection of N-cadherin in Winnie distal colonic
mucosa. A. Distal colon of Winnie mouse having received water only. Labelling of N-
cadherin is restricted to mesenchymal tissues. Occasional cytoplasmic staining is present in
rare elongated pericryptal cells in the mucosa but absent in the epithelium. Prominent staining
of the neuronal tissue of the tunica muscularis is visible. B. N-cadherin immunolabelling of
the Winnie distal colon exposed to three cycles of DSS. N-cadherin present in the cytoplasm
of occasional spindle-shaped cells in the mucosa and submucosa, but absent in colonic
epithelium. C. Increased N-cadherin-positive spindle-shaped cells in the fibromuscular stalk
of a polypoid adenoma arising in the uninflamed distal human colon. D. Adenocarcinoma
arising in the colon of a patient with Crohn’s disease. No staining is visible within the
epithelium
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Figure 5.8: Immunohistochemical detection of vimentin in Winnie distal colonic mu-
cosa. A. Distal colon of Winnie mouse having received water only. Vimentin labelling is
restricted to mesenchymal tissues. Cytoplasmic staining is present in cells in the mucosal
lamina propria but absent in the epithelium. B. Distal colon of from Winnie mouse follow-
ing exposure to three cycles of DSS. Vimentin staining localises to the cytoplasm of the
elongated cells residing in the connective tissue of the mucosa and submucosa and is absent
in the colonic epithelium and smooth muscle layers. C. Adenomatous dysplasia from the
distal colon of a patient with IBD. Vimentin is present in the cytoplasm of cells resident in
the lamina propria. Cytoplasmic vimentin staining is also visible in a of cells with expansive
cytoplasm that appear to be shed from the glandular epithelium into the lumen of several
dysplastic crypts. D. Adenocarcinoma arising in the colon of a patient with IBD. No staining
is visible within the involved epithelium or within the desmoplastic stroma.
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neoplasia also displayed regions where vimentin was absent from the stroma surrounding
invasive crypts (Fig. 5.8D).
5.3.6 DNA methylation
Since gene promoter methylation may establish patterns of pro-tumourigenic gene expression,
pyrosequencing of bisulphite-converted promoter CpG sites was undertaken. Several genes
of interest were identified from the literature describing altered methylation in human
carcinogenesis or DSS-induced carcinogenesis (Primer sets are described in Table A.3).
Optimisation of several primer sets designed to amplify bisulphite-converted sequences was
commenced using DNA isolated from animals exposed to the three cycle DSS regimen
(Fig, 5.9). Pyrosequencing of gene promoter CpG regions may detect differential methylation
of the alcohol dehydrogenase-1 (Adh1) gene. For example methylation of promoter CpG
regions may be lower in wild-type C57BL/6J (Fig. 5.9A) relative to Winnie following three
cycles of 1% DSS (Fig. 5.9B).
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Figure 5.9: Adh1 gene promoter CpG methylation in the distal colonic mucosa. A
Pyrogram of wild-type and B Winnie post-DSS, where nucleotide sequence in order of
dispensation is displayed along the x-axis and y-axis represents the relative light intensity
generated from incorporation of nucleotides (in arbitrary units). Grey vertical bars mark
variable regions associated with CpG sites, orange bars represent the internal methylation
control.
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5.4 Discussion
Previous reports have suggested that histologically identifiable dysplasia in patients with
UC exhibit particularly strong Ki67 expression within the surface epithelium in addition
to the prominent Ki67 expression of the basal crypt epithelium similar to that observed in
non-neoplastic epithelium [283, 289]. The pattern of Ki67 expression in the colonic crypts
in Winnie mice displayed labelling of the crypt base but with an apical extension of the
proliferative zone, as could be expected in inflammation-induced hyperplasia. The typical
Ki67 distribution was expanded somewhat by three cycles of 1% DSS, however surface
staining for Ki67 was not observed. A diffuse pattern of Ki67 expression was observed
in a limited number of abnormal crypts, including those in the submucosa, following DSS
administration. Still other foci of abnormal crypts displayed regions apparently devoid of
Ki67 and were therefore potentially non-proliferative. Although pattern of diffuse epithelial
Ki67 expression has been reported as the predominant pattern of Ki67 expression in invasive
colorectal carcinoma, it is unclear what the cause for loss of Ki67 staining might be [283].
A loss of Ki67 has been observed at the invasive front of sporadic colonic carcinoma may
indicate that the abnormal spreading of these glands may co-incide with a lack of proliferative
activity.
Neutrophil recruitment, into the intestinal mucosa is a defining feature common to active
inflammatory conditions in the mammalian bowel. Patients with UC typically display
a diffuse neutrophilic infiltrate in the inflamed distal colon with neutrophils particularly
associated with crypt epithelial abscesses [290]. Aside from acute and chronic inflammation,
neutrophilic recruitment to the intestinal mucosa is observed in the stroma of colorectal
neoplasms. The recruitment of neutrophils and macrophages to the neoplastic stroma has
been associated with poor prognosis in patients with CRC [291, 292]. Tumour-infiltrating
neutrophils may promote tumour invasion and growth through production of ROS/RNS, pro-
inflammatory cytokines such as IL-6 and degradative matrix metalloproteinases [293, 294].
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The abundance of neutrophils in chronic colitis and CRC begs the question of whether the
presence of these cells in the chronically inflamed intestine is responsible for the rapid
progression to neoplasia in patients with UC.
Recruitment of leukocytes from the circulation requires both the production of a chemotactic
gradient and an alteration of the expression of surface adhesion molecules on endothelial
and leukocytic cells. For this purpose a family of signalling molecules termed chemokines
has evolved in mammals. Several subfamilies of chemokines exist, but two C-X-C motif-
containing ligands (CXCL), CXCL5 and IL-8 (CXCL8) have been identified as the principal
mediators of neutrophil recruitment in the intestine. Both CXCL5 and IL-8 contain a
neutrophil-activating motif containing glutamic acid-leucine-arginine (ELR) which upon lig-
ation with the C-X-C-motif chemokine receptor 2 (CXCR2), trigger chemotaxis, cytoskeletal
re-arrangement and adhesion molecule expression in neutrophils [295].
Consistent with reports of the distribution of CXCL5 protein in the human colon, Cxcl5 in
Winnie was limited primarily to enterocytes and activated monocytes in the distal colon of
Winnie [296]. Increased expression of CXCL5 has been reported in the colon of patients
with IBD, stimulated from epithelial cells by either increased pro-inflammatory cytokines
such as IL-1β or direct exposure to pathogenic bacteria [297]. Altered expression of Cxcl5
in Winnie may therefore facilitate the massive recruitment of neutrophils to the colon
during the active phases of inflammation, especially after DSS administration. Progression
from early dysplasia to carcinoma corresponded with increased Cxcl5 transcription in a
combined azoxymethane/DSS model of carcinogenesis [298]. The apparent positive trend
of increased CXCL5 with increased dysplastic-neoplastic progression has inspired several
studies into the potential use of CXCL5 as a prognostic biomarker. Levels of mucosal
and serum CXCL5 have been shown to reflect the progression of colonic neoplasms in
human patients [299, 300]. Transcription of Cxcl5 in the mucosa of the distal colon of
Winnie however, displayed considerable variation in the degree of up-regulation. The basis
of the variability in Cxcl5 expression was not immediately clear. Testing for a monotonic
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relationship between the severity of dysplasia in each animal and the relative abundance of
Cxcl5 transcript suggested that Cxcl5 transcription was probably unrelated to the degree of
morphological complexity of the colonic crypts in the distal colon of Winnie. Visualisation
of the synthesised Cxcl5 protein indicated differences in expression were associated with
inflammatory activity. Animals exposed to DSS displayed more frequent mucosal erosions,
and within these erosions strong expression of Cxcl5 was visible in infiltrating leukocytes. In
contrast, abnormal crypts often displayed weak labelling of Cxcl5. Transcription of CXCL5
in human colorectal epithelium carcinoma lines is regulated by the binding of nuclear NF-κB
adjacent to the CXCL5 promoter [301]. Therefore disruption of NF-κB binding reduced both
basal CXCL5 transcription and IL-1β-induced up-regulation of transcription in a colonic
carcinoma cell line. Since inactivation of p53 increases activation of NF-κB it would follow
that enhanced CXCL5 would co-incide with accumulated inactivating genetic mutations in
TP53 in the colonic epithelium.
Caveolin-1 is a membrane protein encoded by the gene Cav1 thought to regulate trans-
membrane signalling, particularly through its involvement in the formation of caveolae.
Both mRNA and protein levels of caveolin-1 are markedly reduced in human colon cancers
suggesting that caveolin-1 may serve to suppress tumourigenesis [302]. Homozygous Cav1
gene deletion has been demonstrated to permit increased cell proliferation and cell cycle
progression in mouse embryonic fibroblasts [303]. Modulation of proliferation is likely to be
varied given the multiple signalling pathways utilising caveolae. Reduction of caveolin-1 has
been associated with an increased in the cell cycle regulator cyclin D1 and a corresponding
hyperproliferation and cell cycle progression [304]. Importantly, abrogation of caveolin-1
may permit escape from adhesion-dependent control of cell proliferation [305]. Though dele-
tion of Cav1 in mice results in hyperplasia in respiratory, vascular and mammary tissues in
Cav1-/- mice, no spontaneous carcinoma has been reported [303]. An additional event, such
as mutation of Apc appears to be necessary for the initiation of colonic tumourigenesis [306].
Experimental evidence from ApcMin/+ mice bred with Cav1 depletion supported the notion
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that repression of caveolin-1 promotes expansion of neoplastic epithelial cells [307]. Due to
its apparent function as modifier of pro-proliferative signalling, examination of of the status
of Cav1 expression may be useful in assessing neoplastic transformation in the colon.
Detection of the accumulation of β-catenin in the epithelial cell nucleus through immuno-
histochemistry is typically dependent on inactivation of the APC-Axin-GSK-3β complex
and is thus considered indicative of oncogenic Wnt signalling. In the inflamed mucosa of
Winnie mice we failed to observe a discernible accumulation of immunoreactive β-catenin
in the nuclei of the colonic epithelium. The immunohistochemical localisation of β-catenin
in Winnie is comparable with the distribution of the same protein in the colonic mucosa of
Swiss-Webster mice exposed to repeated administration of DSS [225, 235]. Cooper et al.
describe nuclear accumulation detectable only in polypoid lesions arising from the inflamed
colon, whereas flat lesions described in the same animals, displayed cytoplasmic β-catenin
only. Polypoid adenomata induced by the combined administration of the mutagen 1,2-
dimethylhydrazine and DSS frequently display immunohistochemically detectable β-catenin
accumulation within the nucleus of transformed colonic epithelial cells [270]. However,
it is known that 1,2-dimethylhydrazine and its metabolite AOM produce mutations in the
gene encoding β-catenin when administered to mice [270, 308]. Carcinogenesis induced
by mutations in β-catenin may not be especially relevant in understanding the progression
of UC to CRC. Unlike sporadic neoplasms, in which nuclear beta-catenin was present
in 81% of tumour cells, Aust et al. [309] observed nuclear beta-catenin in only 48% of
tumour cells from colitis-associated neoplasms. Concordant with the reduced β-catenin
accumulation, mutations in APC reportedly occur at a lower frequency in colitis-associated
neoplasia relative to sporadic neoplasms [207, 310]. Given the difficulty in distinguishing
alterations in staining density in the cytoplasm, only the presence or absence of β-catenin
nuclear accumulation was asssessed. Colonic neoplasms arising from the inflamed colon of
mice with Gpx1-Gpx2-deficient animals (mixed C57BL6 and S129Sv/J strain) displayed
a high frequency of β-catenin accumulation in the ileum and colon, with 95% of HGD
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and 69% of adenocarcinoma presenting with visible nuclear accumulation. Given that the
majority of neoplasia arising in the Gpx double-knock-out mice was of a non-polypoid
morphology, the presence of nuclear β-catenin accumulation stands in contrast with the non-
polypoid lesions induced by DSS alone in the Swiss-Webster strain employed by Cooper et
al. [225]. It is important to note that nuclear β-catenin accumulations are not homogenously
distributed throughout colonic tumours. Instead nuclear β-catenin localisation may be more
common at the invasive front of colonic carcinoma, where cell dedifferentiation and motility
is increased [311]. Nuclear β-catenin localisation may in the case of the invasive front, be
indicative of the acquisition of a relatively dedifferentiated cell phenotype.
Perhaps consistent then with the lack of nuclear β-catenin in the abnormal colonic epithelium
in Winnie mice, evidence of mesenchymal-like surface markers was also absent. N-cadherin
was limited to its typical expression by neuronal and other mesenchyme-derived cells in the
colon of both Winnie mice, and the cases of CACC examined. While vimentin was perhaps
increased in the colonic lamina propria during inflammation in Winnie and in the stroma of
neoplasms from the human colon, no epithelial expression was observed. Therefore, the lack
of immunohistochemical evidence for an EMT switch in the colonic epithelium in Winnie
may correspond to the absence of oncogenic Wnt signalling via the canonical β-catenin
pathway.
Epigenetics involves transcriptional regulation through either DNA methylation or chromatin
remodelling and post-transcriptional regulation through micro-RNA (miRNA). Analysis of
colectomy specimens obtained from three patients with long-standing UC (disease present
for 10-20 years) revealed hypermethylation of CDKN2A associated with dysplasia [201].
Increased severity of dysplasia the inflamed mucosa was associated with higher levels of p16
methylation, whereas little methylation was observed in the non-dysplastic mucosa. Alternate
splicing of the first exon of CDKN2A produces the p14 isoform (p14ARF). Hypermethylation
of p14, like p16, has also been associated with neoplasia in the chronically inflamed colon.
While hypermethylation of the p14 exon is low in the non-dysplastic mucosa, paired tumour
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biopsies displayed relatively high levels of p14 methylation [312]. Fifty percent of UC-
associated carcinomata and 33% of dysplastic lesions displayed p14 hypermethylation.
Remarkably, 60% of non-dysplastic biopsies displayed p14 hypermethylation, a feature not
previously reported in the non-dysplastic mucosa of non-IBD patients, suggesting that p14
hypermethylation precedes dysplasia in the chronically inflamed colon.
5.5 Conclusion
In summary, Winnie mice displayed an abnormal pattern of epithelial proliferation that may
be explained by a pattern of abnormal mucosal gene expression. Winnie mice displayed an
apparent lack of Cav1 and Myc up-regulation in response to DSS-induced injury in the distal
colon. Conversely, while Trp53 appeared to be down-regulated after three cycles of 1% DSS
in wild-type mice, it was unaffected by DSS in Winnie. Gene expression of Ccl5 showed
a positive correlation with severity of DSS-induced lesions in the distal colon of Winnie.
Altogether, the absence of a immunohistochemically detectable, nuclear accumulation of
β-catenin complex, and a lack of ectopic N-cadherin or vimentin localised to the cell
membrane indicated that EMT was unlikely to contribute to the abnormal migration of the
colonic epithelium of Winnie following DSS-induced injury. Further characterisation of the
epigenetic activity in the colonic epithelium may yield further insight into the neoplastic
potential of the inflamed epithelium in Winnie.
CHAPTER 6
GENERAL DISCUSSION
Colorectal cancer arising from the chronically inflamed colon represents a considerable
cause of morbidity and mortality in patients with IBD. Non-specific, chronic inflammation
is hypothesised to trigger and promote the transformation of the colonic epithelium to a
neoplastic phenotype. The likely aetiology of IBD appears to lie in a trifecta of microbial
factors; an aberrant host immune response and an impairment of the mucous barrier pro-
tecting mucosal surfaces. Experimental evidence points towards a primary defect in the
integrity of the colonic mucus precipitating UC in particular. However, there is a dearth
of experimental evidence which explains how such defects would transform the normal
epithelium into pre-neoplastic or neoplastic cells. Investigating the pathological mechanisms
in models of colitis initiated by a defect in mucus synthesis and secretion would therefore
allow greater understanding of the link between IBD and colonic neoplasia.
The present study aimed to replicate the hypothetical progression from chronic UC-associated
colitis to neoplasia arising as a result of a defective mucous barrier and ER stress. The
Winnie strain of mice was selected for investigation as it replicates two key features of UC.
Firstly, Winnie displays reduced expression of the primary mucin constituent of the colonic
mucus, Muc2, a feature shared with patients with UC [256, 257]. Defective mucus secretion
is further compounded by the accumulation of defective, intracellular protein within goblet
cells of the colonic epithelium and the concomitant ER stress and activation of the UPR
similar to that reported in patients with UC [250, 313].
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6.1 Atypical regeneration in the Winnie colonic mucosa
The nature of the histopathological changes occurring in the Winnie distal colon following
three cycles of 1% DSS was consistent with regeneration after repeated bouts of mucosal
inflammation. The three-cycle DSS regimen was tolerated in Winnie with the expected
colitic symptoms (diarrhoea, haematochaezia) and attenuated weight gain, but only a single
mortality occurred due to DSS challenge. Consistent with an intact mucous barrier in
the wild-type distal colon, these animals displayed little histological damage or clinical
symptoms following three cycles of 1% DSS, suggesting that the concentration used was
insufficient to cause substantial disease. After exposure to three cycles of 1% DSS, foci
of crypts throughout the distal half of the Winnie colon, displayed an abnormal glandular
architecture suggestive of dysplasia. A subset of these lesions showed changes indicative of
dysplastic crypt architecture and an apparent very subtle cytological dysplasia consistent
with non-polypoid HGD in human patients. Chronic insult derived from DSS to the colonic
mucosa of mice has been shown to initiate and promote morphological changes indicative of
neoplastic transformation [225,226,237]. Thus it is plausible that pre-cancerous lesions may
arise in the Winnie colon with exacerbation of the pre-existing colitis using DSS.
Longer exposure to a 1% DSS solution would be expected to increase the incidence of
dysplasia in Winnie. However, five cycles of 1% DSS did not produce more complex or
invasive neoplasia, and no dysplasia was detected in animals allowed to lived beyond the end
of the fifth cycle (up to 120 days). Although the lack of animals examined at each time-point
following five cycles of DSS makes it difficult make inference about incidence of dysplasia
in Winnie mice, it would suggest that the dysplasia-like pathology regresses slowly after
DSS is removed.
The most well-characterised pre-cancerous, non-adenomatous lesions in the distal colon
identified in rodents are the ACF visible several weeks after administration of AOM-DSS
[314]. The ACF lesion may be readily identified by examining the morphology of the
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crypt opening stained with methylene blue. The crypt openings within ACF will display a
narrow, slit-like and distorted luminal opening. Besides the crypt opening, ACF features
may include a raised profile, thickened epithelia, mucin depletion and dysplasia, all to
varying degrees [315]. The abnormal crypts observed in the distal and mid-colon of Winnie
exhibit some similar features to hyperplastic and dysplastic crypts. In Winnie however,
mucin synthesis is reduced due to the Muc2 mutation, so a reduction in mucin is unlikely
to be a useful predictor of neoplastic potential. Although dysplastic ACF are considered
pre-cursors to colonic carcinoma, a considerable number of ACF may not proceed to form
tumours, despite the presence of genetic mutations in genes such KRAS [316, 317]. The
abnormal crypts observed in Winnie may therefore be expected to regress when the severe
pro-inflammatory stimulus is removed unless tumour-suppressing Apc/β-catenin signalling
is inactivated [318].
Winnie mice at the age of eighteen weeks displayed an abnormally high level of epithelial
cell proliferation, even without DSS administration. Although not measured in the present
study, abnormally high levels of proliferation in the Winnie colonic epithelium may be
explained by increases in pro-inflammatory cytokines in response to a defective colonic
mucous layer. Though the content of the environmental microbiome is likely to differ
between our animal facilities and those from which previous descriptions of Winnie have
originated, it might be assumed that the immune reaction to the luminal bacteria maintains
an IL-1β/TH17-dominant cytokine profile [250, 251]. Repair of the colonic epithelial barrier
following DSS-induced colitis has been shown to be at least partly dependent on the mucosal
production of IL-1β [319]. Also critical to the proliferation of the colonic epithelium
during mucosal inflammation is the production of IL-6 [320]. Thus it is conceivable then
that chronic production of cytokines such as IL-1β and IL-6 in the Winnie distal colon
maintains a heightened epithelial proliferation manifesting as colonic hyperplasia, even
without exposure to DSS. A persistent defect in the colonic mucus in Winnie would therefore
be expected to promote the rapid accumulation of mutant epithelial cells and formation of
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dysplastic lesions. While Winnie mice displayed a florid regenerative response to mucosal
inflammation, this appeared to be a transient phenomenon, which would seem somewhat
contrary to other murine models of mucous defects.
6.1.1 Mouse strain sensitivities to colitis and neoplasia
Interpretation of disease phenotype induced in mice through single gene deletions or inser-
tions is complicated by the differences between the background genetics of the various inbred
mouse strains used. Inbred mouse strains have demonstrated differing susceptibilities to both
colitis and colonic neoplasia. It is well known for example, that the C57BL/6J mouse strain
displays a comparatively higher resistance to the induction of colitis. The concentration of
DSS and length/number of DSS cycles is therefore typically higher in C57BL/6J than that
required to induce a similar disease severity in C3H/HeJ mice [321]. Colitis penetrance and
severity is considerably increased in 129SvEv Il10-/- mice compared to C57BL/6 Il10-/- or
BALB/c Il10-/- animals [239]. Continuous inbreeding of 129SvEv IL-10-/- over a two-year
period in some cases produced mice exhibiting reduction in penetrance and severity of dis-
ease [240]. Similarly, cross-breeding of 129SvEv mice harbouring Gαi2 knock-out mutation
with C57BL/6 mice reduced the severity of disease and produced lower rates of neoplasia
that reported in pure-bred 129SvEv [246,322]. It should come as no surprise then, that colitis
induced by Muc2-deficiency in C57BL/6 mice manifests in early adulthood as opposed to an
onset of colitis during weaning as reported in 129Sv mice [323,324]. Background genetics in
the C57BL/6J strain used as the basis for the Winnie mutation may therefore account for the
lack of advanced neoplasia in Winnie. Susceptibility of the colonic epithelium to neoplastic
transformation appears to be similarly modified by the mouse strain. The C57BL/6 strain
has been reported to be more resistant to induction of tumours using the azoxymethane than
the FVB/N and 129SvJ strains [325]. Since the original description of adenocarcinoma in
the Muc2-/- was derived from a mixed C57BL/6J × 129Sv strain, the incidence of neoplasia
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may therefore be higher in the colon of the mixed strain than a pure-bred C57BL/6 strain
with the same deletion of both Muc2 alleles [99].
6.1.2 ER stress
The Winnie strain offers a unique pathology for the exploration of chronic colitis due
to a primary defect in protein synthesis within the colonic goblet cells. Misfolding of
the Muc2 protein within the ER and secretory network of the colonic goblet cells in the
Winnie colon is associated with activation of the UPR [250, 326]. All three major UPR
pathways (PERK-eIF2α-ATF4, ATF6 and IRE1 pathways) display increased activity in
the distal colon of Winnie mice [326]. The engagement of multiple elements of the UPR
are likely to have wide-ranging effects on the physiological functioning of the colonic
epithelium in Winnie mice, especially where the stress is constantly present. Chronic ER
stress and UPR activation results in a global reduction in protein synthesis within the affected
cell [327]. Transcription of Muc2 may itself be the target of UPR-mediated repression as
Muc2 mRNA is reduced in Winnie mice relative to the wild-type [241, 250, 326]. Notably,
differentiation of the secretory cell lineage in the Winnie colon may be impaired by the
presence of a chronic ER stress since mRNA levels of the transcription factor Spdef are also
reduced [241]. Most of the crypt lesions resembling dysplasia observed in Winnie following
exposure to DSS displayed a depletion in histologically identifiable intracellular mucus.
Here immunolabelling of the intestinal trefoil factor-3 (TFF3) would enable the measurement
of terminally differentiated goblet cell numbers and assistance in determining the extent to
which secretory cell maturation is impaired in the abnormal crypts in Winnie. Differentiation
of the colonic epithelium is determined by interactions between Notch and Wnt/β-catenin
signalling pathways. While Notch and Wnt signalling in the Winnie distal colon has not
been studied in detail, Notch is known to increase the transcription of Myc [329]. Deletion
of Myc within the intestinal epithelium prevents the induction of oncogenic expression
of Wnt/β-catenin target genes in the absence of functional Apc [328]. Artificial over-
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expression of Myc alone has been shown to be capable of suppressing the differentiation
of intestinal goblet cells, perhaps through de-differentiation or trans-differentiation [329].
While repeated exposure of C57BL/6 mice with wild-type Muc2 to 1% DSS appeared to
induce an up-regulation in Myc at the transcriptional level, Winnie mice displayed no such
change. While it is unclear which factors restrain Myc up-regulation in Winnie following
DSS, it is conceivable that the stimulus for this may originate from the UPR. The Myc
protein broadly regulates transcription of a number of genes and their translation through
ribosome biogenesis [330]. Therefore, it would follow that the UPR, which favours decreased
protein synthesis, prevents elevation of Myc transcription. How the UPR and expression
of Myc interact to influence the survival of goblet cells is unclear and will require analysis
of apoptosis and Notch/Wnt signalling. Focal hyperproliferation of goblet cells of the
crypt base was detected histochemically in only a single animal exposed to three cycles of
1% DSS. Similar hyperproliferative goblet cell lesions have previously been reported as a
’transitional mucosa’ induced by a variety of colonic insults including IBD, and have been
observed adjacent to carcinoma [267, 268]. Although it has proved difficult to demonstrate
goblet-cell hyperplasia is a precursor to dysplasia, it may suggest the clonal expansion of
a cell harbouring epigenetic or genetic mutation(s) with the potential to initiate dysplasia
given sufficient time. Indeed immunohistochemically detectable accumulation of p53, a
phenomenon only observed when negative-feedback mechanisms that tightly regulate p53
are disrupted, have been reported in goblet cell hyperplasia [331]. Since genetic mutation
of TP53 has been identified in the non-dysplastic colonic epithelium in patients with UC,
this raises the possibility that the atypical hyperplasia observed in response to chronic
DSS-induced injury could represent a precursor to dysplasia.
6.2 Trp53 as regulator of cell fate in Winnie
Mutations in the TP53 gene have been reported in approximately 85% of UC-associated
cancers [171]. Cancer-associated TP53 mutations typically involve substitution of a single
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amino acid, and do not produce a truncation of the wild-type protein [170]. Oncogenic
mutations in TP53 have been associated with an increased abundance of the p53 protein in
the nucleus, perhaps due to its impaired ability to up-regulate expression of the p53-repressor
mouse double-minute-2 (MDM2). Inactivating mutations in one or both Trp53 alleles render
mice susceptible to colonic tumourigenesis when environmental insults are introduced.
Administration of two cycles of 4% DSS induced neoplasia in up to 100% of Trp53-/-
mice and 46% of Trp53-/- mice, even held under specific pathogen-free conditions [332].
Notably, the morphology of neoplasia arising in the colon of Trp53-/- mice appears to
correspond to a predominantly flattened profile rather than a polypoid structure [332].
While Trp53 mutant mice are useful for modelling the progression of tumours from TP53
mutant clones as is believed to occur in patients with UC, these mice may not replicate
the accumulation of cellular mutations preceding p53 mutation. Despite the absence of
Trp53 mutations, increased expression of the p53 protein was observed in AOM-induced
colonic neoplasia [333]. Subsequent analysis of the ability of p53 to bind directly to DNA
in the colonic epithelium has suggested that the p53 protein may be functionally impaired
post-translation. Being that p53 is regulated at the post-transcriptional levels, it is difficult
to predict the effect of the p53 up-regulation at the gene level reported in the distal colon
of Winnie after three cycles of 1% DSS. In contrast to the findings of the present study, the
colonic epithelium of patients with UC displays an increased IL-6-dependent p53 expression
during inflammation [334]. Increased p53 expression in Winnie may then suggest that the
activity of the p53-dependent DNA damage response is enhanced to prevent the accumulation
of cancerous mutations resulting from DNA lesions induced by ROS/RNS. The apparently
paradoxical up-regulation of Trp53 may suggest that additional mechanisms overwhelm
the effect of the surrounding chronic inflammation. Unresolved ER stress induced by
accumulation of misfolded Muc2 may result in prolonged activation of the UPR in the
goblet cells of the Winnie distal colon [241, 250, 326]. Induction of ER stress and the
UPR through thapsigargin administration suppressed the expression of p21 (Cdnk1a) via
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a mechanism dependent on wild-type TP53, making cells with wild-type p53 susceptible
to DNA damage-induced apoptosis [335]. Through the activation of the PERK-eIF2α-
CHOP pathway perhaps renders goblet cells vulnerable to apoptosis thus preventing the
accumulation of DNA mutations induced by ROS/RNS. However, transcriptional down-
regulation of Trp53 may not promote a oncogenic transformation in the Winnie epithelium
without a concomitant inactivation of p21. Examination of the mutational status of both
Trp53 and Cdkn1a, together with an assessment of oxidative DNA damage, will therefore
be crucial to understanding the mechanisms by which neoplastic transformation may be
repressed in the colonic epithelium containing dysfunctional Muc2 synthesis. Overall,
chronic activation of the UPR may protect against accrual of ROS-induced DNA mutation
and neoplastic transformation through mechanisms that may be mediated by Trp53 and Myc
(Fig. 6.1)
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Figure 6.1: Possible effect of chronic Muc2 misfolding on neoplastic transformation in
the colon of Winnie mice. Misfolded Muc2 accumulations in the colonic goblet cells in
Winnie, activating the unfolded protein response (UPR). Activation of the UPR is char-
acterised by increased activity of the PERK, IRE1 and ATF6 pathways. Global protein
synthesis is inhibited by the UPR pathways induced by chronic Muc2 misfolding. Activation
of the PERK pathway also restricts the acccumulation of reactive oxygen species (ROS)
within the stressed cell, potentially limiting the amount of ROS-induced DNA damage.
Chronic UPR activation may then protect against ROS-induced DNA damage when p53
transcription is suppressed in the Winnie colonic epithelium, thereby preventing oncogenic
genetic mutation. Up-regulation of Myc induced by DSS in the wild-type may be repressed
by engagement of the UPR in Winnie to counteract a Myc-induced increase in protein
translation. Chronic UPR activation in Winnie may eventually in growth arrest via p53 and
p21 or apoptosis initated by the PERK-CHOP pathway.
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6.3 Colonic immune responses in Winnie
At present, many murine models of spontaneously occurring colitis exist. Several of these
have since been demonstrated to display an abnormal permeability in the adherent, inner
colonic mucous layer to bacterium-sized objects, thus suggesting that mucosal inflammation
is initiated by bacterial colonisation of the inner mucous layer [100]. Winnie mice typically
display a mild chronic colitis, both under our housing conditions and elsewhere, perhaps
suggesting that the mucus defect imparted by the missense Muc2 mutation is only partial
[250]. Partial abrogation of the mucous barrier in Winnie may be somewhat supported by the
fact that even the relatively low 1% (w/v) concentration of DSS is capable of exacerbating
the mucosal inflammation and tissue damage further in Winnie. Bacterial contact with the
colonic epithelium likely triggers activation of host innate immunity through engagement
with epithelial and dendritic cell Toll-like receptors [323]. Interactions with bacterial
sensors at the mucosal interface result in the production of the cytokine IL-1β facilitating
the release of various pro-inflammatory cytokines and chemokines [336]. Production
of the chemokine Cxcl-5 by colonic epithelial cells may be stimulated by both Toll-like
receptor signalling and by IL-1β and thus mediates the influx of neutrophils into the colonic
mucosa. Chronic production of NF-κB-activating cytokines IL-1β and IL-6 by neutrophils
and other phagocytes in the colonic mucosa where Muc2 secretion is impaired is likely
amplified by the polarisation of CD4+ T-lymphocytes toward a IL-17-dominant secretion
profile [122, 294]. The combined contribution of IL-6 and members of the TH17 cytokine
family in chronic colitis may have the effect of promoting tumourigenesis in the colonic
epithelium. Production of IL-6 in particular, has been studied heavily due to its ability to
promote tumour growth, invasion and angiogenesis through the STAT-3 signal transduction
pathway [337]. The mechanisms through which pro-inflammatory cytokines promote
tumourigenesis in the colon though are likely to differ depending on the stage of tumour
development. Pro-inflammatory TH17 family members are important in the invasive stages
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of tumour growth. TH17 cytokines (IL-17A, IL-21, IL-23) are capable of increasing the
release of matrix metalloproteinases, the activity of which may degrade the connective tissues
underlying colonic epithelial cells, thereby promoting the invasion of the mucosa and later
the submucosa by neoplastic epithelium [126, 338]. IL-6 may stimulate the early neoplastic
transition in the colonic epithelium is through the activation of DNMT1, thereby increasing
the methylation of tumour suppressor genes such as TP53 [339]. The pro-inflammatory
cytokine milieu in the colonic mucosa is therefore likely to facilitate the rapid progression of
the colonic epithelium through to pre-malignant dysplasia and on to invasive carcinoma.
Chronic colitis of the distal colon in Winnie is dominated by a TH17 immune profile.
Expansion of activated dendritic cell populations co-incides with enhanced production of
lymphoid production of the TH17-promoting cytokines Il-1β, Il-6, Il-23 and Tgf-β1 and
increased TH17 effectors Il-17a and Il-17f [251]. Despite increased expression of IL-6 in the
inflamed colonic mucosa, in our exploratory analysis of gene expression we failed to detect a
difference in the expression of IL-6 between untreated Winnie mice and those having received
DSS. While immunological changes were not the main focus of the thesis, several additional
pro-inflammatory cytokines and chemokines were also analysed due to their potential
involvement in both chronic colitis and carcinogenesis. Of the inflammatory mediators
analysed at the level of mRNA transcription, only Ccl5 displayed differential expression.
Expression of the lymphocyte-chemo-attractant Ccl5 at the gene level corresponded to the
level of colitic inflammation and correlated with the severity of crypt distortions in the
distal colon of Winnie. While increased expression of Ccl5 may simply reflect a heightened
mucosal immune response and damage in the colon of Winnie, Ccl5 is known to promote
tumour growth by suppressing the anti-tumour activity of cytotoxic CD8+ T-lymphocytes
in the colon [340]. Although production of inflammatory mediators after chronic DSS
administration in Winnie is not well-known,the histopathology was somewhat similar to that
induced in Winnie with mono-allelic IL-10 gene deletion [241]. Both the naturally occurring
colitis in Winnie, and the severe colitis in IL-10-/- Winnies display a prevailing TH1/TH17
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cytokine profile suggesting that inflammation in DSS is mediated by a similar character of
immune response.
6.4 Colitis-associated microbiome
A large number of commensal bacterial species are resident within the colon, normally
spatially separated from the colonic epithelium [90, 341]. Although mechanisms through
which an imbalance in the microbiome are able to cause IBD are not well defined, it is
clear that in a permissive background, a certain microbial community may develop that is
capable of producing chronic colitis. For example, goblet cell deficiency in the NLRP6
protein which forms the NLRP6 inflammasome, a complex coupling Muc2 secretion to
TLR activation by microbial PAMPs, produces a colitis in mice [155, 342]. Expansion
of Prevotellaceae in both NLRP6-deficient mice and co-housed wild-type animals was
associated with colitis, suggesting that defects in the mucous barrier and innate immunity
allow persistent colonisation of pathogenic bacteria to produce chronic disease [343].
In a mouse strain with defective Muc2 synthesis such as Winnie, it might therefore be
expected that a defective mucous barrier would permit increased contact with potentially
pathogenic bacteria. While the intestinal microbiota was not studied here, effort has already
been undertaken to identify the changes in bacterial diversity associated with the spontaneous
colitis in Winnie. Like the normal, uninflamed human colon, the colonic microbiota in
wild-type C57BL/6 mice maintained in SPF conditions typically displays a dominance
of the Bacteroidetes and Firmicutes phyla in the colon [344, 345]. In contrast, Winnie
colitis may alter the microbial composition toward a reduction in the relative abundance of
Proteobacteria in the stool of both 12 week-old Winnie mice and 15 week-old Winnie mice
compared to the appendix [346].
Conversely the proportion of Bacteroidetes was higher in stool samples than in the appendix
of 15 week-old Winnie mice. Within the Proteobacteria phylum, the Helicobacteraceae
family was undetected in the appendix of wild-type C57BL/6 mice yet Helicobacteraceae
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expanded greatly in the appendix and stool of age-matched Winnie mice [346, 347]. Future
investigations will focus on the changing microbial community throughout the course of
DSS administration and the period following the cessation of DSS administration using stool
and mucosal tissue samples collected during these studies. The abundance of Helicobacter-
aeceae identified within the appendix raises the possibility of a colonisation of the colon by
enterohepatic Helicobacter species.
6.4.1 Microbiome and progression of CRC
Expansion of bacterial families such as Prevotella in the faecal microbiome of patients with
CRC have pointed to an association between certain bacteria and CRC and its precursor
lesions [348]. Adenomata obtained from human patients display an increased abundance
of Firmicutes, Bateroidetes and Proteobacteria families when compared to healthy patients
without colonic neoplasia [349]. Since members of these bacterial groups increase in the
inflamed colon it raises the question as to whether the presence of these organisms are a
initiating factor in CACC. Fusobacterium nucleatum has been repeatedly observed at up to
100-fold higher abundance associated with human CRC [350, 351]. F. nucleatum expresses
the cell-surface adhesin FadA that enables attachment and invasion of colonic epithelial cells
via attachment to the host E-cadherin [352]. Adhesion through E-cadherin results in the
nuclear translocation of β-catenin and the subsequent oncogenic up-regulation of Myc and
Ccnd1. The increased abundance of F. nucleatum attached to colonic tumours relative to
the normal epithelium may indicate an impairment in the protection provided by the colonic
mucus. Therefore, defective mucus may allow attachment of similar bacteria capable of
modifying molecular pathways such as Wnt-β-catenin to influence neoplastic transformation
of the colonic epithelium. Bacteria in close proximity to colonic epithelium may also cause
genetic mutations through the production of genotoxins. Colibactin (encoded by a gene
within the pks pathogenicity island) is produced by Esherichia coli species and is capable of
enhancing AOM-induced tumourigenesis by inducing DNA damage in Il10-/- mice [353].
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Cytolethal distending toxin produced by Campylobacter jejuni exerts nuclease activity on
host DNA [354].
Gentoxic ROS/RNS are also produced as by-products of bacterial metabolism, and these
may also contribute to epithelial neoplastic transformation. For example, commensal Ente-
rococcus faecalis produces large volumes of extracellular superoxide, thereby producing
genotoxic peroxide and hydroxyl radicals [355].
Long-standing colonisation of the mucous layer may therefore, when in close proximity,
subject the inflamed colonic epithelium to an additional source of DNA damage to the
endogenously produced radicals. Tracing the changes in particular bacterial families thought
to be associated with colonic dysplasia such as Helicobacteria and Fusobacteria may yield
insight into the microbial changes influencing a possible neoplastic transition of the colonic
epithelium.
6.5 Epigenetic control of neoplastic transformation in the colon
Epigenetic alterations are an appealing line of investigation when considering the stage
of transition to early dysplasia. Alterations to epigenetic regulation of gene expression
through DNA methylation and micro-RNA (miRNA) is likely to be present early in chronic
inflammation, potentially initiating and/or promoting the transition to colonic dysplasia.
Quantification of gene promoter methylation may be undertaken through pyrosequencing
of bisulphite-converted DNA. A panel of oligonucleotide primers matching the CpG-rich
promoter regions of CRC-associated genes were designed based on reported methylation in
UC-associated tumours and AOM and DSS-associated tumours in mice. Optimisation of all
pyrosequencing primers were not completed before the time of writing the thesis. Completion
of the pyrosequencing of tumour suppressors such as p16 in the colonic pathology described
in this thesis may provide evidence for a field cancerisation effect in the Winnie colon.
Although the sequencing of the samples obtained from the experiments described in this
thesis are yet to be completed
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Interactions between miRNA and mRNA facilitate the formation of an mRNA-silencing
complex which leads to the degradation or inhibition of translation of the mRNA transcript.
Analysis of the pattern of miRNA expression in the colonic mucosa in UC has suggested that
several miRNAs are abnormally expressed in both active and inactive inflammation [356].
Particularly, miRNA-29a and miRNA-320 were found increased relative to non-IBD tissue
in both inactive and active UC suggests that the targets of these miRNAs, which include
the tumour suppressor PTEN and DNM3TA may be suppress DNA methylation in chronic
UC [356–358]. Characterisation of differentially regulated miRNAs in the colon of Winnie
relative to wild-type Muc2 and quantitative changes with disease progression would provide
further mechanisms by which tumour suppressor genes may be repressed without the
introduction of genetic mutation.
6.6 Study limitations
The studies described in the thesis focus on the pathology of the distal colon in Winnie
mice, following three cycles of 1% DSS. Therefore all the majority of measurements were
derived from mice at the same age (18 weeks old) and the same point in the recovery from
chronic exposure to DSS. The lack of data collected at additional time-points definitely
limits the interpretations that may be made regarding the neoplastic potential of resultant
lesions. Examination of multiple time-points were considered in the five-cycle experiment
however the number of mice available for each time-point was often limited to a single
animal. Therefore it is possible that genuinely neoplastic lesions occurring at a low incidence
would not have been detected.
Rectal prolapse was a common occurrence in the Winnie mice used in our experiments,
likely arising secondary to the inherent Muc2 defect. Similarly, the original phenotypic
characterisation of the Winnie mouse strain reported rectal prolapse in as many as 25% of
mice by the age of 8 weeks [250]. In addition to rectal prolapse, ileo-colonic intussusception
was observed simultaneously in 2/15 Winnie mice. The low incidence of intestinal intus-
6.7. FUTURE DIRECTIONS 138
susception, in addition to the relatively small sample size, makes it difficult to draw any
conclusions as to the relationship between intussusception and the Winnie mutation.
The preparation of DSS may be another factor which may affect the interpretability of
the studies. Though a pilot experiment comparing different commercially available DSS
preparations for the full three DSS cycles was not performed, published evidence exists to
support the efficacy of the DSS preparation used. Comparison of both Affymetrix-USB
and MP Biomedicals DSS preparations suggested comparable levels of tissue damage over
seven days of administration to C57BL/6 mice, though the effect of the housing used is
unclear [359]. It is possible however that longer administration of DSS may reveal greater
differences in the efficacy of the two DSS preparations.
6.7 Future directions
Animal models are useful for improving our understanding of the pathobiology of human
IBD and for the testing of diagnostic methods and therapeutic interventions. Genetically
engineered animal models may be used to replicate a particular aspect of the disease. To
date, a range of genetically engineered models of a chronic colitis arising from defects in the
intestinal barrier have been generated.
Compared to sporadic colorectal neoplasms, the neoplasia arising from the chronically
inflamed colon often follows a more aggressive course and less easily treated with chemoth-
reapeutic agents. Sporadic CRC typically arises from a focal polypoid dysplastic precursor
lesion, whereas IBD-associated neoplasms exhibit more morphological variation. Dysplastic
lesions which are flat, i.e. not raised above the height of the surrounding mucosa, are more
common in patients with IBD. Flat dysplasia is more difficult to detect than visibly raised
polypoid dysplasia without the use of chromo-endoscopy. Therefore, detection of multi-focal
flat dysplasia, even of low-grade, in the context of chronic UC would often justify surgical
resection or perhaps prophylactic colectomy. Given the movement away from a reliance on
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surgical intervention in the management of UC, greater understanding of IBD-associated
cancer development may refine chemotherapeutic management and neoplastic surveillance.
Given the links between colonic cancer and the microbiome in rodents it may prove useful
to study the changes in microbial diversity with the administration of 1% DSS in Winnie.
Detailed investigations into microbial diversity within the Winnie colon, particularly with a
focus on enterohepatic Helicobacter species H. hepaticus and H. bilis may be achievable
through qPCR using stool or colonic biopsies and could provide further insight into whether
such species modify the risk of neoplasia in Winnie mice.
In addition to microbiological study, it may be useful to analyse DNA modification in
the distal colonic epithelium of Winnie mice following DSS. The identification of double-
stranded DNA breaks through examination of markers such as the histone H2γAX would
provide stronger evidence supporting the initiation of carcinogenesis. Detection of oxidative
DNA adducts such as the 8-OHdG lesion may also provide evidence for the existence of
pre-cancerous in Winnie.
6.8 Conclusions
It is suspected that a primary defect in colonic barrier function is responsible for the chronic
inflammation associated with UC. The theory of a primary defect in the effectiveness of
the barrier separating the colonic mucosa from the luminal microbiota has been supported
by experimental evidence derived from Muc2 and Il10 mutant mice. Chronic exposure
to the commensal species now able to colonise the colonic mucus initiates a destructive
TH17-dominant immune response. Sustained production of ROS/RNS induced by chronic
exposure of the resident mucosal immune cells to bacterial antigen, damages DNA while si-
multaneously inhibiting DNA repair thereby inducing initiating genetic mutations. Repeated
and sustained degradation of the mucosal architecture concurrently promote the expansion
of epithelial cells through the stimulation of proliferation via cytokines and growth fac-
tors, while the same pro-inflammatory milieu may suppress apoptosis of cells with DNA
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damage. Additionally, pro-inflammatory signals may also influence epigenetic silencing of
key tumour suppressor genes. Together, these mechanisms promote the rapid acquisition
of genomic instability and malignant transformation, permitting the rapid invasion and
dissemination of tumours from the chronically inflamed mucosa.
Three cycles of 1% DSS increased the severity of mucosal damage to the distal segment of the
colon in Winnie mice. Repeated exposure to the insult provided by 1% DSS triggered a florid
regenerative response in the colonic mucosa, where abnormal crypt foci resembling dysplasia
were present in all Winnie mice exposed to the DSS regimen. Despite the abnormal epithelial
cell proliferation in the distal colon and penetration of epithelium into the submucosa, no
oncogenic β-catenin accumulation was detected in such lesions. However, an extended
observation period after the cessation of the DSS regimen revealed the transient nature of
the dysplasia-like pathology. The relatively small number of mice studied following the five-
cycle DSS regimen may have made genuine neoplasia difficult to detect, thus confirmation
of these results are necessary. Exploratory gene expression analysis in the distal colonic
mucosa suggested transcriptional alterations in the genes encoding p53, Myc, Cav1 and
Ccl5 in Winnie. In particular Ccl5 expression correlated with the severity of dysplasia-like
morphology. Together, these findings may offer a starting point for further investigations
into the molecular mechanisms involved in the transition of atypical hyperplastic lesions to
dysplasia in colonic disease initiated by a primary secretory cell defect.
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A.1 Supplementary tables
Table A.1: Gastro-intestinal neoplasia screening primer assays
Gene Name Gene
Symbol
Assay ID NCBI Reference
ATP-binding cassette,
sub-family B (MDR/TAP),
member 1A
Abcb1a qMmuCID0027076 NC 000071.6,
NT 039299.7
BCL2-like 1 Bcl2l1 qMmuCED0025041 NC 000068.7,
NT 039207.8
CD14 antigen Cd14 qMmuCED0003341 NC 000084.6,
NT 039674.8
C-reactive protein,
pentraxin-related
Crp qMmuCED0003932 NC 000067.6,
NT 039185.8
V-erb-b2 erythroblas-
tic leukemia viral
oncogene homolog 2,
neuro/glioblastoma derived
oncogene homolog (avian)
Erbb2 qMmuCID0005916 NC 000077.6,
NT 096135.6
Insulin-like growth factor I
receptor
Igf1r qMmuCID0005315 NC 000073.6,
NT 187035.1
Mitogen-activated protein
kinase 1
Mapk1 qMmuCID0025360 NC 000082.6,
NT 039624.8
Nuclear factor of kappa
light polypeptide gene en-
hancer in B cells 1, p105
Nfkb1 qMmuCID0005357 NC 000069.6,
NT 039240.8
Phosphatase and tensin ho-
molog
Pten qMmuCID0005543 NC 000085.6,
NT 039687.8
Secreted acidic cysteine
rich glycoprotein
Sparc qMmuCID0023536 NC 000077.6,
NT 096135.6
Tumor necrosis factor Tnf qMmuCED0004141 NC 000083.6,
NT 039649.8,
NT 039662.3,
NT 187004.1,
NT 187027.1
TATA box binding protein Tbp qMmuCID0040542 NC 000083.6,
NT 039649.8
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Gene Name Gene
Symbol
Assay ID NCBI Reference
Actin, beta Actb qMmuCED0027505 NC 000071.6,
NT 039316.8
Brain derived neurotrophic
factor
Bdnf qMmuCED0004519 NC 000068.7,
NT 039207.8
CD44 antigen Cd44 qMmuCID0025677 NC 000068.7,
NT 039207.8
Connective tissue growth
factor
Ctgf qMmuCED0003632 NC 000076.6,
NT 039492.8
Estrogen receptor 1 (alpha) Esr1 qMmuCID0018069 NC 000076.6,
NT 039490.8
Insulin-like growth factor
binding protein 3
Igfbp3 qMmuCID0005232 NC 000077.6,
NT 039515.7
Transformed mouse 3T3
cell double minute 2
Mdm2 qMmuCID0025320 NC 000076.6,
NT 039500.8
Nuclear factor of kappa
light polypeptide gene en-
hancer in B cells inhibitor,
zeta
Nfkbiz qMmuCID0025623 NC 000082.6,
NT 039624.8
Prostaglandin-
endoperoxide synthase
2
Ptgs2 qMmuCED0003742 NC 000067.6,
NT 078297.7
Secreted phosphoprotein 1 Spp1 qMmuCED0040763 NC 000071.6,
NT 109320.5
Tumor necrosis factor re-
ceptor superfamily, mem-
ber 1a
Tnfrsf1a qMmuCID0023110 NC 000072.6,
NT 039353.8
Glyceraldehyde-3-
phosphate dehydrogenase
Gapdh qMmuCED0027497 NC 000072.6,
NT 039353.8
Thymoma viral proto-
oncogene 1
Akt1 qMmuCID0023089 NC 000078.6,
NT 039551.8
Baculoviral IAP repeat-
containing 5
Birc5 qMmuCID0006189 NC 000077.6,
NT 096135.6
Cadherin 1 Cdh1 qMmuCID0005843 NC 000074.6,
NT 078575.7
Catenin (cadherin associ-
ated protein), beta 1
Ctnnb1 qMmuCID0006137 NC 000075.6,
NT 039482.8
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Gene Name Gene
Symbol
Assay ID NCBI Reference
Enhancer of zeste homolog
2 (Drosophila)
Ezh2 qMmuCID0015459 NC 000072.6,
NT 039353.8
Interleukin 10 Il10 qMmuCID0015452 NC 000067.6,
NT 078297.7
Antigen identified by mon-
oclonal antibody Ki 67
Mki67 qMmuCID0018717 NC 000073.6,
NT 039433.8
Nitric oxide synthase 2, in-
ducible
Nos2 qMmuCID0023087 NC 000077.6,
NT 096135.6
Retinoblastoma 1 Rb1 qMmuCID0005286 NC 000080.6,
NT 039606.8
ST3 beta-galactoside alpha-
2,3-sialyltransferase 5
St3gal5 qMmuCID0016681 NC 000072.6,
NT 039353.8
Thymidylate synthase Tyms qMmuCID0005615 NC 000071.6,
NT 165760.3
Hypoxanthine guanine
phosphoribosyl transferase
Hprt qMmuCID0005679 NC 000086.7,
NT 187037.1
Apolipoprotein E Apoe qMmuCED0001025 NC 000073.6,
NT 187034.1
Breast cancer 1 Brca1 qMmuCID0018895 NC 000077.6,
NT 096135.6
Cyclin-dependent kinase 1 Cdk1 qMmuCID0015611 NC 000076.6,
NT 039500.8
Chemokine (C-X-C motif)
ligand 10
Cxcl10 qMmuCED0001068 NC 000071.6,
NT 109320.5
Fibronectin 1 Fn1 qMmuCID0019534 NC 000067.6,
NT 039170.8
Interleukin 1 beta Il1b qMmuCID0005641 NC 000068.7,
NT 039207.8
Matrix metallopeptidase 1a
(interstitial collagenase)
Mmp1a qMmuCID0022392 NC 000075.6,
NT 039471.8
Nuclear receptor subfamily
3, group C, member 1
Nr3c1 qMmuCID0016200 NC 000084.6,
NT 039674.8
V-rel reticuloendotheliosis
viral oncogene homolog A
(avian)
Rela qMmuCID0017564 NC 000085.6,
NT 082868.6
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Gene Name Gene
Symbol
Assay ID NCBI Reference
Signal transducer and acti-
vator of transcription 1
Stat1 qMmuCID0021143 NC 000067.6,
NT 039170.8
Ubiquitin B Ubb qMmuCED0026045 NC 000077.6,
NT 096135.6
Androgen receptor Ar qMmuCID0005164 NC 000086.7,
NT 039706.8
Caveolin 1, caveolae pro-
tein
Cav1 qMmuCID0020997 NC 000072.6,
NT 039340.7
Cyclin-dependent kinase in-
hibitor 1A (P21)
Cdkn1a qMmuCED0025027 NC 000083.6,
NT 039649.8,
NT 187005.1
Chemokine (C-X-C motif)
ligand 12
Cxcl12 qMmuCID0019961 NC 000072.6,
NT 039353.8
FBJ osteosarcoma onco-
gene
Fos qMmuCED0001023 NC 000078.6,
NT 039551.8
Interleukin 6 Il6 qMmuCID0005613 NC 000071.6,
NT 165760.3
Matrix metallopeptidase 2 Mmp2 qMmuCID0021124 NC 000074.6,
NT 078575.7
Proliferating cell nuclear
antigen
Pcna qMmuCED0040851 NC 000068.7,
NT 039207.8
Serine (or cysteine) pep-
tidase inhibitor, clade E,
member 1
Serpine1 qMmuCID0027303 NC 000071.6,
NT 039314.8
Signal transducer and acti-
vator of transcription 3
Stat3 qMmuCID0021132 NC 000077.6,
NT 096135.6
Ubiquitin C Ubc qMmuCID0021036 NC 000071.6,
NT 039313.8
Aurora kinase A Aurka qMmuCID0006166 NC 000068.7,
NT 039207.8
Chemokine (C-C motif) lig-
and 5
Ccl5 qMmuCID0021047 NC 000077.6,
NT 096135.6
Cyclin-dependent kinase in-
hibitor 2A
Cdkn2a qMmuCED0038108 NC 000070.6,
NT 187032.1
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Gene Name Gene
Symbol
Assay ID NCBI Reference
Chemokine (C-X-C motif)
receptor 4
Cxcr4 qMmuCED0026325 NC 000067.6,
NT 078297.7
Hypoxia inducible factor 1,
alpha subunit
Hif1a qMmuCID0005501 NC 000078.6,
NT 039551.8
Jun oncogene Jun qMmuCED0003314 NC 000070.6,
NT 039264.7
Matrix metallopeptidase 9 Mmp9 qMmuCID0021296 NC 000068.7,
NT 039207.8
Plasminogen activator,
urokinase
Plau qMmuCID0022420 NC 000080.6,
NT 039606.8
MAD homolog 7
(Drosophila)
Smad7 qMmuCID0016983 NC 000084.6,
NT 039674.8
Telomerase reverse tran-
scriptase
Tert qMmuCID0018719 NC 000079.6,
NT 039589.8
Vitamin D receptor Vdr qMmuCID0006555 NC 000081.6,
NT 039621.8
BCL2-associated X protein Bax qMmuCID0006274 NC 000073.6,
NT 187035.1
Cyclin B1 Ccnb1 qMmuCED0024590 NC 000079.6,
NT 039590.8
Collagen, type I, alpha 1 Col1a1 qMmuCID0021007 NC 000077.6,
NT 096135.6
Epidermal growth factor re-
ceptor
Egfr qMmuCID0006030 NC 000077.6,
NT 039515.7
Interferon gamma Ifng qMmuCID0006268 NC 000076.6,
NT 039500.8
Kinase insert domain pro-
tein receptor
Kdr qMmuCID0005890 NC 000071.6,
NT 039306.8
Mucin 1, transmembrane Muc1 qMmuCED0003916 NC 000069.6,
NT 039240.8
Peroxisome proliferator ac-
tivated receptor gamma
Pparg qMmuCID0018821 NC 000072.6,
NT 039353.8
Superoxide dismutase 2,
mitochondrial
Sod2 qMmuCID0006109 NC 000083.6,
NT 039638.8
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Gene Name Gene
Symbol
Assay ID NCBI Reference
Transforming growth factor,
beta 1
Tgfb1 qMmuCID0017320 NC 000073.6,
NT 187034.1
Vascular endothelial growth
factor A
Vegfa qMmuCED0040260 NC 000083.6,
NT 039649.8
B cell leukemia/lymphoma
2
Bcl2 qMmuCED0039968 NC 000067.6,
NT 078297.7
Cyclin D1 Ccnd1 qMmuCID0023518 NC 000073.6,
NT 039437.8
Collagen, type I, alpha 2 Col1a2 qMmuCID0021177 NC 000072.6,
NT 039340.7
Early growth response 1 Egr1 qMmuCED0039815 NC 000084.6,
NT 039674.8
Insulin-like growth factor 1 Igf1 qMmuCID0005726 NC 000076.6,
NT 039500.8
V-Ki-ras2 Kirsten rat sar-
coma viral oncogene ho-
molog
Kras qMmuCID0005957 NC 000072.6,
NT 039360.8,
NT 166305.2
Myelocytomatosis onco-
gene
Myc qMmuCID0006528 NC 000081.6,
NT 039621.8
Prominin 1 Prom1 qMmuCID0021742 NC 000071.6,
NT 039305.8
Trans-acting transcription
factor 1
Sp1 qMmuCED0025031 NC 000081.6,
NT 039621.8
Tissue inhibitor of metallo-
proteinase 1
Timp1 qMmuCID0025322 NC 000086.7,
NT 039700.8
Vimentin Vim qMmuCID0005527 NC 000068.7,
NT 039202.8
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Table A.2: TaqMan primer/probe assays
Gene Name Gene
Symbol
Assay ID NCBI Reference
Caveolin-1 Cav1 Mm00483057 m1 NM 001243064.1,
NM 007616.4
C-C-motif chemokine ligand-5 Ccl5 Mm01302427 m1 NM 013653.3
Cyclin-dependent kinase
inhibitor-2A
Cdkn2a Mm00494449 m1 NM 001040654.1,
NM 009877.2
C-X-C-motif chemokine ligand-5 Cxcl5 Mm00436451 g1 NM 009141.3
C-X-C-motif chemokine ligand-12 Cxcl12 Mm00445553 m1 NM 001012477.2,
NM 013655.4,
NM 021704.3
Interleukin-6 Il6 Mm00446190 m1 NM 031168.1
Mucin-1 Muc1 Mm00449604 m1 NM 013605.2
Myelocytomatosis oncogene Myc Mm00487804 m1 NM 010849.4,
NM 001177352.1,
NM 001177353.1,
NM 001177354.1
Peroxisome proliferator-activated
receptor-γ
Pparg Mm01184322 m1 NM 011146.3,
NM 001127330.1
Prominin-1 Prom1 Mm00477115 m1 NM 008935.2,
NM 001163578.1,
NM 001163577.1,
NM 001163582.1,
NM 001163583.1,
NM 001163581.1,
NM 001163584.1,
NM 001163585.1
Prostaglandin-endoperoxide
synthase 2
Ptgs2 Mm00478374 m1 NM 011198.3
Secreted phosphoprotein-1 Spp1 Mm00436767 m1 NM 001204201.1,
NM 001204202.1,
NM 001204203.1,
NM 001204233.1,
NM 009263.3
Telomerase reverse-transcriptase Tert Mm00436931 m1 NM 009354.1
Transformation-related protein-53 Trp53 Mm01731290 g1 NM 001127233.1,
NM 011640.3
Vimentin Vim Mm01333430 m1 NM 011701.4
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Table A.3: Primer sequences for DNA methylation pyrosequencing
Gene Sequence Amplicon No. of CpGs
Adh
F: GGGTTAAGAGTTTAATAATTGATAGTGAG
4R: ATTTCAATTTAACTTTTTTTCCTAACTACT
S: GTGAGAATTGGGTGTT
B3gnt7
F: AGTGAAGGATTTGTTGGTAATATAAGA
3R: CCTCTACAAAAAATCCATTCTTTTACT
S: AGAGTTTTATTAGGGAGATTT
Cdh1
F: TGGTGGAAGAAGAGAATTGATT
10R: AAAAACTTCCCAACTTCCTATTC
S: TGAAGGTTGTAGTTTTATTTTTATA
p16
F: GGGGGGAATAGTAGTGTTTTT
7R: CTCCATACTACTCCAAATAACTCTC
S: GGAAGGAGGGATTTATTG
p19
F: TTGTTAAGGGGATTTTGGGTTTGA
3R: ACATCCCCCACTCTTCCTCTT
S: GGATTTTGGGTTTGATTT
Kcne3
F: GTGTTTAAGATTGGTTTTGAGGGTATT
6R: CTCCTTCAAAACACATCCTTATTATATTA
S: TTAAATTTTTTAGGAGGAGT
Nr5a2
F: GGGTTTTAGTATTAGTTAAAGTATGAGTGT
9R: CCCAAACCAAAACACTAACTTACCTTATT
S: TGTTTTTGGTAAGGGAT
Rassf1a
F: GGGTAGGGGGAGAAGATTGGA
10R: ACACCCCCCCCAAAATCCA
S: GAAAGGGTTTATTTTTGTG
Sorbs2
F: GTTTTTGTTAGTATTGGGAAGGTTTG
7R: ACCTCCACTAAATTCCTCCTTAAATTTCAC
S: TGGTGAGTATGTTAGG
Smad7
F: GGGAGAGGGTGGTAGTAAT
8R: TCCCTCTACTCCACTAATTCCACT
S: TTTTTTAAAGAGATAGGGTGTT
Vdr
F: AGGAATGGTTGAATGTAGATGT
6R: ACTAAACTCAACTTATCAATCCTAATAACA
S: GAGATAAGGAATTTGGGA
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Histology scoresheet for assessment of colitis
Crypt Architecture PC MC DC
0 Normal
1 Irregular
2 Moderate crypt loss (10-50%)
3 Severe crypt loss (50-90%)
4 Small/medium-sized ulcers (>10 crypt widths)
5 Large ulcers (>10 crypt widths)
Crypt Abscesses
0 None
1 1-5
2 6-10
3 >10
Crypt Length
PC 0, <150 μm, 1, 150-199 μm, 2, 200-249 μm, 3, 250-299 μm, 4, ≥300 μm
MC 0, <250 μm, 1, 250-299 μm, 2, 300-349 μm, 3, 350-399 μm, 4, ≥400 μm
DC 0, <200 μm, 1, 200-249 μm, 2, 250-299 μm, 3, 300-349 μm, 4, ≥350 μm
Tissue Damage
0 No damage
1 Focally dilated glands and/or attenuated surface epithelium, decreased goblet
cells
2 Focally extensive gland dilation and/or surface epithelial attenuation
3 Mucosal erosions (necrosis confined to the mucosa)
4 Ulceration (necrosis extending into the submucosa or deeper)
Goblet cell loss
0 Normal
1 <10% loss
2 10-24% loss
3 25-49%
4 ≥50%
Inflammatory cell infiltration
0 Occasional infiltration
1 Small, mucosal leukocyte aggregates
2 Confluent mucosal or submucosal leukocyte aggregates
3 Confluence of mucosal leukocytic infiltrate and mulifocal submucosal
extension ± lymphoid follicle formation
4 Severe diffuse infiltration into the mucosa, submucosa & deeper layers
Lamina propria neutrophils
0 0-5 neutrophils/high-power field
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